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ABSTRACT

Kuriakose, Jerrin. Ph.D., Purdue University, December 2014. Development of Novel
Strategies to Combat Multidrug Resistance Mediated by Efflux Transporters and
Intracellular Bacteria. Major Professor: Jean Chmielewski.

Multidrug resistance (MDR) is the condition where cancer cells or
microorganisms cease to respond to multiple drugs. MDR conferred by efflux
transporters, that deprive the bioavailability of drugs at their site of action, are a threat
to cancer and malarial chemotherapy. Specifically, the mammalian ABC transporter P‐
glycoprotein (P‐gp) has undermined many drugs in treatment of cancer and other
disease states. Mutations in the parasitic transporter Plasmodium falciparum
chloroquine resistance transporter (PfCRT) have given rise to strains unsusceptible to
the aminoquionoline family of antimalarials. Using the very drug substrates, we have
developed bivalent inhibitors of P‐gp. Here, click chemistry has been utilized to rapidly
synthesize a library of dimers based on emetine and quinine. This resulted in triazole
bearing dimers that potently inhibited P‐gp efflux. Bivalent quinine probes were also
developed as potential mechanistic probes of P‐gp. Further, the bivalent strategy was
expanded to the antimalarial drugs hydroxychloroquine, quinine, mefloquine and
primaquine in an effort to inhibit PfCRT. A quinine dimer, Q2, blocked PfCRT mediated
efflux and successfully cleared parasitemia in vivo in a Plasmodium berghei mice model.

xxiii
Efforts to target pathogenic bacteria that evade antibacterial drugs by inhabiting
mammalian cells will be discussed. An unnatural proline‐rich peptide Fl‐PLPRPR‐4 was
developed with dual antibacterial and mammalian cell penetrating ability. Fl‐PLPRPR‐4
was able to clear macrophages from Salmonella typhimurium and Brucella abortus
infection within J774A.1 macrophage cells by 62% and 90% respectively, with no
concomitant toxicity towards the host cells.
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CHAPTER 1. TARGETING INTRACELLULAR PATHOGENIC BACTERIA WITH UNNATURAL
PROLINE‐RICH PEPTIDES: COUPLING ANTIBACTERIAL ACTIVITY AND MACROPHAGE
PENETRATION

1.1

Introduction

The emergence of drug resistant bacteria is a growing challenge to anti‐infective
therapy. Pathogens such as methicillin‐ and vancomycin‐resistant Staphylococcus aureus
(MRSA) and VRSA, and resistant Pseudomonas aeruginosa and Acinetobacter baumanni
have undermined most, and sometimes all, clinically usable antibacterial drugs.1,2,3 As
new bacterial strains continue to evolve,4 the concomitant discovery of novel
antibacterial agents has drastically lagged behind.5 Furthermore pathogens such as
Bacillus anthracis and Brucella abortus, classified as bioterrorism agents, pose an
ongoing threat to security.6 The generation of novel antibacterial agents, therefore, is a
priority to sustain the capacity to treat infectious disease.
Another challenge in the development of effective antibacterial agents arises from
bacterial pathogens that have evolved to inhabit mammalian cells, such as phagocytic
macrophages.7,8,9 Within these intracellular safe havens the bacteria reproduce and
form a repository, causing recurrent infections. Such intracellular pathogenic bacteria
include Mycobacterium tuberculosis, Salmonella typhimurium, Listeria monocytogenes,
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and Brucella abortus. When localized within mammalian cells, bacteria are able to evade
the host immune response as well as a number of antibiotic drugs. A significant subset
of antibiotics, such as β‐lactams and aminoglycosides, are unable to achieve therapeutic
concentrations within the host cell due to poor cell permeability and/or efflux
transporters.10 These difficulties have spurred efforts to target intracellular pathogens
using vehicles such as liposomes and nanoparticles containing antibiotics.11,12,13
Antimicrobial peptides (AMPs) are evolutionarily conserved molecules produced
widely by plants and animals to defend against microbes.14,15,16 The majority of AMPs
exert their antibiotic effect by targeting the microbial cell membrane resulting in cell
lysis. This mechanism of action is also one of the major drawbacks associated with
clinical use of AMPs due to host cell toxicity.17 However, a small class of non‐membrane
lytic AMPs have been identified.18,19 Unifying features of these non‐membrane lytic
AMPs, including bactenectin, PR‐39, apidaecin, pyrrhocoricin and drosocin, are a high
proline content and an overall cationic charge due to high levels of arginine. These
proline‐rich AMPs (P‐AMPs) predominantly target Gram negative bacteria, while having
minimal effect on Gram positive strains. In some cases the intracellular targets of P‐
AMPs have been identified, such as the heat shock protein DnaK.20 While P‐AMPs are
less toxic than membrane‐lytic AMPs, as seen in their lack of hemolytic activity and
safety in animal models,18 the majority do not enter mammalian cells.21
AMP‐inspired analogs have been widely explored,22 including scaffolds based on
β‐peptides,23,24,25 peptoids,26 arylamide oligomers27 and polymethacrylate derivatives.28,
29

We sought to interrogate the interplay of structure and function for P‐AMPs with
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idealized, de novo designed sequences. At the same time, we wished to enhance the
antibiotic activity of these proline‐rich structures with an innate mammalian cell
penetrating ability. Ultimately we sought to generate non‐lytic antibacterial peptides
with the ability to localize within mammalian cells, thereby providing agents that target
elusive intracellular pathogenic bacteria.

1.2

Results and Discussion

1.2.1 Design
P‐AMPs are characterized by their abundance of proline residues (25‐50%). As a
result, these sequences have a propensity to adopt a polyproline type II helical (PPII)
conformation as seen in PR‐39, bactenicin and apidaecin.19,30,31 Another characteristic
feature of P‐AMPs is conserved repeating units of proline and arginine. For instance PR‐
39 and bactenicin contain tetrad repeats of PRPX and RPPX, respectively, across their
primary sequence, with X most often found to be the hydrophobic amino acids leucine,
isoleucine and phenylalanine.18
With these key features in mind, we designed a series of peptides with varying
levels of proline and proline‐based amino acids, differing numbers of positively charged
residues and increased hydrophobicity. We started with a peptide containing four
copies of the PRP triad repeat found in PR‐39, Fl‐PRP‐4 (Figure 1.1a). To investigate the
effect of a higher cationic character relative to Fl‐PRP‐4, we moved to a PRR triad (Fl‐
PRR‐4) in an effort to improve mammalian cell uptake (Figure 1.1a). This latter sequence
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was further modified to contain all proline‐based residues, including an unnatural amino
acid containing a guanidinium group (PR, Fl‐PPRPR‐4) to investigate possible links

Figure 1.1 Structures of the idealized P‐AMP sequences containing (a) natural amino
acids and (b) unnatural proline‐based residues PR (blue modification) and PL (red
modification). (c) Model of Fl‐PPRPR‐4looking down the PPII helix (Pro in red, PR in blue).

between activity and the ability to adopt a PPII conformation (Figure 1.1b‐c). Finally,
using PR‐39 and bactenicin as models, we introduced additional hydrophobicity into the
PPRPR design by replacing proline with an isobutyl‐modified proline analog (PL) in two
different length peptides Fl‐PLPRPR‐3 and Fl‐PLPRPR‐4 (Figure 1.1b).32,33 These latter three
peptides were designed to possess a PPII scaffold, such that every third amino acid
along the peptide backbone would be aligned along the same face of the helix, resulting
in amphiphilic structures (Figure 1.1c). Additionally fluorescein (Fl) was incorporated at
the amino‐terminus of each peptide, after a glycine spacer, to facilitate the monitoring
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of cellular localization. The Fl‐PRP‐4 and Fl‐PRR‐4 peptides were synthesized using an
Fmoc‐based, solid phase strategy on the Rink amide resin. The unnatural proline‐based
amino acids with the appropriate protecting groups were synthesized as previously
described.32 All unnatural amino acids and the five designed peptides used in this study
were synthesized by Chmielewski group coworkers.

1.2.2 Secondary Structure of Designed Peptides
Circular dichroism (CD) was used to evaluate the conformation of the designed
peptides, since a PPII conformation displays a characteristic maximum in the CD
spectrum at 225 nm.34 The CD spectrum of Fl‐PRP‐4 exhibited a very weak maximum at
225 nm, while Fl‐PRR‐4 lacked the characteristic 225 nm maximum entirely (Figure 1.2).
These data are reasonable since Fl‐PRP‐4 contains 64% proline content as compared to
a proline content of only 36% for Fl‐PRR‐4. A similar lack of PPII helical content has been
observed with the P‐AMP drosocin which contains only 33% proline content.35
Alternatively, Fl‐PPRPR‐4, Fl‐PLPRPR‐3 and Fl‐PLPRPR‐4 each displayed a strong peak at 225
nm, indicating that an all‐proline backbone was essential for the peptides to adopt the
PPII helix.32 Also, the CD data demonstrate that modifying the proline residues with
additional functionality did not preclude the formation of a PPII conformation.

1.2.3 Antibacterial Activity of Designed Peptides
With information concerning the conformation of the peptides in hand, we
turned our attention to both activity against bacteria and penetration of mammalian
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cells. The antibacterial activity of the five peptides was explored using a standard broth
micro‐dilution assay with E. coli (Gram negative) and S. aureus (Gram positive). The
resulting minimum inhibitory concentrations (MIC) are listed in Table 1.1. Amoxicillin
(MIC 25 µM) and ampicillin (MIC 0.4 µM) were used as controls for E. coli and S. aureus,

Figure 1.2 CD spectra of designed peptides (50 µM) at 25 °C in 20 mM phosphate buffer
(pH 7.2).

respectively. The minimalistic PRP‐based peptide (Fl‐PRP‐4) was not active against both
bacterial strains up to a concentration of 100 µM. However, increasing the cationic
character of this peptide with the PRR‐based peptide (Fl‐PRR‐4) led to modest, but
observable activity in both Gram positive and negative bacteria (20 µM and 40 µM,
respectively). Electrostatic interactions between cationic AMPs and the negatively
charged bacterial membrane are believed to be the first step in antibacterial action,14,36
thereby explaining the improved antibacterial activity when going from Fl‐PRP‐4 (+4
charge) to Fl‐PRR‐4 (+8 charge). A similar trend was also observed for Fl‐PLPRPR‐3 and
Fl‐PLPRPR‐4 which differ in one triad repeat, and hence a charge of +2. The more cationic
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Fl‐PLPRPR‐4 peptide is 15‐ and 5‐fold more active than Fl‐PLPRPR‐3 against E. coli and S.
aureus, respectively. Interestingly, restricting Fl‐PRR‐4 to a rigid PPII conformation had a
detrimental effect on activity, as seen in the case of Fl‐PPRPR‐4, a peptide with either
very weak or no observable antibacterial activity against E. coli (60 µM) and S. aureus
(>100 µM). However, the addition of hydrophobic isobutyl groups to the proline

Table 1.1 Antibacterial activity of designed P‐AMPs and controls. The minimum
inhibitory concentration (MIC) was defined as the lowest concentration of peptide at
which no growth was observed.

Fl‐PRP‐4
Fl‐PRR‐4
Fl‐PPRPR‐4
Fl‐PLPRPR‐3
Fl‐PLPRPR‐4
Melittin
Amoxicillin
Ampicillin

E. coli
MIC (µM)
>100
40
60
60
4
4.637
25

S. aureus
MIC (µM)
>100
20
>100
60
12
2.137
0.4

backbone of Fl‐PPRPR‐4 (Fl‐PLPRPR‐4) resulted in a dramatic improvement in activity
against both strains with MIC values of 4 µM for E. coli and 12 µM for S. aureus. While
both Fl‐PPRPR‐4 and Fl‐PLPRPR‐4 adopt a PPII conformation, the hydrophobic side chains
in the latter make it additionally amphiphilic. Amphiphilicity is well known to influence
the antibacterial activity of AMPs16 and may be responsible for the observed activity for
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the two peptides. Fl‐PLPRPR‐4 was hence identified as the most potent antibacterial
among our designed proline‐rich peptides.
Since the peptide Fl‐PLPRPR‐4 displayed potent antibacterial activity and
macrophage penetration, we proceeded to test this peptide against a range of Gram
positive and Gram negative bacterial pathogens in collaboration with Prof. Mohamed
Seleem of Purdue University. Fl‐PLPRPR‐4 has potent broad spectrum antibacterial
activity, as summarized in Table 1.2, including MRSA (8 µM) as well as the biological
warfare agents Bacillus anthracis (8 µM) and Brucella abortus (16 µM). Also of interest
was activity against the biofilm‐forming clinical‐isolates of Pseudomonas aeruginosa as

Table 1.2 Antibacterial activity of Fl‐PLPRPR‐4 against pathogenic bacteria. aThe minimum
inhibitory concentration (MIC) was defined as the lowest concentration of peptide at
which no growth was observed. bThe minimum bactericidal concentration (MBC) of the
peptide against each species was reported as the lowest concentration producing more
than 99.9% reduction of the initial inoculum.

Pathogen
Gram positive
Bacillus anthracis
S. aureus
methicillin‐resistant S. aureus
Listeria monocytogenes
Vancomycin resistant Enterococcus faecalis
Gram negative
Salmonella typhimurium
Brucella abortus
Pseudomonas aeruginosa

a

MIC/bMBC (µM)

8/8
8/32
8/16
16/32
>64
8/8
16/32
32/32
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well as that of Staphylococcus aureus. Fl‐PLPRPR‐4 was further shown to inhibit the
growth of Salmonella, Listeria and the aforementioned Brucella at 8, 16 and 16 µM
respectively, which are all classified as intracellular pathogens.

1.2.4 Hemolysis Activity of Designed Peptides
Many AMPs are limited by their toxicity toward human red blood cells (hRBCs)
due to their membrane lytic mode of action. To test our designed proline‐rich peptides
for erythrocyte lysis we performed hemolysis assays with hRBCs. Triton X‐100 was used
as positive control at a concentration known to cause complete hemolysis (100 %
hemolysis).38 For comparison, we also used the membrane lytic AMP melittin.39 As
expected both control agents lysed hRBCs, as evidenced by the spectrophotometrically
measured release of hemoglobin. In contrast the de novo designed proline‐rich peptides

Table 1.3 Hemolytic activity of the designed peptides and controls.

Peptide

Hemolysis (µM)

Fl‐PRP‐4

>100

Fl‐PRR‐4

>100

Fl‐PPRPR‐4

>100

Fl‐PLPRPR‐3

>100

Fl‐PLPRPR‐4

>100

Melittin

5
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caused only minimal levels of damage to hRBCs (<5%) after 1 h of incubation up to a
concentration of 100 µM, compared to 80% hemolysis by melittin at just 5 µM (Table
1.3). A similar lack of hemolysis has been observed for P‐AMPs such as pyrrhocoricin – a
reasonably potent agent against E. coli that is inactive against S. aureus.19 This lack of
observed hemolysis with our designed P‐AMPs is a crucial feature for potential in vivo
applications.

1.2.5 Effect of Fl‐PLPRPR‐4 on the Bacterial Membrane
P‐AMPs have been shown to exert their antimicrobial activity without lysing the
bacterial membrane. For instance, the insect‐derived P‐AMP apidaecin was
demonstrated to not promote leakage of the cytosolic enzyme β‐galactosidase from E.
coli.40 On the other hand, E. coli treated with melittin has been reported to rapidly
release β‐galactosidase as a consequence of membrane lysis.41 To test the effect of Fl‐
PLPRPR‐4 on the membrane integrity of E. coli we performed the β‐galactosidase leakage
assay, with melittin as a positive control and buffer as a negative control.42,43 This

11

Figure 1.3 Peptide‐induced leakage of β‐galactosidase from E. coli treated with melittin,
control and Fl‐PLPRPR‐4. Absorbance due to ONPG cleavage was monitored at 405 nm.

traditional method monitors the unmasking of the cytosolic enzyme β‐galactosidase as a
consequence of membrane lysis and the released β‐galactosidase is monitored
spectrophotometrically with 2‐nitrophenyl‐β‐D‐galactopyranoside (ONPG). As expected,
melittin caused a linear increase in absorbance over 60 min due to cleavage of ONPG by
the β‐galactosidase that was released from E. coli (Figure 1.3). In contrast, Fl‐PLPRPR‐4
showed no increase in absorbance at both its MIC (4 µM) as well as 5 times (20 µM) it’s
MIC, proving the absence of any β‐galactosidase leakage. These data support a
mechanism of antibacterial action for Fl‐PLPRPR‐4 that does not involve lysing the
bacterial membrane.
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1.2.6 Visualization of Fl‐PLPRPR‐4 Interaction with Bacteria
In an effort to elucidate the interactions between Fl‐PLPRPR‐4 and bacteria, we
visualized the association of Fl‐PLPRPR‐4 and its shorter analog Fl‐PLPRPR‐3 with E. coli by
confocal microscopy, with untreated bacteria as a control. Strong fluorescence was
visible within 10 min of treatment with Fl‐PLPRPR‐4 (Figure 1.4a).

Figure 1.4 Confocal microscopy images of E. coli incubated with (a) buffer control, Fl‐
PLPRPR‐4 and Fl‐PLPRPR‐3 (20 µM) for 10 min. (b) E. coli incubated with Fl‐PLPRPR‐3 and Fl‐
PLPRPR‐4 (20 µM) for 6 h. Bright field (left) images of E. coli, blue channel (middle) and
green channel (right) representing hoechst and fluorescein fluorescence, respectively.
Scale bar 5 µm.
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The green fluorescence of the peptide is seen throughout the bacteria and seems to
have been internalized into the bacterial cytosol.44 In contrast Fl‐PLPRPR‐3 was found to
poorly interact with E. coli, as evident by the much lower levels of cellular fluorescence
under identical conditions. Longer incubation with Fl‐PLPRPR‐3 (6 h) did not increase the
levels of cellular fluorescence and the bacteria looked identical to the control (Figure1.
4b). However E. coli treated with Fl‐PLPRPR‐4 for 6 h appeared to be unhealthy with a
fragmented morphology.

1.2.7 Macrophage Internalization of Designed Peptides
To rescue mammalian cells infected with intracellular bacteria, antimicrobial
agents need to effectively penetrate within host cells. Macrophages are commonly
invaded by intracellular bacteria and thus J774A.1 cells were selected for uptake studies
The guanidinium side chain is highly prevalent among cell penetrating agents, including
both peptides and synthetic constructs.45,46,47 We evaluated the cell penetrating ability
of the designed peptides by flow cytometry with J774A.1 macrophage cells. Fl‐PPRPR‐4
showed unspecific plasma membrane associated fluorescence while Fl‐PRP‐4 displayed
negligible levels of uptake.48 The remaining three peptides (Fl‐PLPRPR‐4, Fl‐PLPRPR‐3, Fl‐
PRR‐4) were analyzed along with the well‐known cell penetrating peptide, Tat at 25 µM
concentration. As seen in Figure 1.5 the uptake of peptides into J774A.1 cells varied
considerably. The differences could be rationalized based on properties known to
influence cellular internalization. For instance, increased cationic character has been
linked to greater cellular internalization, and in these data a trend of increasing uptake
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with cationic character was evident.49 For instance Fl‐PLPRPR‐4 (+8 charge) was 20‐fold
higher internalization than Fl‐PLPRPR‐3 (+6 charge). Fl‐PRR‐4 (+8 charge) also displayed
higher uptake than Fl‐PLPRPR‐3 but was about 4‐fold lowed than Fl‐PLPRPR‐4. CD studies
showed Fl‐PLPRPR‐4 to exist in a PPII conformation, as compared to the more disordered
structure of Fl‐PRR‐4. The higher uptake of the structurally restricted peptides, such as
Fl‐PLPRPR‐4, is in agreement with reports where rigidity and an enforced PPII
conformation, enhanced cellular internalization of arginine rich peptides.50 Moreover
the role of amphiphilicity, imparted by the incorporation of the hydrophobic residue PL

Figure 1.5 Flow cytometry histograms showing internalization of designed peptides. Fl‐
PLPRPR‐4 (purple) displayed internalization similar to Tat (grey) and about 4‐ and 20‐fold
higher than Fl‐PRR‐4 (orange) and Fl‐PLPRPR‐3 (red) respectively. All peptides studied at
25 µM concentration and 1h incubation in J774A.1 cells.

in Fl‐PLPRPR‐4, in improving cellular penetration is also well known.32 Fl‐PLPRPR‐4 showed
highest internalization, comparable to that of Tat. Thus among the designed P‐AMPs, Fl‐
PLPRPR‐4 was found to be most potently internalized within J774A.1 macrophage cells.
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1.2.8 Subcellular Localization of Fl‐PLPRPR‐4
Localization of Fl‐PLPRPR‐4 within cells is crucial for its ability to interact with
intracellular pathogens. We used confocal microscopy to investigate the sub‐cellular
localization of Fl‐PLPRPR‐4 within J774A.1 cells at 15 µM concentration after 1 h of
incubation. We utilized the mitochondria specific dye MitoTracker to study co‐
localization of Fl‐PLPRPR‐4. The green channel (Figure 1.6B) showed fluorescence from
internalized Fl‐PLPRPR‐4 by virtue of the covalent fluorescein group, while MitoTracker
was visible in the red channel (Figure 1.6C). The overlay showed good correlation in the
location of the two fluorophores (Figure 1.6D), indicating mitochondrial localization of
Fl‐PLPRPR‐4. Similar to mitochondria, bacteria have a negative transmembrane potential,
which could electrostatically interact with the cationic amphiphilic peptide once inside
the cytosol.51,52,53 Similarly studies with LysoTracker Red revealed co‐localization of Fl‐
PLPRPR‐4 with lysosomes as well.48 Arginine rich cell penetrating peptides and synthetic
vectors are believed to internalize by endocytosis or direct translocation or a
combination of both pathways depending on concentration, cell type and cargo.54 For
instance, Fl‐PLPRPR‐4 has previously been shown to preferentially localize with
mitochondria or lysosomes in HeLa cells depending upon the concentration used.51 The
presence of Fl‐PLPRPR‐4 in both endosomes and at the mitochondria of J774A.1 cells
suggests that both mechanisms are at play. Crucially this suggests that Fl‐PLPRPR‐4 could
access bacteria residing within infected J774A.1 cells.
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Figure 1.6 Confocal images of live J774A.1 cells treated with Fl‐PLPRPR‐4 (15 µM) in (A)
bright, (B) green, (C) red and (D) overlaid channels. Scale bar 10 µm.

1.2.9 Effect of Fl‐PLPRPR‐4 on Mitochondrial Membrane Potential
To complement the confocal images, a physiological study was performed using
tetramethyl rhodamine methyl ester (TMRM) dye to investigate the mitochondrial fate
of Fl‐PLPRPR‐4. TMRM aggregates in the mitochondrial membrane to give intense orange
fluorescence. Upon membrane depolarization, this cationic dye moves into the cytosol
(where the aggregates break) and fluorescence decreases dramatically. Carbonyl
cyanide

4‐(trifluoromethoxy)phenylhydrazone

(FCCP),

a

known

mitochondrial

membrane decoupling agent, was used as a control. As seen in Figure 1.7, under these
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conditions, Fl‐PLPRPR‐4 was found to have a very limited influence on mitochondrial
membrane depolarization (~10%), whereas the known mitochondrial depolarizer FCCP
showed stronger depolarization (~30%).

Figure 1.7 Analysis of mitochondrial membrane depolarization using TMRM dye. J774.A1
cells were treated with either Fl‐PLPRPR‐4 (15 μM), FCCP (50 μM) or media alone
(control), followed by TMRM. Cellular fluorescence was monitored by flow cytometry.

1.2.10 Enzymatic Stability of Fl‐PLPRPR‐4
P‐AMPs also have had limited applications due to enzymatic degradation, and
this has led to efforts in designing stable variants.55 To test the proteolytic stability of Fl‐
PLPRPR‐4 we incubated the peptide with bovine pancreatic trypsin for up to 48 h and
monitored the reaction by analytical HPLC (Figure 1.8).56,24 Fl‐PLPRPR‐4 was found to be
resistant to proteolysis by trypsin over this time course, a reasonable outcome in light of
the unnatural amino acid composition of Fl‐PLPRPR‐4. In contrast N‐α‐Benzoyl‐L‐arginine
ethyl ester hydrochloride (BAEE), a standard substrate of trypsin, was completely
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cleaved under the same conditions. Thus Fl‐PLPRPR‐4 satisfies a vital property for
application against intracellular bacteria: resistance to proteolytic degradation by
trypsin.

Figure 1.8 Analytical HPLC profiles showing Fl‐PLPRPR‐4 (200 µM) incubated with trypsin
in tris buffer at various time points.

1.2.11 Clearance of Intracellular Infection by Fl‐PLPRPR‐4
With knowledge of the separate cell penetrating and antibacterial activities of Fl‐
PLPRPR‐4, we sought to investigate the ability of this P‐AMP to clear intracellular
bacterial pathogens within macrophage cells using an in vitro bacterial protection assay.
These studies were carried out in collaboration with Prof. Mohamed Seleem of Purdue
University. It is imperative that Fl‐PLPRPR‐4 be benign towards the host macrophage cells.
Thus MTS cytotoxicity assay was first performed to check the effect of Fl‐PLPRPR‐4 on
J774A.1 cell viability.
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Figure 1.9 (A) MTS assays showing the percent mean absorbance at 490 nm after
incubating J774A.1 cells with Fl‐PLPRPR‐4 at a concentration of 15 µM for 9 h. Water was
used as a control. Results are expressed as means from four measurements ± SD.
*statistically significant difference compared with controls (P < 0.01). (B) Intracellular
antibacterial activity of Fl‐PLPRPR‐4 (15 µM) in J774A.1 cells infected with Salmonella
typhimurium and Brucella abortus after 9 h of treatment. The data represent the
average of two independent experiments each in triplicates ± standard deviations. The
data points without error bar indicate that standard deviation is too small to be seen.

MTS assays with 15 µM Fl‐PLPRPR‐4 conducted after 9 hours of incubation showed no
significant differences in percentage mean absorption between peptide and control
(Figure 1.9A), indicating that the peptide is not toxic to J774A.1 under these conditions.
However at higher concentrations of the peptide loss in cell viability was observed.48
Thus Fl‐PLPRPR‐4 at a concentration of 15 µM and incubation period of 9 hours was
selected for the subsequent cell rescue assays. The gentamicin protection assay was
carried out with two intracellular pathogens, Salmonella and Brucella.57 J774A.1 cells
infected with Salmonella and Brucella for 30 min and 1h, respectively, were
subsequently washed with gentamycin (non‐cell penetrating antibiotic) to clear non‐
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phagocytized bacteria. The cells were then incubated with media supplemented with
and without Fl‐PLPRPR‐4 (15 µM) for 9 h. Cell lysates were plated to determine the
number of surviving bacteria (Figure 1.9B). While intracellular Salmonella was
significantly reduced by approximately 62% with the addition of Fl‐PLPRPR‐4, intracellular
Brucella was found to be reduced by 90%. The difference in inhibition between
Salmonella and Brucella could be the result of many factors, such as the pathogens sub‐
cellular localization and compartmentalization within phagosomes. For instance
Salmonella is known to reside in endosome like compartments called Salmonella
containing (SCV) while Brucella localizes to the endoplasmic reticulum.7 The vacuolar
protection afforded by these compartments would influence the ability of Fl‐PLPRPR‐4 to
interact with and subsequently kill these bacteria, which could explain the observed
difference in clearance. Antibacterial therapeutics should ideally eliminate both
extracellular and intracellular bacteria without being limited to either one niche. The cell
penetrating peptide Pep1 has been shown to inhibit growth of the intracellular
pathogen Chlamydia, but was inactive against extracellular Chlamydia.58 In contrast Fl‐
PLPRPR‐4 was able to clear Salmonella and Brucella in both extracellular and intracellular
environments. Thus Fl‐PLPRPR‐4 is a potent AMP in its own right and its mechanism is
not limited to intracellular dynamics of the pathogen. The substantial reduction in
intracellular pathogen levels, observed upon treatment with Fl‐PLPRPR‐4, provides proof
of concept for this study.
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1.3

Conclusion

Overcoming bacterial resistance will necessitate the continuous development of
therapeutic agents that also target intracellular bacterial reservoirs, so as to avoid
recurrence and emergence of resistance. These goals led us to design a series of
peptides with varying levels of proline and proline‐based amino acids, differing numbers
of positively charged residues and increased hydrophobicity. Rigidity of the peptide
backbone, amphiphilicity and cationic character were found to play key roles in
determining both the antibacterial and cell penetrating properties of the peptide series.
One particular P‐AMP, Fl‐PLPRPR‐4, displayed potent antibacterial action and mammalian
cell penetration. Fl‐PLPRPR‐4 was found to be non‐hemolytic to hRBCs and was resistant
to tryptic degradation. Fl‐PLPRPR‐4 successfully rescued J774A.1 macrophage cells that
were infected with the intracellular bacteria Salmonella and Brucella under conditions
benign to the host cells. Preliminary studies indicated that Fl‐PLPRPR‐4 does not act by
lysing the bacterial membrane, contrary to the action of many AMPs, such as melittin. In
summary, Fl‐PLPRPR‐4 represents an exciting addition to the evolving arsenal of new age
antibiotic agents.

1.4

Future Directions

Future studies will probe the antibacterial mechanism of action of Fl‐PLPRPR‐4 in
more detail, as it is an attractive starting point for the development of more potent P‐
AMP analogs. Bacterial protein targets with non‐human counterparts are highly sought
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after. Fl‐PLPRPR‐4 conjugates with cell‐impermeable antibiotics can be further used to
deliver dual payloads, to maximize infection clearance.

1.5

Materials and Methods

1.5.1 Circular Dichroism Spectroscopy (CD)
Data were recorded on a Jasco circular dichroism spectropolarimeter (Model
J810) at 25 °C using a 1 mm path length quartz cell.The spectra were averaged over
three scans taken from 250 to 190 nm, with a data pitch and bandwidth of 1 nm, at a
scan rate of 20nm/min. All peptides were analyzed at 50 μM concentration in 20 mM
Phosphate Buffer (pH 7.2). The spectra were background subtracted and processed
from degrees of rotation to mean residue ellipticity by dividing by the appropriate path
length, peptide concentration and number of residues in the peptide.

1.5.2 Antibacterial Activity of the Designed Peptides Against E. Coli and S. Aureus
In a sterile 250 mL erlenmeyer flask, E. coli (ATCC 25922) or S. aureus (ATCC
25923) was grown to the mid‐exponential phase in Tryptic Soy Broth (TSB) (~ 50 mL) at
37 °C with shaking. A 4 mL aliquot of the bacterial suspension was centrifuged for 5 min
at 3000 rpm, the supernatant aspirated and the pellet re‐suspended in Muller Hinton
Broth (MHB) to a final optical density of 0.001 as measured by absorbance at 600nm
(OD600). Next, 90 μL of this culture was added in a sterile 96‐well plate (Cellstar 655180)
and then supplemented with 10 μL of sterile water or two‐fold serial dilutions of the
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designed peptides in water. Amoxicillin (Sigma A8523) and Ampicillin (USB 11259) were
used as positive controls for E. coli and S. aureus, respectively. The plate was then
incubated for 6 h at 37 °C. The OD590 was determined using a microplate reader (TECAN
SpectraFluor Plus). The minimum inhibitory concentration (MIC) was defined as the
lowest concentration of peptide at which no growth was observed. Data was obtained
in duplicates from at least two independent experiments.

1.5.3 Hemolytic Activity of the Designed Peptides
Fresh human red blood cells (hRBCs) were obtained from healthy volunteers.
hRBCs were collected by centrifugation at 2000 rpm for 5 min followed by washing
three times with phosphate buffered saline (PBS, pH 7.4). An 8% suspension (v/v) of
hRBCs was prepared in PBS and 50 μL of the solution was added into a 96‐well plate.
Then 50 μL of a two‐fold serial dilution of the designed peptides and controls in PBS
were added to give a final suspension of 4% (v/v) of hRBCs. The plate was incubated at
37 °C for 1 h to allow for hemolysis. The plate was subsequently centrifuged at 1000
rpm for 5 min at 4° C. Next 75 μL aliquots of the supernatants in each well were
carefully transferred to a new sterile 96‐well plate. Finally the release of hemoglobin
was monitored by measuring the absorbance at OD405 with a micro‐plate reader. As
controls, wells treated with PBS, the known hemolysing agents 0.1 % Triton X‐100 and 5
μM melittin from honey bee venom (Sigma M2272) were used. The hemolysis
percentage was calculated based on the 100% release with 0.1 % Triton X‐100. Data was
obtained in duplicates from two independent experiments.
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1.5.4 Antibacterial Activity of Fl‐PLPRPR‐4 Against Pathogenic Bacteria
The minimum inhibitory concentration (MIC) and the minimum bactericidal
concentration (MBC) of Fl‐PLPRPR‐4 were tested in triplicates against Salmonella
enterica serovar Typhimurium LT2 (ATCC 700720), biofilm forming clinical isolate
Pseudomonas aeruginosa (ATCC 47085), Bacillus anthracis Sterne strain (34F2), Brucella
abortus strain RB51, methicillin‐resistant Staphylococcus aureus (MRSA) ATCC 43300 ,
biofilm forming clinical isolate S. aureus (ATCC 6538) and Listeria monocytogenes F4244
in micro dilution broth method in 96 well‐plate and according to Clinical and Laboratory
Standards Institute (CLSI).59 The bacterial cultures were incubated at 37 °C for 20 h. The
MIC was defined as the lowest concentration of peptide at which no growth was
observed. The MBC of the peptide against each species was defined as the lowest
concentration producing more than 99.9% reduction of the initial inoculum.

1.5.5 Flow Cytometric Analysis of the Designed Peptides
J774A.1 murine macrophage‐like cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% Fetal Bovine Serum (Cambrex
bioscience, WalkersVille, Inc.), 5 mM L‐glutamine, 50 units/mL penicillin and 50 μg/mL
streptomycin (Cellgro Mediatech). Cells were grown at 37 °C in 5% carbon dioxide
atmosphere. 125,000 cells were counted and collected in round bottom tubes (BD
Falcon). Next 400 μL of FBS supplemented DMEM containing the peptides at 25 μM
concentration were added to the tubes and incubated for 1 h at 37 °C. Media containing
no peptide served as control. The samples were centrifuged at 1500 rpm at 4 °C, the
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media was aspirated and re‐suspended in 400 μL fresh DMEM. Finally, the cells were
centrifuged, media aspirated and re‐suspended in 400 μL PBS. Samples were then
analyzed using a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA) equipped
with a 488 nm argon laser. Emissions for fluorescein labeled peptides were collected in
the FL1. Ten thousand cells were counted for each data point.

1.5.6 Leakage of β‐Galactosidase from E.Coli Treated with Fl‐PLPRPR‐4
In a sterile 250 mL erlenmeyer flask E. coli (ATCC 25922) was grown to mid‐
exponential phase (OD590≈0.6) in TSB (~ 50 mL) at 37 °C with shaking. β‐Galactosidase
expression was induced by the addition of freshly prepared isopropyl‐β‐D‐
thiogalactopyranoside (IPTG) (Gold Biotechnology I2481C5) in PBS (1 mM final
concentration). A 4 mL aliquot of the bacterial suspension was centrifuged, washed
twice with fresh TSB and plated into a sterile 96‐well plate (90 μL). Next, 10 μL aliquots
of Fl‐PLPRPR‐4 in sterile water were added to give final concentrations of 4 μM and 20
μM. Bacteria treated with sterile water and melittin (20 μM final concentration) served
as controls. The plate was then incubated for 1 h at 37 °C. At the end of the incubation
period, the plate was centrifuged at 3000 rpm at 4 °C for 10 min. 80 μL of the
supernatant from each well was carefully transferred to a new sterile 96‐well plate. Next,
20 μL of freshly prepared 2‐Nitrophenyl‐ β‐D‐galactopyranoside (ONPG) (Sigma 73660)
in PBS was added to each well (0.8 mg/ml final concentration). The β‐ Galactosidase
activity was monitored at OD405 every five minutes for a period of 1 h using a micro‐
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plate reader. Data was obtained in duplicates from at least two independent
experiments.

1.5.7 Confocal Microscopy: Interaction of Designed Peptides with E. Coli
In a sterile 250 mL erlenmeyer flask E. coli (ATCC 25922) was grown to the mid‐
exponential phase in MHB (~ 50 mL) media at 37 °C. 4 mL of the bacterial suspension
was centrifuged for 5 min at 3000 rpm, the supernatant aspirated and the pellet re‐
suspended in fresh MHB media. 90 μL of the bacterial suspension was added in a sterile
96‐well plate, followed by addition of 10 μL of the peptides Fl‐PLPRPR‐3 and Fl‐PLPRPR‐4
(20 μM final concentration each in sterile water) or sterile water as the control. The
plate was then incubated for 6 h at 37 °C. Aliquots of 10 µ L were taken out at 10 min
and 6 h time points, centrifuged and washed twice with PBS before being fixed in 10%
formalin solution. Hoechst dye was added 10 min prior to imaging at 1 μM final
concentration. Bacterial samples were loaded on a poly‐lysine cover‐slip (BD BioCoat)
and imaged using Nikon A1R Multiphoton inverted Confocal Microscope using a 60X oil
objective. 488 nm and 405nm laser lines for fluorescein and Hoechst excitation were
employed, respectively.

1.5.8 Confocal Microscopy: Uptake of Fl‐PLPRPR‐4 in J774A.1 Cells
Murine J774A.1 macrophage‐like cells were seeded into 4‐well LabTek
chambered slides at a density of 200,000 cells/well in 1 mL of DMEM media and
incubated for 18 h at 37 °C. The media was aspirated, cells washed with 400 μL PBS and
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15 μM Fl‐PLPRPR‐4 in 400 μL DMEM was added. The cells were incubated for 10 min, 30
min and 1 h at 37 °C. Excess peptide was then aspirated and the cells washed with 400
μL PBS thrice. Next, 400 μL of DMEM supplemented with 100 nm MitoTracker
(Invitrogen 7512) was added. The cells were incubated for 30 min at 37 °C. The excess
dye was aspirated, the cells washed with 400 μL PBS twice and 400 μL DMEM added.
Imaging was performed using a Nikon A1R Multiphoton inverted Confocal Microscope
using a 60X oil objective. 488 nm and 561 nm lines for fluorescein and MitoTracker
excitation were employed,respectively.

1.5.9 Macrophage Mitochondrial Depolarization Assay
J774A.1 murine macrophage‐like cells were cultured as described in section X.
125,000 cells were counted and collected in round bottom tubes (BD Falcon). The cells
were treated with either Fl‐PLPRPR‐4 (15 μM in 400 μL DMEM), FCCP (50 μM in 400 μL
DMEM) or DMEM alone (control) and incubated for 1 h at 37 °C. The cells were
centrifuged, media aspirated and washed twice with 400 μL fresh DMEM. The cells were
then incubated with tetramethylrhodamine methyl ester (25 nM in 400 μL DMEM) for
20 minutes at 37 °C. Following incubation, the cells were centrifuged, the media
aspirated and re‐suspended in 400 μL ice‐cold PBS. The analysis was done on a BD ARIA
SORP flow cytometer using the 488 blue laser with a 525/50 detector and a 505 LP
mirror to detect the fluorescein and the 561 yellow‐green laser with a 585/15 filter to
detect the TMRM.
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1.5.10 Stability of Fl‐PLPRPR‐4 to Trypsin Digestion
Stability of Fl‐PLPRPR‐4 to trypsin degradation (EC 3.4.21.4, from bovine pancreas)
was studied over 48 h by analytical RP‐HPLC. A 150 μL mixture consisting of 8.9 μL
trypsin (0.1 mg/ml stock dissolved in 1mM HCl), 70.8 μL of Fl‐PLPRPR‐4 peptide (1.26
mg/ml stock) and 70.3 μL of digestion buffer (50mM Tris, 20mM CaCl2, pH 8.2) was
incubated at 37 °C for 48 h (trypsin to substrate ratio of 1:100).4‐5 Aliquots of 40 μL
were withdrawn at 1h, 24h and 48h time points from the mixture and quenched with 40
μL of 1% TFA solution. The quenched solution was centrifuged at 4 °C and the
supernatant injected on analytical RP‐HPLC. N‐α‐Benzoyl‐L‐arginine ethyl ester
hydrochloride (BAEE) (Alfa Aesar A18181) was used as the standard substrate for trypsin,
which was completely cleaved at the same concentration and conditions. Samples were
run using a gradient of 20‐65% B (A:0.05% TFA/H2O, B:0.05% TFA/CH3CN) for 30 min on
a C18 reverse phased analytical column (5μm, 4mm x 250mm; Phenomenex Luna) with
monitoring at 214nm.

1.5.11 In Vitro Cell Cytotoxicity Studies
An in‐vitro homogeneous, colorimetric method for determining the number of
viable J774A.1 cells (mitochondrial function) using the CellTiter 96® AQueous Non‐
Radioactive Cell Proliferation Assay (Promega) was used to determine cytotoxicity of the
peptide. The solution reagent contains a tetrazolium compound [3‐(4,5‐dimethylthiazol‐
2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfophenyl)‐2H‐tetrazolium, inner salt; MTS]
and an electron coupling reagent (phenazine ethosulfate; PES) and is used to measure
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the succinate dehydrogenase mitochondrial activity as an indicator of cell
viability/proliferation. Briefly, ~2 x 104 J774A.1 cells suspended in 200 µL of DMEM
supplemented with 10% fetal bovine serum (FBS), L‐glutamine, NaHCO3, pyridoxine‐HCl,
and 45,000 mg/L glucose were seeded in 96‐well plates and incubated at 37 °C in a 5%
CO2 atmosphere. The cells were cultured for 24 hours (60% confluency) before the
assays. The J774A.1 cells were further incubated with 15 µM Fl‐PLPRPR‐4 for 9 hours. The
culture media was discarded, and the cells in each well were washed with PBS and 100
µL of cell culture media and 20 µL assay reagent were added. The plates were incubated
for 2 hours at 37 °C in a humidified 5% CO2 atmosphere. The absorbance at 490 nm was
recorded using a 96‐well Elisa plate reader (SoftMax ProInc., USA). Results were
expressed as the percentage mean absorbance by cells upon incubation with peptide
with respect to incubation with control. Statistical analysis: The mean absorbance in the
MTS assay was compared between the groups using the two‐tailed Student t test (P
˂0.05).

1.5.12 Rescue of J774.A1 Cells Infected with Pathogenic Bacteria
J774A.1 murine macrophage‐like cells were seeded at a density of 1 x105 cells per
well in 96‐well plates (Corning Incorporated) 22 h and 26 h before infecting with
Salmonella and Brucella, respectively. The cells were grown in DMEM supplemented
with 10% heat‐inactivated fetal calf serum (FCS, Sigma Chemical Co.) in a humidified 5 %
CO2 atmosphere at 37 °C. The J774A.1 cells were infected with Salmonella for 30 min at
a 1:10 multiplicity of infection (MOI) or Brucella for 1 h at a 1:100 MOI.57 At the end of
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the infection, the cells were washed three times with DMEM medium containing 50
μg/mL gentamicin (Sigma) to kill and wash off non‐phagocytized bacteria. Next, 15 μM
Fl‐PLPRPR‐4 in DMEM (supplemented 10% FBS) was added. The plate was returned to
the incubator for 9 more hours. Finally the infected cells were washed three times and
lysed to collect the intracellular bacteria.57 The colony forming units (CFUs) of
Salmonella and Brucella in the lysates were determined by plating a series of 10‐fold
serial dilutions onto TSA and incubating the plates at 37 °C for 20 h (Salmonella) or 72 h
(Brucella). Experiments were performed in triplicate in two independent experiments.
Statistical analyses were performed using the Student two‐tailed t‐test using microsoft
excel. P values ≤0.05 were considered significant.
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CHAPTER 2. BIVALENT INHIBITORS OF MUTANT PLASMODIUM FALCIPARUM
CHLOROQUINE RESISTANCE TRANSPORTER BASED ON THE AMINOQUINOLINE
ANTIMALARIAL DRUGS

2.1

Introduction

In 2012, the worldwide malarial burden was estimated at approximately 200
million cases and 600,000 fatalities, mostly children under the age of five and pregnant
women.1 There is a striking correlation between malaria and poverty, indicative of the
huge social and economic cost paid by affected regions.2 Malaria is considered the most
lethal parasitic disorder and is counted among the top three infectious diseases
affecting the world today, along with HIV and TB.3 The causative agents of malaria are
protozoan parasites, belonging to the genus Plasmodium that is spread to humans by
the female anopheles mosquito. Among the four species (P. falciparum, P. vivax, P.
ovale and P. malariae) that infect humans, P. falciparum accounts for the highest
prevalence and mortality.4 P. vivax and P. ovale are less lethal, but are capable of hiding
in the liver for prolonged dormant periods resulting in recurring malaria.
The parasite has a complex lifecycle involving two hosts (mosquito and human)
and multiple forms (Figure 2.1A).3,4,5,6 During a blood meal, the infected anopheles
mosquito injects Plasmodium sporozoites into the bloodstream, which travel to their
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Figure 2.1 (A) Various lifecycle stages of the Plamosdium parasite and stage of action of
representative antimalarial drugs.3 Red: RBC stage, brown: liver stage and yellow:
mosquito stage; CQ/Q chloroquine/quinine; PM/SX, pyrimethamine/sulphadoxine;
ATOV atovaquone; ART, artemesinin; PQ, primaquine. (B) Sub‐cellular representation of
the Plasmodium parasite.7 Adapted from Goldberg3 and Biot7 et. al.

first site of action: the liver. Within the hepatocytes, the sporozoites mature into
schizonts, where thousands of merozoites are formed. The hepatocytes are ruptured
and the merozoites enter the bloodstream to invade their next target site: red blood
cells (RBC). Here the merozoites replicate further and eventually rupture the RBC (~48h
post RBC infection) resulting in the characteristic symptoms of malaria such as high
fever and chills. During the blood stage, some merozoites transform into male and
female gametocytes. These are taken up by mosquitoes during a meal. Within the
mosquito gut, the male and female gametocytes mature into gametes and fuse to form
ookinetes. These ookinetes migrate to the gut walls and form oocysts. Meiotic division
occurs to produce sporozoites that travel to the mosquito’s salivary glands, thus
completing the cycle. An initial infection of ten parasites from the mosquito can expand
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a thousand‐fold in the liver and further into many trillions in the blood stage. Physical
manifestations of malaria include delirium, metabolic acidosis, cerebral malaria, multi‐
organ system failure and eventually death.
Most antimalarial drugs target the parasite at the blood stage (Figure 2.1A). This
is due to the ease of culturing P. falciparum in RBC supplemented growth medium and
the ability to monitor symptoms characteristic of this stage in patients.8 These include
the anti‐folates, aminoquinolines and artemisinin derivatives.3 The aminoquinolines,
such as quinine (Q) and chloroquine (CQ), localize to the digestive vacuole (DV) (Figure
2.1B) and inhibit heme polymerization. The antifolate drugs, such as pyrimethamine and
sulphadoxine, target enzymes in the parasite’s cytosol, while artemisinin derivatives
target both the DV and cytosolic enzymes (Figure 2.1B). Besides the blood stage,
atovaquone and primaquine target the elusive liver stage.3,8 Atovaquone attacks the
parasite’s mitochondria. Primaquine is the only drug capable of clearing liver stage
dormant hypnozoites and is almost exclusively used for this purpose. Currently,
artemisinin is administered in combination with antimalarials from other classes such as
mefloquine and lumefantrine. These artemisinin combination therapies (ACT) are the
cornerstone of antimalarial chemotherapy against resistant malaria,4 although some
recent cases of resistance have been reported.9
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2.1.1 The Aminoquinoline Class of Antimalarial Drugs
The first member of the aminoquinoline family, quinine (Q), was isolated in 1820
from the bark of the cinchona tree, which is indigenous to certain regions of South
America.10 The success of Q and shortages during World War II lead to the development
of synthetic variants such as chloroquine (CQ), hydroxychloroquine (HCQ), amodiaquine
(AQ), primaquine (PQ) and mefloquine (MQ) (Figure 2.2). Q, MQ, AQ and CQ are
classified as 4‐aminoqionolines and PQ as an 8‐aminoquinoline, referring to the position
of the side chain connected to the quinoline ring. These drugs proved to be potent, long
lasting, safe and cheap, making them the mainstay of antimalarial therapy. A 3‐day
course of CQ costs less than $0.2 compared to $1‐2 for AT based drugs, an enormous
price difference in the developing world.11 CQ is cheaply synthesized compared to AT
which is an isolated natural product. AT, ACTs and anti‐folates therapies suffer from
rapid clearance in the body while the aminoquinolines are relatively long lasting. Further,
resistance to anti‐folates arose within just one year of usage, while it took centuries and
decades before Q and CQ were challenged, respectively.12 The aminoquinoline drugs
also have an antipyretic effect which provides relief from the severe fever condition that
is characteristic of malaria. For all of the above mentioned reasons, it is estimated that
the quinoline antimalarials have saved more human lives than any other class of drugs
in history.12,13
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Figure 2.2 Chemical structures of representative aminoquinoline antimalarials.

2.1.2 Mechanism of Action of Aminoquinoline Drugs
During the blood stage, the parasites infecting the RBC break down hemoglobin
(Hb).7,14 This is done to sequester amino acid nutrients from the globin component of Hb
and to maintain osmotic stability to prevent premature RBC lysis. Since all of the
enzymes needed for Hb digestion are optimal at pH <5, the process is carried out in a
lysosome‐type compartment called the digestive vacuole (DV). Hb digestion produces
~20 mM of toxic Fe2+‐heme which can cause metabolic disruption by peroxidation of
membranes and inhibition of enzymes by generating reactive oxygenated species
(ROS).To avoid this, the Fe2+ is oxidized forming Fe3+‐heme (also called
ferriprotoporphyrin ,FPIX). These molecules dimerize through iron‐carboxylate bonds via
the propionic acid side chain of each porphyrin and form chains attached by hydrogen
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bonds (β‐hematin) as shown in Figure 2.3A. This process results in bio‐mineralization of
heme into biologically innocuous and chemically inert hemozoin crystals.

Figure 2.3 (A) Molecular structure of heme and packing into β‐hematin.14 Binding of (B)
CQ and (C) Q to β‐hematin. Adapted from Weissbuch et. al.14

These insoluble hemozoin crystals are easily visualized by microscopy as malarial
pigments and are usually of the order of 100‐200nm in length, containing about 80000
heme molecules.14 The aminoquinoline drugs are weak monoprotic (Q, MQ, PQ) and
diprotic bases (CQ, HCQ, AQ).10 At physiological pH, they readily cross the RBC and
Plasmodium membranes as neutral species by passive diffusion. They move down the
pH gradient inside the parasite’s DV (pH = 5‐5.2) where they are readily protonated and
remain trapped. This pH trapping mechanism results in nanomolar concentration of CQ
in plasma to result in millimolar levels in the DV. Greater than 85% of CQ inside RBC
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infected with Plasmodium exists as CQH22+ within the DV. Here the aminoquinolines
block the hemozoin chain growth by blocking the growing face of the crystals, hence
preventing heme detoxification and resulting in ROS mediated toxicity, cell lysis and
parasite cell auto‐digestion. The mechanism of binding of the aminoquinoline drugs with
heme species varies and is still not completely understood. The principal interactions
are the pi‐pi stacking of the quinoline and porphyrin rings as well as the electrostatic
interactions between the cationic drug and carboxylate groups of the heme (Figure
2.3B‐C).

2.1.3 Resistance to Aminoquinoline Drugs
The success of aminoquinoline antimalarials (CQ in particular) and the discovery
of the insecticide DTT, lead to efforts to eradicate malaria in the 1950s. This program
was later discontinued, but had resulted in the uncontrolled and excessive usage of
CQ.15 Subsequently, CQ resistant (CQR) strains emerged independently from at least six
different parts of the world.16 Specifically CQR P. falciparum was isolated from regions
as far as Colombia and Cambodia in the late 1950s. The region with the highest malaria
related mortality, Africa, saw the emergence of CQR P. falciparum in the 1970s. Today,
CQ is ineffective in most endemic regions and is no longer officially used for treating P.
falciparum. HCQ is very closely related to CQ, sharing similar mechanism of action,
physiochemical and metabolic properties.17 Early studies with South American patients
have demonstrated cross resistance between CQ and HCQ.18 CQR P. falciparum strains
are also resistant to Q, although the magnitude varies with geographical origin.12, 19 In
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contrast strains resistant to MQ were observed to display an inverse relationship with
CQ sensitivity.20 PQ is the only drug to date capable of clearing latent P. vivax
hypnozoites and its combination with CQ was the frontline therapy for P. vivax
treatment. However CQR P. vivax first emerged in Papa New Guinea and has now been
isolated across the world.21,22 The definitions of CQR phenotype can vary but the general
consensus for defining CQR is based on two key characteristics (i) a 4‐10 fold drop of CQ
accumulation in the DV relative to the respective CQS strain and (ii) chemo‐sensitization
or resistance‐reversal of CQ by verapamil (VP).15,12

2.1.4 Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT).
Pioneering work by Fidock et. al. using a genetic cross of a CQ sensitive (CQS)
strain (HB3) and a CQR strain (Dd2) identified the “chloroquine resistance transporter”
gene, as the primary determinant of the CQR phenotype.23 This gene encodes a 424
amino acids residue protein with ten putative transmembrane helices called the
Plasmodium falciparum chloroquine resistance transporter (PfCRT). PfCRT is localized at
the DV membrane with the N and C termini exposed to the parasitic cytosol (Figure
2.4A). In silico analysis predicted PfCRT to be part of the drug/metabolite transporter
(DMT) superfamily.25,26 PfCRT knock‐out parasite lines were unviable, suggesting that
PfCRT is essential to the parasite’s viability.27,28 The natural substrates of PfCRT are
believed to be peptides and/or amino acids produced as by‐products of Hb degradation
in the DV.24
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Comparison of the Dd2 (PfCRTCQR) and HB3 (PfCRTCQS) alleles, identified eight
distinct point mutations. PfCRT is a highly polymorphic protein that contains anywhere
from 4 to 10 mutations, with up to 32 variant residues identified to date. However, in
virtually all the CQR strains, the lysine at position 76 was mutated to a threonine.12,16,24

Figure 2.4 (A) Topological model of PfCRT.24 Polymorphic residues are highlighted by
black arrows. The conserved K76T mutation found in PfCRTCQR is shown in red and
phosphorylation sites are shown in green. (B) A model of PfCRT mechanism of action.25
In CQS strains, PfCRT is proposed to function as a dimer, to export natural substrates
such as amino acids (AA) and/or peptides generated as byproduct of Hb degradation in
the DV. The K76T mutation in CQR strains results in removal of the positive charge and
consequent access to protonated CQ species. Adapted from Sanchez25 et. al. and
Martin24 et. al.

Reversing the K76T mutation in CQR strains restore CQ sensitivity. A T76K
mutation alone in CQS strains does not impart the CQR phenotype, stressing the
importance of the accompanying mutations. Thus, K76T is a necessary but not a
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sufficient criterion for rendering CQ resistance. The role of the mutations accompanying
the conserved K76T mutation are thought to be compensatory, in order to maintain the
physiological role of PfCRT, in addition to transporting CQ. The universal selection of
K76T in CQR strains has allowed this mutation to be a highly sensitive marker for CQ
treatment failure.
The mechanism by which PfCRT reduces drug accumulation has been debated.16
It is currently accepted that as a result of the loss of the lysine’s positive charge,
PfCRTCQR is able to interact and transport cationic CQH+/CQH2+ species down the
electrochemical gradient out of the DV (Figure 2.4B). The reduction in CQ bioavailability
at its site of action (DV) results in the observed increase in IC50 values. Many studies
have indicated the ability of PfCRTCQR to transport CQ,29,30,31 but the most direct
demonstration has been achieved by the Martin lab, who successfully expressed PfCRT
in the Xenopus laevis oocyte (X. oocyte) plasma membrane.32 PfCRTCQR was shown to
transport [3H]‐CQ in a verapamil sensitive manner while PfCRTCQS did not. The transport
was observed to be temperature dependent, saturable and inhibited by a range of drugs.
Aminoquinolines such as Q, MQ, PQ, AQ and halofantrine were observed to compete
with CQ for transport by PfCRTCQR. These properties strengthened the argument of
PfCRT being a transporter and not a voltage gated channel as was previously
proposed.33 While some concerns regarding variations in protein levels in different X.
oocyte membranes and the effect of deletions in the expressed PfCRT have been
raised,34 the oocyte system is the most widely accepted and utilized model for studying
PfCRTCQR mediated transport.
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PfCRTCQR is also the primary determinant of Q resistance. Sanchez et. al. showed
the reduced accumulation of [3H]‐Quinine in PfCRTCQR expressing strains relative to the
CQS strains.29 Quinine efflux was also demonstrated by H+ leakage from the DV of CQR P.
falciparum strains.35 Further, multiple studies in vitro have shown HCQ to be
substantially less active in CQR strains carrying PfCRTCQR.17,36 Recent genomic profiling
experiments have directly implicated PfCRT mutations to be responsible for differential
HCQ activity.37 PQ resistance has not been linked to any protein yet while MQ resistance
has been ascribed to the Plasmodium falciparum multidrug resistance‐1 transporter
(PfMDR1).38,39

2.1.5 PfCRTCQR Inhibitors
To overcome PfCRTCQR mediated drug resistance, co‐administration of CQ with
resistance reversal agents (RRA) was proposed. RRA are molecules that chemosensitize
CQR strains to CQ but have no antiplasmodal activity themselves.19,40,41 Since the
discovery of the first RRA, verapamil (VA) in 1987, a plethora of structurally and
functionally unrelated RRA have been reported.40 QSAR studies have proposed two
hydrophobic aromatic rings and a cationic charge at the pH of the DV as the basic
features of an RRA.42 Most RRA agents act by directly competing with CQ for binding
with PfCRTCQR.43,35 However the application of an RRA/CQ co‐administration strategy has
been limited by poor potency, drug‐drug interactions and high toxicity. For instance
efforts to develop VA were stalled due to its high binding to serum proteins (up to 90%),
such as albumin and α1‐acid glycoprotein.44,45 The anti‐histamine drug chlorpheniramine
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was identified as an effective RRA with low serum binding.46 Small clinical trials using CQ
with chlorpheniramine in children showed 70% parasite clearance in 4 days compared
to only 30% in CQ‐only groups.47,48 Chlorpheniramine is the only RRA to be tested

Figure 2.5 Chemical structures of 2nd generation RRA with the heme binding
(antimalarial) and resistance reversing moieties highlighted in blue and red respectively.

clinically to date. Further, the PQ/CQ combination used for P. vivax treatment has been
found to be active against CQR P. falciparum.49 PQ thus acts as a RRA to sensitizie the
parasite to CQ. It must be noted, however, that this effect has not been shown in vivo or
clinical trials.
The next generation of RRA covalently combined both the antimalarial and CQR‐
reversal moieties in the same molecule (Figure 2.5). An early demonstration of this
concept was realized in “reversed chloroquine” (Figure 2.5).50 This molecule combined
the RRA imipramine and the aminoquionline core of CQ. It cleared both CQS (D6) and
CQR (Dd2) P. falciparum strains as well as parasitemia in a P. chabaudi mice model.
However, direct studies of reversed chloroquine interaction with PfCRT were not done.
Further, Risco et. al. developed an agent named T3.5 that incorporated an acridone
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moiety to block heme polymerization and tertiary amine for resistance reversal (Figure
2.5).51 Studies of T3.5 with various PfCRTCQR expressing mutant lines showed its ability to
chemosensitize resistant strains. T3.5 cleared P. yoelli infection in a mice model by itself
and in synergy with Q. Two recent examples include the dibemethin modified quinolines
(Figure 2.5) and the HIV protease inhibitor saquinavir.52,53 In these examples direct
interaction with PfCRTCQR was unequivocally proven using the Martin lab’s oocyte model.
The dimeric antimalarial drug piperaquine contains two 7‐chloroquinoline
moieties linked by a polyamine tether. Piperaquine does not show cross resistance with
CQ in field isolates and is unaffected by PfCRT polymorphisms. It also does not inhibit
[3H]CQ transport by PfCRTCQR in the oocyte model. Synthetic bisquinoline agents have
been developed and shown to be active against drug resistant P. falciparum strains.54,55
56,57

However, development of a majority of these agents has been discontinued due to

high toxicity in animal models. A brief survey of bisquinoline antimalarials revealed a
preference for longer tether lengths (6 or more atoms) against CQR P. falciparum strains
known to express PfCRTCQR. It must be noted that no direct studies of these molecules
with PfCRTCQR have been performed.

2.2

Results and Discussion

2.2.1 Design of Bivalent Aminoquinoline Inhibitors of PfCRTCQR
The drug‐metabolite transporters (DMT) superfamily, to which PfCRT belongs,
contain a conserved XaaaaaaX sequence (X=G, S, A, T and a=hydrophobic residue) in the
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transmembrane domains (TMD).25,58 This motif facilitates packing of TMD resulting in
oligomer formation.59

For instance DMT proteins such as the nucleotide‐sugar

transporter and triose‐phosphate transporter are known to form homodimers.
Mutations in this packing motif result in loss of structure/function.60,61 Thus it has been
proposed by Martin et. al. that PfCRT similarly functions as a homodimer to transport its
substrates (Figure 2.4B).25
We envisioned bivalent antimalarial agents based on the PfCRTCQR drug
substrates as potential inhibitors of PfCRTCQR. When linked by the appropriate tether,
each drug, within the bivalent agent could simultaneously occupy the two adjacent
PfCRTCQR proteins, respectively (Figure 2.6). This would result in an increased binding
affinity and lower off‐rates resulting in the inhibition of PfCRTCQR mediated drug
transport.
Further, we hypothesized that the bivalent inhibitors would accumulate in the
DV and antagonize the detoxification of heme. Thus, these molecules could elicit
antimalarial activity in their own right. Another mode of antimalarial action could be the
inhibition of the physiological functions of PfCRTCQR. By blocking the transport of the
natural substrates of this essential protein the parasite’s viability can be compromised.
Thus the dimers could be used to overcome CQR P. falciparum strains by themselves or
in combination/synergy with other antimalarials drugs as an RRA. The dimers would also
serve as mechanistic probes to explore the binding region of this complex
transmembrane protein. Variations in the tether linkage, composition and length could
be used as modules to fine tune activity. Cost is a critical parameter when designing

51
antimalarial agents. These dimers can be generated by facile single step synthesis from
cheap and readily available starting materials. While the dimers will have to be tested
for toxicity as novel entities, they would potentially be benign, having been derived

Figure 2.6 (A) Schematic representation of RBC infected by P. falciparum (CQR) where
aminoquinolines drugs, such as Q, are not sequestered in the DV due to PfCRTCQR
mediated transport, allowing the propagation of hemozoin crystals. (B) Quinine dimers
inhibits PfCRTCQR by potentially simultaneously occupying the binding site in each half of
the dimer. Consequently Q‐Q accumulates in the DV, binds to heme and antagonizes
hemozoin bio‐crystallization.

from FDA approved drugs. We selected the PfCRTCQR aminoquinoline substrates HCQ
and Q to test the bivalent inhibitor paradigm. Dimers of PQ and MQ were also explored
in an effort to identify molecules with PfCRTCQR inhibition.
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2.2.2 Synthesis of Quinine Dimers
Initial investigations focused on dimers based on Q (Scheme 2.1). The secondary
alcohol moiety of quinine was used as a handle for functionalization. Taking note of the
ideal tether lengths identified in previously reported bisquinoline agents, we chose a

Scheme 2.1 Synthesis of quinine dimers Q2 and Q2Q3ck.

tether length of eight atoms. To test the effect of flexibility, a dimer with an all
methylene tether (Q2) and another centered with a rigid triazole ring (Q2Q3ck) were
synthesized (Scheme 2.1). The Q2 dimer was synthesized by EDC coupling as reported
earlier.62 The synthesis of Q2Q3ck dimer was carried out by first synthesizing the
respective azide (Q3Z) and alkyne (Q2A) modified quinine monomers by EDC coupling.
Q3Z and Q2A were subject to click chemistry conditions to form the Q2Q3ck dimer (see
Chapter 3 for details).63 Dimers were purified to homogeneity by RP‐HPLC, characterized
by 1H‐ and 13C‐NMR, ESI mass spectrometry and analytical RP‐HPLC.
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2.2.3 Inhibition of PfCRTCQR by Quinine Dimers
The ability of Q2 and Q2Q3ck to inhibit [3H]‐CQ transport in the X. oocyte
model system was tested in collaboration with Dr. Rowena Martin at the Australian
National University. A preliminary screen of the dimers at 100 µM concentration
revealed a dramatic reduction in [3H]‐CQ accumulation relative to the monomer.64 The

Figure 2.7 (A) Inhibition of PfCRTCQR mediated [3H]‐CQ transport in X. oocytes by quinine
dimers and controls at 100 µM concentration, unless otherwise mentioned (B) IC50
values for Q2 and controls for inhibition of PfCRTCQR mediated [3H]‐CQ transport in X.
oocytes (C) Antiplasmodal activity against field derived drug sensitive (HB3) and
resistant (Dd2, FCB, P31) strains of P. falciparum (D) Structure of Q2C.

reduction levels for both dimers were comparable, revealing the tolerance of PfCRTCQR
for a triazole ring in the tether. Considering the need for cost effectiveness of
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antimalarial agents, we focused on Q2 for further studies, since it can be synthesized in
one step, as compared to the three steps for Q2Q3ck. The activity of Q2 against
PfCRTCQR was found to be concentration dependent and an IC50 of 5.3 µM was obtained.
These data demonstrate an approximately 10‐fold improvement of Q2 over the
monomeric Q (Figure 2.7A). Further, Q2 was about 6‐fold more active than VA, long
considered the gold standard RRA. Q2 is one of the most potent PfCRTCQR inhibitors
tested in the X. oocyte model to date.

2.2.4 Antiplasmodal Activity of Q2 in vitro
The efficacy of Q2 against field derived CQS (HB3) and CQR (Dd2, FCB, P31) P.
falciparum strains were measured using the [3H]‐hypoxanthine assay. This assay, carried
out, in collaboration with Dr. Michael Ferdig at University of Notre Dame, measures the
incorporation of [3H]‐hypoxanthine within the parasites’ nucleic acid machinery as a
read out of parasite viability. The results demonstrated the expected trend for Q being
less active in CQR strains than the CQS strain, with a maximum difference of 5‐fold
(P31/HB3) (Figure 2.7B). In contrast, Q2 was much more effective in the CQR lines than
the CQS, with a maximum difference of 5.6‐fold (HB3/FCB).This shows that (i) Q2 is a
potent antiplasmodal agent against field derived CQR strains (ii) Q2 is more active
against CQR than CQS strains. The latter could be a result of the inhibition of PfCRTCQR
physiological functions, making Q2 more lethal in the CQR strains. Such a trend has
indeed been observed in RRA as well.65,66
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2.2.5 Q2 Antimalarial Activity in vivo
The antimalarial action of Q2 was explored in vivo using a mice model harboring
the CQS P. berghei strain.67 The Peter’s 4‐day test was carried out in collaboration with
Dr. David Fidock at Columbia University using a daily dose of 120 mg/kg for Q and Q2. At
the end of the experiment the parasitemia in mice blood was determined by flow
cytometry. Q2 successfully cleared the infection with an ED50 of 38.2 mg/kg comparable
to Q (ED50 48.7 mg/kg). The mice lost only about 5% body weight and were deemed
normal. In contrast, another promising Q dimer Q2C was found to have in vivo toxicity
(Figure 2.7D).64 A pivotal difference between this molecule and Q2 is the latter’s ability
to revert to monomeric Q in vivo for downstream metabolism. It is possible that the
improper clearance and toxic build‐up of Q2C and/or Q2C‐metabolites are responsible
for the observed deleterious effects on mice. Thus while Q2 antimalarial efficacy in vivo
could have been reduced from its potential breakdown to Q, it could also be the reason
for its non‐toxicity and efficacy in animal models.

2.2.6 Synthesis of Hydroxychloroquine Dimers
We wished to make CQ based dimers with the following conditions: (i) cheap and
biologically benign starting materials (ii) maintain the core CQ structure and (iii) a single
step synthesis. Dimerization of CQ itself would require functionalization of the
secondary aniline moiety. This functionality is somewhat unreactive and will also result
in the modification of the core CQ structure. Bisquinolines based on the CQ
pharmacophore have been synthesized by other labs, resulting in extensive
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modifications of the quinoline ring or the exocyclic side chain,54 requiring multistep
synthesis. These compounds were discontinued due to low potency and undesirable
toxicity profiles. HCQ is a readily available FDA approved antimalarial drug. HCQ differs
from CQ only in the presence of the primary alcohol group. HCQ has a similar
mechanism of action, physiochemical and metabolic properties as CQ.17 HCQ is also a

Scheme 2.2 Synthesis of HCQ ester (HCQ‐Cn‐E) and carbamate (HCQ‐Cn‐C) dimers.

known PfCRTCQR substrate. The alcohol moiety of HCQ can be used as a convenient
handle for synthesizing HCQ dimers (Scheme 2.2). The chloroquine structure remains
unmodified in these dimers. The secondary alcohol of Q has been implicated in some
reports to be vital to its activity in heme binding.68 Thus functionalization of this
secondary alcohol of Q could compromise its antiplasmodal activity. In contrast the HCQ
dimers have an unmodified CQ core and may prove more potent antimalarial agents.
Similar to Q2, the first dimer in the HCQ series was HCQ‐C8‐E (Scheme 2.2). This
dimer was synthesized by PyBOP coupling methods. A library of HCQ ester dimers, HCQ‐
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Cn‐E, with varying methylene units was constructed to investigate the effect of length
on activity. To explore the effect the nature of the linkage on inhibition by the nature of
linkage we also made carbamate linked HCQ dimers, HCQ‐Cn‐C. CDI chemistry was
utilized to make three dimers with varying tether length (Scheme 2.2). Dimers were
purified to homogeneity by RP‐HPLC, characterized by ESI or MALDI‐TOF mass

Figure 2.8 Fragmentation sites (red dotted line) of HCQ, PQ and MQ dimers obtained
from ESI and MALDI‐TOF mass spectrometry.

spectrometry and analytical RP‐HPLC. The mass spectra for both HCQ‐Cn‐E and HCQ‐Cn‐
C dimers showed signature fragmentation patterns69 which confirmed the site of
functionalization as the primary alcohol (Figure 2.8).
The carbamate linked quinine dimer (Q2C) was seen to be resistant to
degradation in both blood serum and esterases.64 We investigated whether the HCQ‐Cn‐
C dimers would be similarly stable. Preliminary stability studies in both human plasma
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and pig liver esterases were carried out using HCQ‐C5‐C as a representative dimer. The
results in plasma and porcine esterases showed the HCQ‐C5‐C dimer to be unmodified
under both conditions at 70 h and 33 h, respectively (Table 2.1).

Table 2.1. Stability of HCQ‐C5‐C dimer in human plasma and pig liver esterase.
Dimer

t1/2 (plasma)

t1/2 (esterase)

HCQ‐C5‐C

>70 h

>33 h

Q2C

>90 h64

>90 h64

2.2.7 Synthesis of Primaquine Dimers
PQ dimers were synthesized via amide bonds linked at the primary amine
moiety with flexible dicarboxylic acid tethers (Scheme 2.3). This design results in the loss
of the primary cationic center in the PQ dimers and it remained to be seen whether the
presence of the charge is vital to PQ’s interaction with PfCRTCQR.

Scheme 2.3 Synthesis of primaquine amide dimers PQ‐Cn.
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HATU coupling conditions were used to synthesize a library of amide linked PQ dimers
(PQ‐Cn) as shown in Scheme 2.3. Functionalization under similar coupling conditions is
known to occur at the more reactive primary amine selectively.70 The tether length was
varied from two to twelve methylene units to identify the optimal distance between the
putative PfCRTCQR binding sites. Dimers were purified to homogeneity by RP‐HPLC,
characterized by 1H‐NMR and analytical RP‐HPLC. The mass spectra for PQ‐Cn dimers
showed signature fragmentation patterns70 (Figure 2.8) thus confirming the primary
amine moiety to be the site of linkage.

2.2.8 Synthesis of Mefloquine Dimers
MQ has two nucleophilic centers, the piperidine amine and the secondary
alcohol. The higher nucleophilic character of the piperidine amine allows for its
functionalization directly without the need for protecting the alcohol (MQ‐Cn‐A).71
HATU coupling was utilized to make amide linked dimers of MQ (Scheme 2.4). Tethers
were composed of 4, 6 and 8 methylene units respectively. However the use of amino
group to link the dimers results in the loss of a cationic center. RRA have been shown to
possess a charged nitrogen atom. In an effort to preserve the cationic center in the
dimer, we also synthesized a tertiary amine based dimer, MQ‐C5‐Am. Reductive
amination using sodium cyanoborohydride and glutraldehyde was carried out to obtain
the MQ‐C5‐Am (Scheme 2.4).72 The dimers were purified to homogeneity by RP‐HPLC,
characterized by ESI mass spectrometry and analytical RP‐HPLC. The mass spectra for
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both dimer types displayed the signature fragmentation pattern for MQ73 (Figure 2.8)
confirming the piperidine amine to be the site of functionalization.

Scheme 2.4 Synthesis of mefloquine amide (MQ‐Cn‐A), amine (MQ‐C5‐Am) and ester
linked (MQ‐C10‐E) dimers.

Finally a representative ester linked dimer of mefloquine (MQ‐C10‐E) was
synthesized by first protecting the piperidine amine with a Boc group.74 Next the Boc‐
mefloquine was subject to EDC coupling with a flexible dicarboxylic acid to obtain the
Boc protected MQ‐C10‐E dimer (Scheme 2.4). The Boc groups were lastly deprotected
under standard TFA conditions to obtain the MQ‐C10‐E dimer. The EDC coupling
reaction was observed only to proceed when stoichiometric amounts of DMAP were
used. The mass spectral fragmentation was consistent with an ester linked mefloquine
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dimer (Figure 2.8). However, upon storage these compounds showed an impurity,
possibly arising from the rearrangement of the ester to the piperidine‐linked amide.
Such rearrangements have been reported in literature for MQ esters.71 Thus these
dimers were not pursued for in vitro assays.

2.2.9 PfCRTCQR Inhibition by HCQ, PQ and MQ Dimers
The HCQ, MQ and PQ dimers were tested for PFCRTCQR inhibition in the X. oocyte
model by Dr. Rowena Martin at the Australian National University. [3H]CQ uptake into
oocytes expressing Dd2 PfCRTCQR or D10 PfCRTCQS was studied in the presence of the
dimers and relevant controls. The wild‐type PfCRTCQS does not transport CQ and hence
minimal accumulation of [3H]‐CQ, by virtue of passive diffusion, is expected. In contrast
the oocytes expressing PfCRTCQR would accumulate much higher levels of [3H]CQ.
Inhibitors of PfCRTCQR would have no effect on [3H]‐CQ accumulation in the PfCRTCQS
expressing oocytes while they would cause a substantial reduction in the PfCRTCQR
oocytes. An initial screen of representative dimers, at 100 µM concentration from each
drug class revealed the HCQ‐C8‐E dimer to be a potent inhibitor (Figure 2.9A). The
percent inhibition was about 1.6‐fold higher with HCQ‐C8‐E than VA and 200 µM CQ. In
contrast MQ‐C8‐A, MQ‐C5‐Am and PQ‐C8 dimers did not elicit any inhibition.
Further analysis of the small library of HCQ‐Cn‐E dimers revealed a striking
dependence of tether length on activity (Figure 2.9B). While the C2 and C4 tethered
dimers caused modest inhibition of PfCRTCQR at 100 µM concentration (~ 50%), the C8,
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C10 and C12 blocked [3H]‐CQ transport by ≥ 90%. A similar trend was also observed for
the carbamate dimers where the HCQ‐C8‐C dimer displayed strong inhibition of

Figure 2.9 (A) Effect of representative PQ, HCQ ,MQ dimers (100 µM) and (B) various
HCQ and PQ tethered dimers (100 µM) on PfCRTCQR mediated transport of [3H]‐CQ in X.
oocyte. PfCRTCQR transports and accumulates a greater amount of [3H]‐CQ into the
oocytes relative to the wild‐type PfCRTCQS.

transport unlike the C2 and C5 tethers. A threshold tether length might be needed to
bridge the distance between the two binding sites in the putative dimeric PfCRTCQR
proteins, resulting in bivalent inhibition. Tethers longer than the threshold value could
possibly be accommodated in the interim space, given the flexibility of the methylene
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chain. However, shorter tethers would not be able to effectively position the drugs
simultaneously in the two binding sites resulting in inactivity.
Similar to PQ‐C8, the rest of the PQ‐Cn dimers also showed minimal (about 20‐
30% reduction in [3H]‐CQ uptake) activity (Figure 2.9B). In fact the PQ monomer resulted
in slightly higher inhibition than the dimers (about 50% reduction in [3H]‐CQ uptake). It
is possible that amine moieties of PQ and MQ that were modified for dimer synthesis
were vital for the binding of PfCRTCQR, thereby resulting in their observed inactivity.

2.3

Conclusion

We have successfully exploited bivalency to overcome PfCRTCQR mediated
transport of two landmark aminoquionline drugs, HCQ and Q. The dimers generated
from these drugs are the most potent inhibitors of PfCRTCQR to date in the X. oocyte
model. The dimers were synthesized in one step from inexpensive and benign
precursors. Q2 showed potent antiplasmodal activity in CQR strains of P. falciparum and
cleared parasitemia in mice with no toxic side effects. This dimer can thus be used as an
antimalarial in its own right or in combination with other therapies limited by PfCRTCQR.
All the HCQ‐Cn‐E and HCQ‐Cn‐C dimers are broadly active against PfCRTCQR. The potency
improves substantially as the tether length is increased to 8 or higher number of atoms.
These dimers can be synthesized in one step from cheaply available HCQ. The PQ‐Cn
dimers were inactive across variations of tether length. Similarly the MQ dimers showed
no activity irrespective of tether length and type of linkage.
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2.4

Future Directions

The tether length dependence on PfCRTCQR inhibitory activity could be a feature of
the Q dimers as well. Q dimers with shorter tethers (four and two methylene) can thus
be explored. So far only Q2 and Q2C have been tested in vivo. To balance the
antimalarial potency and non‐toxic features of these respective dimers, hindered ester
dimer of Q could be studied. Such dimers would potentially be more resistant to
hydrolysis in vivo resulting in greater potency that Q2, but also eventually breakdown to
monomeric Q for metabolism and clearance. Stability of the hindered dimers could be
studied in vitro in liver microsomes to understand metabolism relative to Q2 and Q2C.
Concentration dependent inhibition studies (IC50 values) have to be generated for
the HCQ‐Cn‐E dimers. The tether length dependence could be studied in more detail by
testing the odd numbered tethered HCQ‐Cn‐E dimers. It would also be interesting to
note the maximum tether length that is tolerated by PfCRTCQR. Further, a more rigid
tether, such as one containing aromatic rings, may provide insights into the need for
flexibility. Polarity in the tether can be introduced by using PEG based linkers as well.
Finally selected HCQ‐Cn‐E dimers will need to be tested against field‐isolated CQS and
CQR P. falciparum strains, as well as in mice models.
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2.5

Material and Methods

2.5.1 Materials
Quinine was purchased from TCI America (Portland, OR). Mefloquine was
purchased

from

Amplachem

(Carmel,

IN).

1‐ethyl‐3‐(3‐

dimethylaminopropyl)carbodiimide (EDC) was purchased from AK Scientific (Union City,
CA). Hydroxychloroquine was purchased from Acros Organics. Primaquine was
purchased from Sigma Aldrich (St. Louis, MO). 4‐dimethylaminopyridine (DMAP) was
obtained

from

GenScript

(Piscataway,

NJ).

Benzotriazol‐1‐yl‐

oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) was obtained from
Genscript

(Piscataway,

NJ).

1,1'‐Carbonyldiimidazole

(CDI)

and

sodium

cyanoborohydride were purchased from TCI America (Portland, OR). Glutaraldehyde
was purchased from Alfa Aesar (Ward Hill, MA). All other chemicals were purchased
from Sigma‐Aldrich and used without purification.

2.5.2 Synthesis of Q2
Q2 was synthesized as reported earlier with slight modifications.75 To a solution
of the commercially available sebacic acid (0.25 g, 1.2 mmol) in dry dichloromethane (7
mL) was added EDC (0.94 g, 4.9 mmol), DMAP (0.075 g, 0.6 mmol), and DIEA (2.1 mL,
12.3 mmol) at 0 ºC under nitrogen atmosphere. After 20 min, quinine (1.2 g, 3.7 mmol)
was added. The reaction mixture was stirred for 4 h at 0 ºC and overnight at room
temperature (rt). The solvent was removed under vacuum and the residue was worked
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up using ethyl acetate and aqueous saturated sodium bicarbonate solution. The organic
layers were combined, dried with magnesium sulfate and filtered. The filtrate was
concentrated under vacuum and the crude mixture was purified by flash column
chromatography using 3% methanol‐DCM solvent system. Relevant fractions were
combined and concentrated to obtain Q2 in 72% yield (705 mg). For in vivo applications
the Q2 salt was formed by dissolving Q2 (405 mg) in 12% concentrated sulfuric acid in
THF (0.1 ml concentrated sulfuric acid and 0.7 ml THF) solution at 0 ⁰C. The mixture was
stirred for 15 min at 0 ºC, after which the solvent was removed under vacuum. The
crude was dissolved in minimal amount of methanol (~1 ml), followed by the dropwise
addition of excess diethyl ether until no more white precipitate crashed out of solution.
The co‐solvents were removed under vacuum to yield Q2 sulfate salt as a white
crystalline solid (560 mg).Characterization was done by MALDI‐TOF mass spectrometry :
Q2 [M+H]+: 815.47 (calculated) [M+H]+ 815.94 (observed). Purity (~99%) was
determined by analytical HPLC with a retention time of 13.05 min using a C5 analytical
column (Phenomenex) with an eluent consisting of solvent A (acetonitrile and 0.05%
trifluoroacetic acid (TFA)) and solvent B (water and 0.05 % TFA) with gradient of 20–75%
solvent A, a flow rate of 1.20 mL/min with UV detection at 254 nm.
1

H NMR (300 MHz, CDCl3) δ 8.71 (d, J=4.8 Hz, 2H), 7.99 (d, J=9.3 Hz, 2H), 7.43‐7.32 (m,

6H), 6.48‐6.46 (m, 2H), 5.88‐5.79 (m, 2H), 5.02‐4.96 (m, 4H), 3.93 (s, 6H), 3.37‐3.34 (m,
2H), 3.06‐2.98 (m, 4H). 2.66‐2.57 (m, 4H), 2.35‐2.26 (m, 6H), 1.83 (m, 4H), 1.7‐1.54 (m,
10H), 1.17 (m, 8H).13C NMR (75 MHz, CDCl3) δ 172.7, 157.7, 147.3, 144.6, 143.6, 141.6,
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131.6, 126.9, 121.7, 118.8, 114.4, 101.3, 73.4, 58.9, 56.4, 55.5, 42.3, 39.5, 34.2, 28.8,
27.6, 27.4, 24.6, 24.3

2.5.3 Synthesis of Q2Q3ck
The click reaction was carried out under conditions described in detail in Chapter
3. Briefly, in a 2:1 mixture of tert‐butanol‐water (400 µL) were added Q3Z (50 mg, 0.12
mmol) and Q2A (48 mg, 0.12 mmol). Next, sodium ascorbate (10 mol%, 12 µL of 1M
solution) was added followed by copper sulfate (5 mol%, 6 µL of 1M solution). The
reaction mixture was stirred for 24 h at 65 ºC. The reaction mixture was cooled to room
temperature, diluted with methanol and filtered. The filtrate was concentrated under
vacuum and the crude mixture was dissolved in DMSO. Purification was carried out by
RP‐HPLC using a C5 semipreparative column (Vydac) with an eluent consisting of solvent
A (acetonitrile/0.1% TFA) and solvent B (water/0.1%TFA) with a 60 min gradient
consisting of 10‐95% A, a flow rate of 12 mL/min, and UV detection at 230/280 nm.
Q2Q3ck was obtained in 13% yield (13 mg). Product was characterized by MALDI–TOF
mass spectrometry: Q2Q3ck [M+H]+ = 840.02 (expected), [M+H]+ = 840.19 (observed).
Purity (~99%) was determined by analytical HPLC, with a retention time of 11.5 min
using a C5 analytical column (Phenomenex, USA) with an eluent consisting of solvent A
(acetonitrile/0.05% TFA) and solvent B (water and 0.05% TFA) with gradient of 15–95%
solvent A, a flow rate of 1.20 mL/min with UV detection at 230 nm.
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2.5.4 General Synthesis of Hydroxychloroquine Ester Dimers (HCQ‐Cn‐E)
To a solution of the bis‐carboxylic acid (0.1 mmol) in anhydrous DMF (2 mL) at
room temperature was added PyBOP (0.3 mmol), DMAP (0.05 mmol), and DIEA (1.0
mmol) under nitrogen atmosphere. After 20 min hydroxychloroquine (0.3 mmol) was
added and the mixture was stirred for 24 h at room temperature. The reaction mixture
was diluted with aqueous saturated sodium bicarbonate solution and extracted with
DCM thrice. The organic layers were combined, dried with sodium sulfate and filtered.
The filtrate was concentrated under vacuum and the crude residue dissolved in DMSO.
Purification was done using RP‐HPLC on a C18 column (Phenomenex) with an eluent
consisting of solvent A (acetonitrile and 0.1% TFA) and solvent B (water and 0.1% TFA)
with a 60 min gradient of 5–75% solvent A, a flow rate of 12.0 mL/min and UV detection
at 230 nm and 254 nm. The HCQ‐Cn‐E dimers were obtained in a typical yield of 30%
and were characterized by ESI mass spectrometry (Table 2.2). Purity of the dimers was
determined by analytical RP‐HPLC using a C8 (for HCQ‐C2‐E, HCQ‐C4‐E HCQ‐C10‐E HCQ‐
C12‐E) or C18 (for HCQ‐C8‐E) analytical column (Phenomenex) with an eluent consisting
of solvent A (acetonitrile and 0.05% TFA) and solvent B (water and 0.05% TFA) with
gradient of 5–75% A (for HCQ‐C2‐E, HCQ‐C4‐E HCQ‐C10‐E HCQ‐C12‐E) and 5‐95% A (for
HCQ‐C8‐E) a flow rate of 1.20 mL/min with UV detection at 254 nm (Table 2.2).
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Table 2.2 Mass spectral and purity data for HCQ‐Cn‐E dimers.

Dimer

Expected Mass [M+H]+

Observed Mass [M+H]+

Purity (%)

Retention times
(min)

HCQ‐C2‐E

752.3

753.1

99

12.1

HCQ‐C4‐E

780.3

781.5

99

12.5

HCQ‐C8‐E

836.4

837.2

99

13.0

HCQ‐C10‐E

864.4

865.6

99

12.8

HCQ‐C12‐E

892.5

893.5

98

14.2

2.5.5 General Synthesis of Hydroxychloroquine Carbamate Dimers (HCQ‐Cn‐C)
To a solution of hydroxychloroquine (0.3 mmol) and anhydrous DIEA (3 mmol) in
anhydrous DCM (3 ml) under nitrogen atmosphere, CDI (0.32 mmol) was added. The
mixture was stirred at room temperature for 4 h. The relevant bis‐amine (0.09 mmol)
was added next and the reaction mixture was stirred overnight. The solvent was
removed under vacuum and the crude residue was dissolved in DMSO. Purification was
done using RP‐ HPLC on a C8 column (Vydac) with an eluent consisting of solvent A
(acetonitrile and 0.1% TFA) and solvent B (water and 0.1% TFA) with a 60 min gradient
of 5–75% A, a flow rate of 10.0 mL/min with monitoring at 254 nm. The HCQ‐Cn‐C
dimers were obtained in a typical yield of 62% and were characterized by ESI mass
spectrometry (Table 2.3). Purity of the dimers was determined by analytical RP‐HPLC
using a C8 analytical column (Phenomenex) with an eluent consisting of solvent A
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(acetonitrile and 0.05% TFA) and B (water and 0.05% TFA) with gradient of 5–75% A, a
flow rate of 1.20 mL/min with UV detection at 254 nm (Table 2.3).

Table 2.3 Mass spectral and purity data for HCQ‐Cn‐C dimers.
Dimer

Expected Mass [M+H]+

Observed Mass [M+H]+

Purity (%)

Retention times
(min)

HCQ‐C2‐C

783.8

784.0

99

11.7

HCQ‐C5‐C

825.9

825.6

99

12.1

HCQ‐C8‐C

867.9

868.0

99

13.7

2.5.6 General Synthesis of Primaquine Dimers (PQ‐Cn)
To a solution of the bis‐carboxylic acid (0.13 mmol) in anhydrous DMF (3 mL)
under nitrogen atmosphere were added HATU (0.39 mmol) and DIEA (1.5 mmol). The
reaction mixture was stirred for 20 min at room temperature. Primaquine (0.39 mmol)
was added and the mixture was stirred overnight. The reaction mixture was diluted with
aqueous saturated sodium bicarbonate solution and extracted with DCM thrice. The
organic layers were combined, dried with sodium sulfate and filtered. The filtrate was
concentrated under vacuum and the crude reaction mixture was purified by flash
column chromatography using 3% methanol‐DCM solvent system. Relevant fractions
were combined and concentrated under vacuum. All the dimers, except PQ‐C8, were
further purified by RP‐HPLC using a C8 column (Vydac) with an eluent consisting of
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solvent A (acetonitrile and 0.1% TFA) and solvent B (water and 0.1% TFA) with a 60 min
gradient of 5–95% A, a flow rate of 10.0 mL/min with UV detection at 254 nm. The PQ‐
Cn dimers were obtained in a typical yield of 63%. Dimers were characterized by ESI
mass spectrometry (Table 2.4) and 1H‐NMR. Purity of the dimers was determined by
analytical RP‐HPLC on a Phenomenex C18 (for PQ‐C2, PQ‐C4, PQ‐C6, PQ‐12) or C5 (for
PQ‐C8) analytical column with an eluent consisting of solvent A (acetonitrile and 0.05%
TFA) and solvent B (water and 0.05% TFA) with gradient of 20‐85% A (for PQ‐C2, PQ‐C4,
PQ‐C6, PQ‐12) or 5‐95% A (for PQ‐C8), a flow rate of 1.20 mL/min with UV detection at
254 nm (Table 2.4).

Table 2.4 Mass spectral and purity data for PQ‐Cn dimers.
Dimer

Expected Mass [M+H]+

Observed Mass [M+H]+

Purity (%)

Retention times

PQ‐C2

600.7

601.4

99

13.3

PQ‐C4

628.8

629.5

99

13.6

PQ‐C6

656.8

657.5

99

15.4

PQ‐C8

684.4

685.5

99

16.4

PQ‐C12

741.0

741.7

97

21.3

PQ‐C12: 1H NMR (300 MHz, CDCl3) δ 8.63‐8.61 (m, 2H), 8.10‐8.06 (m, 2H), 7.43‐7.38 (m,
2H), 6.40‐6.35 (m, 4H), 5.69 (s, 2H), 3.89 (s, 6H), 3.63‐3.61 (m, 2H), 3.28‐3.25 (m, 4H),
2.10 (t, J=9 Hz, 4H), 1.72‐1.54 (m, 12), 1.30‐1.1 (m, 24)
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PQ‐C6: 1H NMR (300 MHz, CDCl3) δ 8.81‐8.80 (m, 2H), 8.5‐8.47 (m, 3H), 7.70‐7.65 (m,
2H), 6.57‐6.56 (m, 5H), 3.94 (s, 6H), 3.63 (m, 2H), 3.3‐3.28 (m, 4H), 2.19 (t, J=9 Hz, 4H),
1.85‐1.28 (m, 14H), 1.30‐1.28 (m, 10H)
PQ‐C4: 1H NMR (300 MHz, CDCl3) δ 8.79‐8.78 (m, 2H), 8.41‐8.38 (m, 3H), 7.63‐7.59 (m,
2H), 6.52 (m, 5H), 3.93 (s, 6H), 3.61 (m, 2H), 3.28‐3.26 (m, 4H), 2.2 (m, 4H), 1.75‐1.62 (m,
14H), 1.29‐1.27 (m, 6H)
PQ‐C2: 1H NMR (300 MHz, CDCl3) δ 8.81 (m, 2H), 8.41‐8.38 (m, 2H), 7.63‐7.61 (m, 2H),
6.80 (s, 2H), 6.52 (m, 4H), 3.92 (s, 6H), 3.61 (m, 2H), 3.25 (m, 4H), 2.51 (m, 4H), 1.73‐1.66
(m, 8H), 1.29‐1.27 (m, 6H)

2.5.7 General Synthesis of Mefloquine Amide Dimers (MQ‐Cn‐A)
To a solution of bis‐carboxylic acid (0.13 mmol) in dry DMF (1.5 mL) under
nitrogen atmosphere temperature were added HATU (0.53 mmol) and DIEA (1.04 mmol).
The reaction mixture was stirred for 20 min at room temperature. Mefloquine (0.39
mmol) was added and the reaction mixture was stirred for 24 h. The reaction mixture
was diluted with aqueous saturated sodium bicarbonate solution and extracted with
DCM thrice. The organic layers were combined, dried with sodium sulfate and filtered.
The filtrate was concentrated under vacuum and the crude residue was purified by flash
silica column chromatography using 3% methanol‐DCM solvent system. In the case of
MQ‐C4‐A and MQ‐C6‐A further purification was carried out by RP‐HPLC using a C18
column (Phenomenex) with an eluent consisting of solvent A (acetonitrile and 0.1% TFA)
and solvent B (water and 0.1% TFA) with a 60 min gradient of 5–95% solvent A, a flow
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rate of 10.0 mL/min with UV detection at 230 nm and 254 nm. The dimers were
obtained in a typical yield of 35% and were characterized by ESI mass spectrometry
(Table 2.5). Purity of the dimers was determined by analytical RP‐HPLC using a C8
analytical column (Phenomenex) with an eluent consisting of solvent A (acetonitrile and
0.05% TFA) and solvent B (water and 0.05% TFA) with gradient of 5–95% solvent A, a
flow rate of 1.20 mL/min with UV detection at 254 nm.

Table 2.5 Mass spectral and purity data for MQ‐Cn‐A dimers.
Dimer

Expected Mass [M+H]+

Observed Mass [M+H]+

Purity (%)

Retention times
(min)

MQ‐C4‐A

866.7

866.9

99

22.3

MQ‐C6‐A

894.8

895.0

95

22.6

MQ‐C8‐A

922.9

922.8

99

23.9

2.5.8 Synthesis of Mefloquine Amine Dimer (MQ‐C5‐Am)
The reductive amination was carried out under conditions as described by Magid
et. al. with slight modifications.72 Briefly, to a stirred solution of mefloquine (50 mg, 0.13
mmol) and glutaraldehyde (5.3 mg, 0.05 mmol) in dichloroethane solvent (1 mL) was
added with sodium cyanoborohydride (13 mg, 0.2 mmol). The reaction mixture was
initially turbid and turned clear after 20 min. The mixture was stirred for 24 h at room
temperature, after which it was diluted with aqueous saturated sodium bicarbonate
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solution. The mixture was extracted with DCM thrice. The organic layers were combined,
dried with sodium sulfate and filtered. The filtrate was concentrated under vacuum and
the crude reaction mixture was purified by flash column chromatography using a 3%
methanol‐DCM solvent system. Relevant fractions were combined and concentrated
under vacuum. The residue was dissolved in acetonitrile and further purified by RP‐HPLC
using a C8 column (Phenomenex) with an eluent consisting of solvent A (acetonitrile and
0.1%TFA) and solvent B (water and 0.1% TFA) with a 60 min gradient of 5–95% solvent A,
a flow rate of 10.0 mL/min and UV detection at 230 nm and 280 nm. MQ‐C5‐Am (14%
yield, 6 mg) was characterized by MALDI–TOF mass spectrometry: MQ‐C5‐Am [M+H]+ =
825.30 (expected), [M+H]+ = 825.08 (observed). Purity (95%) was determined by
analytical RP‐HPLC. A retention time of 20.9 min was obtained using a C5 analytical
column (Phenomenex, USA) with eluent consisting of solvent A (acetonitrile and 0.05%
TFA) and solvent B (water and 0.05% TFA) with gradient of 5–95% solvent A, a flow rate
of 1.20 mL/min with UV detection at 254 nm.

2.5.9 Synthesis of Mefloquine Ester Dimer (MQ‐C10‐E)
Boc protection of mefloquine was carried out as per the protocol reported by
Jayaprakash et. al.74 To a solution of dodecanedioic acid (8 mg, 0.03 mmol) in dry DMF
(3 mL) at 0 ⁰C was added EDC (20 mg, 0.105 mmol), DMAP (12 mg, 0.105 mmol) and
DIEA (61 µL, 0.35 mmol) under nitrogen atmosphere. After 20 min, Boc‐mefloquine (50
mg, 0.105 mmol) was added. The reaction mixture was stirred for 24 h at room
temperature, after which the solvent was removed under vacuum. The crude reaction
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mixture was dissolved in DMSO and the purification was carried out using RP‐HPLC on a
C5 Vydac column with an eluent consisting of solvent A (acetonitrile and 0.1% TFA) and
solvent B (water and 0.1% TFA) with a 60 min gradient of 5–95% solvent A, a flow rate of
10.0 mL/min and UV detection at 230 nm and 280 nm. The Boc‐Mef‐C10‐E was isolated
in 32% yield (13 mg). The material was subsequently subjected to Boc deprotection by
stirring in 10% TFA in anhydrous DCM (about 1 mL) solution at 0 ⁰C for 2 h. The solvent
was removed under vacuum to obtain Mef‐C10‐E in quantitative yield (10 mg). The
dimer was characterized by MALDI‐TOF mass spectrometry: Mef‐C10‐E [M+H]+ = 950.91
(expected), [M+H]+ = 951.48 (observed). Purity (~99%) was determined by analytical RP‐
HPLC. A retention time of 20.91 min was obtained using a C5 analytical column
(Phenomenex) with an eluent consisting of solvent A (acetonitrile and 0.05% TFA) and
solvent B (water and 0.05% TFA) with gradient of 5–95% solvent A using a flow rate of
1.20 mL/min monitoring at 254 nm.

2.5.10 Stability Study of HCQ‐C5‐C in Human Plasma
Plasma stability studies were performed as described previously, with some
modifications.76,77 100 μM HCQ‐C5‐C (5 μL of 20 mM stock) in DMSO was incubated in a
solution of 55% human plasma (550 μL) and 10 mM PB (445 μL, pH 7.4) to make a total
volume of 1 mL. The solution was incubated at 37 °C in a water bath. At different time
points, 70 μL of ice cold acetonitrile containing an internal standard (bromobenzyl
alcohol, 2 mM) was added to 70 μL of the reaction mixture to deactivate the proteins.
The solution was vortexed for 20 sec and centrifuged at 6000 x g for 10 min. The
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supernatant solution was analyzed using RP‐HPLC on a C18 analytical column
(Phenomenex), with an eluent consisting of solvent A (acetonitrile and 0.05 % TFA) and
solvent B (water and 0.05 % TFA) with a 30 min gradient of 1‐65% solvent A with flow
rate of 1.20 mL/min and UV detection at 254 nm.

2.5.11 Stability Study of HCQ‐C5‐C in Pig Liver Esterases
Porcine liver esterases stability studies were performed as described
previously.75 100 μM HCQ‐C5‐C (5 μL of 20 mM stock in DMSO) was incubated with 10
units/ml porcine liver esterase (218 μL of 46 units/ml stock) and 777 μL PB (10 mM, pH
7.4) to make a total volume of 1 mL. The solution was placed in a 37°C water bath. At
different time points, 50 μL of ice cold acetonitrile containing internal standard
(bromobenzyl alcohol, 2 mM) was added to 50 μL of the reaction mixture to deactivate
proteins. The solution was vortexed for 20 sec, then centrifuged at 6000 x g for 10 min.
The supernatant was analyzed using RP‐HPLC on a C18 analytical column (Phenomenex),
with an eluent consisting of solvent A (acetonitrile and 0.05% TFA) and solvent B (water
and 0.05 % TFA) with a 30 min gradient of 1‐65% solvent A, a flow rate of 1.20 mL/min
and UV detection at 254 nm. The area under curve (AUC) corresponding to HCQ‐C5‐C
dimer at each time point was normalized to the bromobenzyl alcohol standard and
plotted.
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2.5.12 Measurements of CQ Transport in X. laevis Oocytes Expressing PfCRT
Briefly, oocytes were injected with cRNA encoding PfCRT (25 ng per oocyte) and the
uptake of [3H]CQ (0.3 μM; 20 Ci/mmol, American Radiolabeled Chemicals) was
measured 4−6 days post injec on using a method described previously.32 The influx
measurements were made over 1−2 h at 27.5 °C and in medium that contained 96 mM
NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM MES, 10 mM Tris‐base (pH 6.0), and
15 μM unlabeled CQ. Statistical comparisons were made with the Student’s t‐test for
paired or unpaired samples or with ANOVA in conjunction with Tukey’s multiple
comparisons test.

2.5.13 In Vitro Parasite Proliferation Assays
Parasite proliferation was measured in 96‐well plates using the [3H]‐
hypoxanthine incorporation assay.78 Parasites were cultured for at least two cycles after
thawing prior to assaying and assays were initiated with predominantly ring‐stage
parasites. Assays performed with the field‐derived strains were set up at 1% hematocrit
and 0.2% parasitemia in a low‐hypoxanthine media (RPMI 1640 with L‐glutamine, 2.94
μM hypoxanthine, 50 mM HEPES, 0.5% Albumax I (w/v), 10 μg/mL gentamicin, and
0.225% NaHCO3 (w/v)). For experiments with the PfCRT transfectant lines, the starting
hematocrit and parasitemia were 1% and 0.4%, respectively, and the low‐hypoxanthine
media consisted of RPMI 1640 with L‐glutamine and NaHCO3 supplemented with 10 mM
glucose, 2.4 µM hypoxanthine, 25 mM HEPES, 0.5% Albumax II (w/v) and 25 µg/mL
gentamicin sulfate. The parasites were exposed to two‐fold dilutions of the drugs of
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interest for 68‐72 h, with [3H]hypoxanthine was added 48 h after the start of the assay.
The concentration of DMSO did not exceed 0.2%. The assays were terminated by
freezing the plates and thawing them at a later stage for processing. Parasite DNA and
RNA was harvested onto glass fiber filters and the amount of [3H]hypoxanthine
incorporated into nucleic acids was determined by scintillation counting. Parasite
proliferation in the presence of each drug concentration was determined relative to the
no‐drug controls present on each plate. IC50 values were obtained from three
independent experiments and were determined by fitting a sigmoidal curve to the data
in SigmaPlot.

2.5.14 Four‐day Peters Test
Animals (CD‐1 mice, Charles‐River) were housed for at aleast 4 days upon arrival,
weight‐matched in groups of five, infected intraperitoneally with 107 red blood cells
parasitized with P. berghei N‐strain, and administered a weight‐adjusted drug dose per
oral gavage 2 h later.67 The treatment was commenced one day later, and then
administered again at 48 and 72 h post‐infection. The drugs were dissolved in
pharmacological grade water, kept in the dark at 4°C, and filter‐sterilized prior to use.
The parasitemia was assessed by flow cytometry on day 4. Tail vein blood (2 µL) was
added to 48 µL of citrate‐buffered dextrose (CPD) solution. A 25 µL sample of the blood‐
CPD solution was diluted in 45 µL of a 2.5X SYBR‐green solution containing 150 nM
MitoTracker Deep Red (Molecular Probes), supplemented with 5% fetal calf serum, and
incubated for 40 min at 37°C. PBS‐diluted samples were centrifuged for 1 min at 400 x g
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in a swing‐bucket rotor. The supernatant was removed, and the samples were
resuspended in 200 μL of PBS supplemented with 0.5% fetal calf serum. Plates
containing the samples were analyzed on a two‐laser cytometer (Accuri Cytometers)
equipped with a 96‐well plate auto‐sampler (Intellicyt). The parasitemias were
calculated using FlowJo™ software (Tree Star).
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CHAPTER 3.

DEVELOPMENT OF BIVALENT INHIBITORS AND MECHANISTIC PROBES
OF P‐GLYCOPROTEIN USING CLICK CHEMISTRY

3.1

Introduction

3.1.1 P‐glycoprotein
P‐glycoprotein (P‐gp) is a member of the ATP Binding Cassette (ABC) super
family of transporters.1,2 P‐gp is the product of the MDR1 gene located on human
chromosome region 7q21. It is a 170‐kDa membrane bound polypeptide, consisting
of 1280 amino acids, organized in two tandem repeats of 610 amino acids joined by
a linker region of approximately 60 amino acids.3,4 The C‐ and N‐terminus halves of
P‐gp share about 43% sequence homology. Each half is composed of six
transmembrane (TM) helices and a nucleotide binding domain (NBD). The NBDs
extend into the cytosol, where they are responsible for the binding and hydrolysis of
ATP. Two ATP molecules are utilized to power each catalytic cycle.
Quantification of human P‐gp mRNA in tissues showed that P‐gp is widely
expressed in organs such as the liver, kidney, lungs, brain, prostate, heart, ovary and
intestine.3,5,6,7 At these sites P‐gp plays a protective role by blocking the entry of
xenobiotics and toxic metabolites. For instance, P‐gp at the apical membrane of the
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Figure 3.1 Anatomical sites of P‐gp expression in the body. P‐gp is highlighted in blue
lines and the red arrows indicate direction of transport. Adapted from Borst et. al.6

intestine limits the absorption of toxic molecules by actively effluxing them into the
lumen (Figure 3.1). P‐gp is most highly expressed at blood‐tissue barriers, such as
the blood‐brain barrier (BBB), blood‐testes barrier and placental fetal‐maternal
barrier. At these sensitive sites it restricts entry of toxic compounds by transporting
them into the blood vessel lumen (Figure 3.1).

3.1.2 P‐gp and Multi‐Drug Resistance (MDR)
While no natural substrate has been conclusively identified yet, P‐gp binds a
large variety of structurally and functionally unrelated exogenous molecules.8
Unfortunately, this includes a large proportion of marketed drugs from almost every
area of therapy. Few representative examples are shown in Table 3.1 but the actual
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Table 3.1 Representative examples of P‐gp drug substrates in different disease areas.
Therapeutic area

P‐gp Drug Substrates

Anti‐cancer

Taxol, Doxorubicin, Colchicine, Etoposide

Anti‐HIV

Abacavir, Darunavir, Nelfinavir, Saquinavir

Anti‐psychotic

Phenytoin, Olanzapine, Quetiapine

Anti‐bacterial

Erythromycin, Sparfloxocin, Tetracycline

Anti‐parasitic

Itraconazole, Ivermectin, Emetine, Quinine

Anti‐inflammatory

Dexamethasone, Methylprednisolone

Immunosuppressants

Cyclosporine

Calcium channel antagonists

Verapamil, Diltiazem

H2‐receptor antagonist

Ranitidine, Cimetidine

number is significantly larger.8 P‐gp was discovered by Juliano and Ling in MDR
cancer cells, where it was observed to substantially reduce the permeability of
anticancer drugs.9 Cancer cells overexpress P‐gp at the plasma membrane to efflux
cytotoxic anti‐cancer drugs, thereby not allowing them to reach the relevant
intracellular concentrations (Figure 3.1). P‐gp conferred MDR in tumors can be both
intrinsic and acquired. Tumors arising from tissues that naturally express P‐gp, such
as liver, pancreas, kidney, and colon are intrinsically resistant to P‐gp drug substrates.
In the case of breast cancer, ovarian cancer, neuroblastoma and non‐hodgkin’s
lymphoma, P‐gp expression is induced after the initial round of chemotherapy.10,11
Besides affording protection to the tumors directly, P‐gp reduces the oral
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bioavailability of drugs by limiting their absorption in the intestine. P‐gp knockout
mice have proven to be invaluable models to study the effects of P‐gp on drug
bioavailability in vivo.12 Orally administered taxol has been shown to accumulate up
to six times higher in P‐gp knockout mice relative to wild type mice.13 Further, P‐gp
at the BBB limits anti‐HIV and anti‐psychotic drugs from reaching their sites of action
in the brain. For instance, the anti‐viral drugs indinavir and saquinavir showed 10‐35
fold higher brain accumulation in P‐gp knockout mice compared to wild‐type mice.14
Similarly, the antipsychotic drug risperidone reached 10‐fold higher brain to serum
ratio in P‐gp knock out mice relative to wild‐type mice.15 Drug discovery programs
now regularly screen candidate molecules for interaction with P‐gp. Those
candidates identified as P‐gp substrates are usually not pursued further.16 In
summary, P‐gp challenges multiple areas of therapy by limiting the systemic
bioavailability of drugs and creating P‐gp protected sanctuaries, such as the brain
and MDR tumors. This has led to efforts to decipher P‐gp’s structure and mechanism.

3.1.3 P‐gp Binding Sites and Mechanism
The location and number of binding sites in P‐gp has been an area of intense
research. Bruggemanntt et. al.17 developed a photoaffinity probe based on azidopine
which was used to label both wild‐type and mutant P‐gp in MDR KB cells. Azidopine
was observed to bind to two distinct sites, one in each half of P‐gp. They also
showed that vinblastine competitively blocked azidopine labeling at both these sites
equally. This led them to postulate that both halves of P‐gp come together to form a
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common binding region. Stein et. al.18 studied transport of

tritium labeled

daunomycin by P‐gp in P388 leukemia cells with increasing concentrations of
modulators and pairs of modulators. They analyzed the results in kinetic parameters
and classified the drug interactions as co‐operative, competitive or non‐competitive.
They found P‐gp modulators such as mefloquine, vinblastine and tamoxifen bind to a
common site while verapamil, dipyridamole and trifluoperazine localized to another
site. Cyclosporin A competed with mefloquine and verapamil, thus being capable of
binding to both sites. Hence they proposed a model of P‐gp that exhibits at least two
binding sites with distinct substrate specificities. Shapiro and Ling19 supported this
idea of two distinct binding sites and further showed them to be capable of allosteric
cooperation. These authors analyzed the transport of Hoechst 33342 (H) and
Rhodamine 123 (R) dyes in P‐gp rich inside‐out plasma membrane vesicles. Both
dyes are P‐gp substrates and their spectra do not overlap, allowing monitoring of the
transport of one in presence of the other. Transport of one dye stimulated that of
the other, demonstrating positive allosteric cooperation between their respective
binding sites. Further, modulators such as colchicine stimulated R transport and
inhibited H transport, while doxorubicin displayed the opposite trend. Vinblastine
was able to block transport of both sites. These data correlated with earlier
mentioned studies and the two binding sites have hitherto been referred to as the H
and R sites. These authors later also proposed the existence of a third binding site,
based on studies with prazosin.20 Loo and Clarke developed single cysteine P‐gp
mutants by site directed mutagenesis in the TM regions. 21 These were expressed in
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HEK 293 cells and treated with MTS‐rhodamine, which formed a covalent adduct
with the cysteine residues. Among all the mutants tested, only one MTS‐rhodamine
bound mutant (F343C in TM helix 6) trapped P‐gp in a state of high ATPase activity.

Figure 3.2 (A) C. elegans P‐gp crystal structure.4 (B) Binding cavity with disordered
TM helices 10 and 12 highlighted in red.4 (C) Ball and socket residues of P‐gp (D)
Mouse P‐gp crystal structures with bound cyclic peptide inhibitors.22 (E) Mechanism
of P‐gp substrate efflux.22 Adapted from Jin et. al.4 and Aller et. al.22

Verapamil and H stimulated the ATPase activity of this MTS‐rhodamine treated
mutant, while R and colchicine had no effect. These observations lent provided
further credibility to H/R binding sites theory and their specific substrate specificity.
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The recent Caenorhabditis elegans (C. elegans ) P‐gp crystal structure (3.4 Å),
which shares 46% homology with human P‐gp, provided further insights (Figure
3.2A).4 P‐gp was crystallized in the inward facing conformation (open to the cytosol)
without bound ligands or nucleotides. The membrane bound drug binding region
was shown to be accessible to the cytosol as well as the inner plasma membrane
leaflet. Results from ATPase studies of P‐gp in membranes vs. detergents supported
the hydrophobic vacuum cleaner model, which proposes the entry of the substrates
into the P‐gp binding region through the inner membrane leaflet.4 Discontinuity in
TM helices 10 and 12 was also evident (Figure 3.2B, highlighted in red). The authors
postulated that this disorderliness facilitates conformational changes needed for
substrate transport, by acting as hinge‐like supports. Another key observation was
the “ball‐and‐socket” region at the interface of the TM domain and NBD. The
importance of this region is highlighted by its high degree of homology (80%)
between human and C. elegans P‐gp. A homology model, created to aid functional
investigations of P‐gp, on the basis of this crystal structure was in good agreement
with Loo and Clarke’s cysteine mutagenesis studies.23
To date only the mouse P‐gp crystal structure (3.8 Å) has been obtained with
co‐crystallized ligands.22 The location and stoichiometry of the bound stereo‐
isomeric cyclic peptides were observed to differ considerably. While the RRR isomer
of the cyclic peptide inhibitor bound one molecule per P‐gp, the SSS isomer bound
two molecules per P‐gp in distinct binding pockets (Figure 3.2C).22 This provided
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direct evidence of the presence of at least two distinct binding sites within P‐gp, in
agreement with all the previous studies.
Several models have been proposed for the mechanism of substrate
transport by P‐gp. These include the flippase,8 pore24 and two cylinder engine25
model, but the most widely accepted model is the hydrophobic vacuum cleaner.26
Most P‐gp substrates/modulators are characterized by a high membrane
partitioning coefficient,27 resulting in a high drug concentration in the plasma
membrane leaflets. Upon partitioning into the membrane bilayer the substrate
enters the binding cavity of P‐gp, putatively through the lateral membrane opening
observed in the C. elegans P‐gp crystal structure. Binding of the substrate causes an
increased binding affinity for ATP in the NBDs. Subsequent binding of two ATPs
causes dimerization of the NBDs, resulting in an outward facing conformation of the
protein that is now open to the extracellular milieu (Figure 3.2D). Substrate binding
affinity is reduced in this state and the substrate is expelled out of the cell. ATP
hydrolysis destabilizes the NBD dimer and the protein is set back into its original
resting conformation. The precise sequence of ATP binding and hydrolysis, with
respect to substrate transport, is still under investigation.28

3.1.4 Photoaffinity Labeling for Mechanistic Investigations of P‐gp
Photoaffinity labeling is the most widely employed methodology to study the
site of binding of P‐gp substrates/modulators.29,30,31,32,33,34 This technique relies on a
probe that reversibly binds P‐gp with high affinity.35,36 Upon UV irradiation of the
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resulting probe‐protein complex, a photochemical reaction occurs, resulting in an
irreversible covalent cross‐link. Since the lifetime of the photochemical species
generated (nitrene or carbene) upon irradiation is very short, the cross‐linking
should occur at or very close to the binding pocket of the probe. The protein is
separated by SDS‐PAGE and the band of interest is isolated. For visualization, a
radiolabel such as 3H or

125

I is commonly incorporated into the probe structure.

Once the photolabeled protein is isolated, it is chemically or enzymatically degraded
to peptide fragments. These fragments are mapped using site‐directed antibodies or
mass spectrometric techniques to identify probe modified peptide fragments.
Photoaffinity labeling provides information of the binding of the probe to the
peptide fragments. This technique is complimented with kinetic competition studies
and binding with P‐gp mutants, to build an overall understanding of the probe’s
interaction with P‐gp.
P‐gp photoaffinity labels have almost exclusively employed the phenyl azide
moiety as the photoreactive group.30 The exceptions include the diazirine based
cyclosporine analog37 and inherently photoactive molecules such as iodomycin38,
progesterone39 and corticosterone.40 All probes have employed either 3H or

125

I

radiolabels for visualization/quantification. Photolabeling studies have been carried
out in P‐gp overexpressing cells, crude membranes and purified vesicles.
Photoaffinity probes have been synthesized by modifying both P‐gp substrates and
modulators (Figure 3.3). Examples of the former include vinblastine,41 daunomycin,38
daunorubicin,42

doxorubicin,29

taxol,43,44,45

colchicine,46

rhodamine,47
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beznimidazoles,47 progesterone39 and corticosterone.40 Probes derived from P‐gp
modulators include verapamil,48 cyclosporine,37 prazosin,49 azidopine,50 forskolin,51

Figure 3.3 Examples of photoaffinity labels based on P‐gp substrates (A) vinblastine
(B) verapamil (C) taxol and (D) prazosin. The photo‐reactive group and radioisotope
tag are circled in blue. Adapted from Safa et. al.32

isoprenoids,52 estramustine,53 propafenone,54 stipiamide,55 and flupenthixol56.
[125I]iodoarylazidoprazosin (IAAP) is the most widely used photoaffinity probe due to
its commercial availability and stability.49 Synthesis of these reagents has been
approached by various designs, but the most common route has been the
incorporation of a primary amine moiety on the substrate/modulator structure,
followed by conjugation with a radiolabeled ([3H] or [125I]) NHS derivative.29
Immunological mapping of the P‐gp peptide fragments has been used to
assign the region of photolabeling. For this technique, a set of site‐specific
antibodies (Ab) are employed. These Ab were raised using synthetic P‐gp peptide
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fragments (14‐20 amino acid residues) that mimic the hydrophilic loops of P‐gp or
from bacterial fragments of P‐gp.30 Kinetic competition assays have further provided
valuable insights. For instance, cyclosporin A competitively inhibited the
photolabeling of P‐gp vesicles by a vinblastine based probe ([125I] NASV).57 In
another study, Tamai et. al. showed the inhibition of photolabeling by an azidopine
probe by cyclosporin A and vinblastine was non‐competitive. Thus, azidopine was
concluded to have a separate binding site than both cyclosporin A and vinblastine.58
Stereochemical discrimination of photolabeling of IAAP was seen with cis‐ and trans‐
flupentixol. While the former stimulated IAAP labeling, the latter inhibited the same.
Proteomics/mass spectrometric approaches have also been utilized to
characterize the photolabeled P‐gp peptide fragments.54,59 Compared to
immunological methods, the mass spectrometric technique has the advantage of
not being sequence dependent and better at accessing the hydrophobic regions of
P‐gp.59 Borchers et. al. used a dexniguldipine probe ([3H]B9209‐005) to photolabel P‐
gp overexpressing membranes.59 Photolabeled P‐gp was subject to trypsin digestion,
followed by RP‐HPLC and MALDI analysis. The major peak at m/z 7416 was assigned
to a dexniguldipine‐bound peptide fragment containing residues 468‐527. In a
separate study by the Ecker lab, P‐gp expressed in crude membranes were
photolabeled by propafenone based probes. P‐gp was separated by SDS‐PAGE
followed by digestion using trypsin or chymotrypsin and analysis by MALDI.
Photolabeling in the TMD 3, 5, 6, 8, 10, 11 and 12 segments was seen, highlighting
their role in contributing to the binding domain.54,60 These studies have provided
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invaluable information about the binding region of many probes, as summarized in
Figure 3.4. The majority of the identified labeling sites lie in the transmembrane
domains (TMDs), especially TMD 5, 6, 8 and 12. The IAAP binding pocket has been

Figure 3.4 Schematic representation of P‐gp with known regions of photoaffinity
label binding highlighted in thick colored lines. Dotted lines indicate the plasma
membrane. Labeled regions for iodomycin are indicated in black, taxanes in red,
IAAP in yellow, propafenone analogs in magenta and forskolin in green. The colored
boxes refer to domains in the NBDs. Adapted from Peer e.t al.34

shown to be made of at least three different binding epitopes61 (Fig 3.4, yellow line)
by Isenberg et. al while Greenberger et. al. identified TMD 6 and TMD 12.62 In
contrast dexniguldipine binds between the Q loop and C‐sequence of the NBD(Fig
3.4, blue line). These studies were followed up by functional studies using mutant P‐
gp to verify the importance of the predicted binding regions.30
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3.1.5 P‐gp Inhibition
Numerous studies have shown that co‐administration of a known P‐gp
inhibitor along with P‐gp drug substrate can lead to higher systemic drug
accumulation.63 For instance, the β‐secretase inhibitor GSK188909 showed poor
accumulation in the brain as a result of efflux by P‐gp at the BBB.64 When co‐
administered with the P‐gp inhibitor GF120918, the drug attained about 9‐fold
higher brain accumulation and reduced β‐amyloids in vivo. The anti‐HIV drug
nelfinavir showed over 140‐fold increase in accumulation in the brain when
administered with P‐gp inhibitor zosuquidar, than when administered by itself in a
macaque model.65 Similarly, the anti‐psychotic drug phenytoin showed greater
accumulation in mice brain when administered along with verapamil as the P‐gp
inhibitor.66 P‐gp knockout mice are viable, fertile and have a normal life span,
suggesting that P‐gp inhibition may have low side effects. The only known exception
is when the BBB integrity is compromised. This was identified when P‐gp knock‐out
mice accumulated over 100‐fold higher levels of ivermectin in the brain, than wild‐
type mice and were consequently unviable.12 However, it must be noted that
ivermectin has been used as an anthelmintic agent by millions of people with no
adverse side effects.
Inhibition of P‐gp is a viable strategy for reversing MDR, however there are
currently no clinically approved P‐gp inhibitors.67,68,69,70 A rational drug design
approach has been difficult to pursue due to the presence of multiple binding sites,
transport of a large group of structurally unrelated molecules and the lack of a
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sufficiently high resolution crystal structure.71 An alternative approach to discover P‐
gp inhibitors was the screening of available drugs. Thus, the first generation P‐gp
inhibitors, such as cyclosporin and verapamil were discovered.72 Being P‐gp
substrates themselves, these agents act as competitive inhibitors. However, they
showed poor potency, lack of selectivity and caused toxic side effects.73 Second
generation inhibitors, such as PSC833 and dexverapamil, were structural analogs of
the first generation drugs with better potency and pharmacological profiles. These
inhibitors however competed with the anti‐cancer drugs for the P450 system
causing unpredictable drug–drug interactions and were thus discontinued.72
The third generation inhibitors were identified using high throughput
screening (HTS) and quantitative structure‐activity relationship (QSAR) studies.
These inhibitors, including zosuquidar, tariquidar, biricodar and elacridar (GF120918),
are very potent with activities in the range of 30‐100 nm.74 They are selective for P‐
gp and do not interact with the P450 system. However, most these have been
discontinued in clinical trials due to poor clinical trial results or toxicity, as recently
reviewed by Yu et. al.63 For instance, tariquidar showed unfavorable toxicity during
phase 3 clinical trials of non‐small cell lung cancer (NSLC) when used in combination
with taxol and carboplatin.75,76 Biricodar along with doxorubicin similarly showed
hematologic toxicity in a phase II clinical trials of recurrent NSLC.77 GF120918
showed only marginal benefit in combination with intravenously administered
topotecan.78,79 Similarly, tesmilifine showed no benefit in phase III clinical trials for
breast cancer.80 Zosuquidar also resulted in no improvement in overall survival in
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phase III trials for acute myeloid leukemia.81 In silico modeling in tandem with SAR
profiles of propafenone‐type82 and benzophenone‐type P‐gp inhibitors have been
pursued to facilitate the development of lead molecules.83 A set of structural criteria
for P‐gp modulators were proposed: (a) The presence of at least one tertiary
nitrogen atom for electrostatic interactions (b) high hydrophobicity to allow
membrane partitioning (c) at least one aromatic ring to form stacking interactions
and (d) multiple hydrogen bond acceptors and/or donors to form hydrogen bonds
with P‐gp.
Natural products have been screened for novel scaffolds that would inhibit P‐
gp. Examples including kendarimide,84 diosmin85 and triterpenoids86 have shown
activity in vitro. However their medicinal applicability is yet to be explored.
Hydrophobic peptides that disrupt the assembly of P‐gp in the transmembrane
regions have shown to modulate P‐gp activity and sensitize resistant cancer cells.87
Further, techniques to down regulate the MDR1 gene itself have been utilized.88,89
Short interfering double stranded RNA (siRNA) has been shown to completely
reverse P‐gp mediated MDR in doxorubicin resistant cancer cells. The challenge here
is the selective and efficient delivery of the plasmid vector to the cells and stability
of the nucleotides in vivo.90 Drug delivery vehicles such as liposomes91 loaded with
taxol and tariquidar and folate targeted micelles92 containing taxol and verapamil
have shown success in vitro.
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3.1.6 Bivalent P‐gp Inhibitors
The confirmed presence of at least two distinct binding sites in P‐gp opens up
polyvalency as a strategy to develop inhibitors. Nature often uses polyvalency for
strong binding where univalent ligand‐protein interactions are weak.93 The concept
of polyvalence inhibition lies in presenting multiple copies of the same ligand‐
protein association. Two or more ligands bind simultaneously to two or more
binding sites, resulting in an enhanced binding affinity. This is a result of many
cooperative factors94 like the (a) chelate effect that causes an increase in affinity and
decrease in the off‐rate (b) statistical effects favor rebinding of polyvalent inhibitor
to the receptor due to high local concentration and (c) steric effects of the bulky
inhibitor which shield the receptor binding pockets from further interactions. The
net effect is a highly effective competitive inhibitor.94 Ambudkar et. al. first showed
that stipiamide dimers inhibit P‐gp transport activity in vitro.95 Flavnoid dimers have
also been found to inhibit P‐gp.96,97 Teodori et. al. developed N,N ‐bis(alkanol)amine
aryl esters (heterodimers) that were also potent bivalent inhibitors of P‐gp.98
Our lab has utilized polyvalency to build bivalent inhibitors based on P‐gp
drug substrates themselves (Figure 3.5A). We have proved that dimerization of P‐gp
drug substrates leads to potent P‐gp inhibition and reversal of the MDR phenotype
in resistant cells.99,100,101,102 The paradigm’s broad applicability has been
demonstrated by the development of bivalent inhibitors based on P‐gp drug
substrates from different disease areas (anti‐HIV, anti‐parasitic, anti‐psychotic)
(Figure 3.5C). This strategy has several advantages. The bivalent dimer approach
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obviates the need for a separate P‐gp inhibitor, thus avoiding the deleterious drug‐
drug interactions and toxic side effects that plagued earlier inhibitors. Since the
bivalent inhibitors are based on FDA approved drugs, the toxicity profile of these
agents could potentially be benign.

Figure 3.5 (A) Schematic representation of a bivalent inhibitor and a P‐gp expressing
cancer cell. (B) General representation of the modular design of a bivalent inhibitor.
(C) Examples of bivalent P‐gp inhibitors.

The design of a bivalent inhibitor allows for three modules of diversity
(Figure 3.5B): (a) The first module is the P‐gp drug substrate. This drug must have
necessary moieties (commonly alcohols and amines) to allow for site specific
functionalization to form the dimer. Synthesis is carried out under mild coupling
conditions, so as not to alter the drug’s innate chemical and biological properties.
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Besides homodimers, heterodimers for combination therapy, as commonly used in
anti‐cancer and anti‐HIV regimen, can be synthesized by this approach. (b) The
nature of the linkage joining the drug substrate and tether is the second module.
Depending on the specific drug in context, different linkages (ester, carbonate,
carbamate, amide) can be employed with appropriate tethers. The nature of this
linkage decides crucial pharmacological factors, such as stability of the dimer in
different biological environments like the blood plasma or the cell cytosol.
(c) The nature of the tether is the final module and affords maximum
diversity in design. For instance the length of the tether can be varied to probe the
distance between the putative P‐gp binding sites. Dimers with tethers containing 2
to 16 atoms have been developed. In many cases, only specific tether lengths show
inhibition, revealing crucial information regarding the disposition of the dimer within
the binding sites. The chemical composition of the tether can be made hydrophobic
or hydrophilic. This is especially useful for hydrophobic drugs, where the tether can
be selected to improve solubility. The flexibility of the tether can be varied to
optimize activity as well. Using an all methylene chain imparts flexibility, while
aromatic or cyclic rings can induce rigidity. Further, appropriately placed alkyl
substitutions on the tether were shown to significantly affect the stability (t1/2) of
the dimer in presence of plasma and esterases.102
Bivalent inhibitors based on emetine and quinine developed by our lab
exemplify many of the above mentioned properties.99,100 In the case of the former, it
was found that aliphatic hydrophobic tethers up to a maximum of seven methylene
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units were well tolerated, with five giving the lowest IC50. Addition of hydrophilic
ether or amino groups caused a substantial loss of activity. Decreasing the flexibility
of the aliphatic tether by incorporating aromatic groups like phenyl, pyridyl and
naphthyl did not yield any increase in activity. The optimum tether length was
determined to be 10 Å, thus giving us an insight into the different binding sites in P‐
gp. In contrast, bivalent P‐gp inhibitors based on quinine showed that eight
methylene aliphatic tethers (Q2) gave the best binding affinity. Aromatic groups, like
phenyl rings, were well tolerated while naphthyl caused a drop in potency.
The tether also allows the bivalent dimer to extend into a prodrug format.
Using a symmetrical disulfide based tether, the bivalent agent not only inhibited P‐
gp but also acted as a self‐immolative linker that delivered drug monomers once
inside the cell (Figure 3.5A).102,103 The disulfide tether takes advantage of the
reducing environment inside the cell, by virtue of the high glutathione concentration.
The disulfide tether based dimers thus act as elegant prodrugs.
Finally, the tether can be used to incorporate various motifs for mechanistic
investigations of P‐gp. For instance, photoreactive groups can be incorporated to
build bivalent mechanistic probes.

3.1.7 Tether Explorations: Click Chemistry
Click chemistry is a general term used for reactions satisfying certain
common features. These reactions are: (a) energetically “spring loaded” i.e. they are
highly exergonic (b) give high yields with a variety of substrates (c) are insensitive to
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water and air (d) produce no byproducts and (e) are easy to purify. The
quintessential example is the copper‐catalyzed azide‐alkyne cycloaddition, which is
simply referred to as the click reaction (Scheme 3.1).104,105,106,107 The click reaction
has found tremendous application in the chemical biology context.108 This has been
possible due to its biocompatible properties. Both the alkyne and azide
functionalities are biologically inert and stable. The click reaction is bioorthogonal,
making selective conjugations possible in the presence of a myriad of reactive
species found in biological systems. The alkyne and azide moieties are small and
relatively easy to incorporate into complex molecules, biopolymers and even live
cells.

Scheme 3.1 Copper‐catalyzed azide‐alkyne cycloaddition (CuAAC) or click reaction.

The click reaction can also yield mechanistic insights into proteins binding
sites. Sharpless et. al. showed that enzymes, such as acetylcholinesterase, with
adjacent binding pockets can be used to click together monomers functionalized
with the alkyne and azide moieties, without the need for copper catalysis.109 This is
attributed to increased local concentration of the monomers in the binding pockets
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and restricted entropy.110 In this method, the enzyme is incubated with the alkyne‐
and azide‐ functionalized monomers with varying tether lengths. The enzyme
chooses the most fitting combination in its active site and irreversibly clicks the two
monomers. In situ click has since been successfully carried out in other soluble
enzymes such as carbonic anhydrase,111 HIV protease112 and chitinase.111,112,113

Figure 3.6 Examples of photoaffinity‐click probes based on (A) staurosporine,117 (B) a
γ‐secretase modulator,118 (C) acetylcholine119 and (D) vancomycin.120 The
photoreactive groups are highlighted in blue circles and click handles in green circles.

3.1.8 Tether Explorations: Photoaffinity‐Click Labeling
Click chemistry has become a widely utilized methodology to compliment
photoaffinity labeling.114,115,116 In this two‐step technique the photoaffinity probes
are modified with either an azide or an alkyne, to be used as a click reaction handle
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(Figure 3.6). The alkyne or azide modification results in minimal change to the core
structure of the probe, thus not altering its innate biological function, target binding
or cell permeability. After photolabeling, the click reaction can be used to attach a
reporter tag, such as biotin or fluorescent dyes. Evaluation of the photolabeling
process can be done by monitoring in‐gel fluorescence or Western Blot analysis. It
has been shown that probes modified with alkyne retain higher target binding than a
conjugated fluorescent dye.114 Further, the click based photoaffinity methodology
circumvents the need for incorporating a radioisotope tag in the probe molecule,
resulting in safer and cheaper probes. Cravatt et. al. modified metalloprotease
inhibitors, such as marimastat, with a benzophenone photoactive group and an
alkyne tag, in an effort to identify different metalloprotease targets in whole
proteomes.121 They also studied the histone deacetylase family using a probe based
on the inhibitor SAHA, modified with the benzophenone/alkyne combination.122,123
Shao Yao et. al. modified the kinase inhibitor staurosporine with a diazirine
photoactive group and an alkyne (Figure 3.6A).117 This probe was cross‐linked in
HepG2 cells and clicked with rhodamine‐azide or biotin azide. Labeled proteins were
further analyzed by LCMS, identifying 43 kinase targets. This group has also
developed probes to study the tyrosine kinases based on the core structure of
imatinib124 and dasatinib.125 Tantama et. al. developed a BPyneTEA probe, for
studying the nicotinic acetylcholine receptor using the benzophenone/alkyne
combination. The probe selectively photolabeled the receptor in the closed state in
HEK293 cells (Figure 3.6C).119 Further, γ‐secretase, a key enzyme in Alzheimer’s
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diseases therapy, has been investigated extensively using this approach. 118,126,127
Probes based on the prenyl group were developed to investigate proteins
interacting with isoprenoid chains in the yeast proteome.128 In an effort to explore
phospholipid biology, such as protein‐lipid binding, various lipid derived probes have
been

developed

such

as

phosphatidylcholine,129

phosphatidic

acid,130

phosphatidylserine131 and phosphatidylinositol.132 The antitumor macrolide
aplyronine was modified to bear an aryldiazirine group and an alkyne and shown to
interact with actin‐related proteins.133 Further, a cyclodepsipeptide inhibitor of co‐
translational translocation was modified with a diazirine‐based leucine residue and
tagged with rhodamine‐azide, which led to the identification of the Sec61alpha
translocation channel as its target.134 Derivatives of dantrolene with an aromatic
azide and alkyne were designed to study the mechanisms involved in skeletal muscle
contractions.135 Vancomycin based probes identified two previously unknown
targets. Autolysin Atl in S. aureus and an ABC transporter in E. faecalis were labeled,
suggesting that vancomycin exerts its actions by mechanisms beyond inhibiting
nascent peptidoglycans (Figure 3.6D).120 It has been observed that in the vast
majority of these cases, the alkyne bearing probe is preferred over the azide
counterpart.114
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3.2

Results and Discussions

3.2.1 P‐gp Inhibition by Clicked Emetine and Quinine Dimers

3.2.1.1 Design
We aimed to utilize click chemistry to develop bivalent P‐gp inhibitors. The click
reaction would provide a rapid and chemoselective methodology to assemble homo‐
and heterodimers of P‐gp drug substrates. The hydrophilic triazole ring has the
capability to form vital interactions, such as H‐bonding, within the P‐gp binding
region. The anti‐parasitic P‐gp drug substrates emetine (E) and quinine (Q) were
selected as model P‐gp substrates. E and Q contain 2⁰ amine and 2⁰ hydroxyl groups,
respectively, that can be used to conjugate the azido‐ and alkynoic acids (Scheme
3.2).99,100 Initially, the various azide and alkyne functionalized emetine and quinine
analogs would be synthesized. These would then be clicked to form dimers.

Scheme 3.2 Chemical structures of emetine and quinine. Sites of functionalization
are highlighted in red.
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We envisioned clicked homodimers and heterodimers, with different tether
lengths, to map the P‐gp binding region. Next, the P‐gp inhibition profile of these
dimers would be tested using the P‐gp overexpressing cell line MCF‐7/DX1. A library
format would be employed to study the effect of tether length on activity.

3.2.1.2 Synthesis of Azido‐ and Alkynoic Acid Tethers
The azido‐acids were synthesized by following literature protocols.136,137 In
some cases, the azido ‐acids (n=2, 8) were obtained directly from the corresponding
bromo‐acid by treatment with sodium azide, while others (n=3, 4, 6) were
synthesized from the requisite bromo‐ester, followed by saponification.
Representative examples for both methods are shown in Scheme 3.3A and 3.3B
respectively. All of the azido acids were characterized by 1H‐NMR and were found to
be consistent with literature reports. The alkynoic acids were commercially available,
with the exception of 8‐nonynoic acid. Synthesis of this acid was done using lithium
acetylide‐ethylene diamine complex and 7‐bromo heptanoic acid (Scheme 3.3C).138

Scheme 3.3 Representative synthesis of azido‐ and alkynoic acids.
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3.2.1.3 Synthesis of Azide(EnZ) and Alkyne(EnA) Conjugated Emetine
The emetine alkyne analogs (E2A, E3A) and the azide analog (E3Z) were
synthesized by HATU coupling (Scheme 3.4).139 Purification was performed by silica
gel flash column chromatography and the products were obtained as colorless oils.
Characterization was performed by ESI mass spectrometry. However, E2Z could not
be synthesized under these conditions. Even after varying the solvent, time and
coupling reagents (HCTU, EDC, PyBOP) the reaction only provided unreacted
emetine. A similar situation was found with the 2‐azidoacetic acid, while the product
formed readily for tethers containing 3 (E3Z) or more methylene units between the
azide and carboxylic acid. The acid chloride activation route was eventually
employed (Scheme 3.4) to obtain E2Z.

Scheme 3.4 Synthesis of azide(EnZ) and alkyne(EnA) conjugated emetine.
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3.2.1.4 Synthesis of Azide(QnZ) and Alkyne(QnA) Conjugated Quinine
The quinine alkyne (Q2A, Q4A, Q6A, Q8A) and azide (Q2Z, Q4Z, Q6Z, Q8Z)
analogs were synthesized using EDC as the coupling agent (Scheme 3.5).140
Purification was performed by silica gel flash column chromatography.
Characterization was performed by ESI mass spectrometry. Q2Z could not be
synthesized by EDC coupling, reminiscent of the problem faced with HATU coupling
of E2Z. Once again the acid chloride route was employed to synthesize Q2Z (Scheme
3.5).

Scheme 3.5 Synthesis of azide(QnZ) and alkyne(QnA) conjugated quinine.

3.2.1.5 Synthesis of Clicked Emetine Dimers
With the emetine alkyne/azide analogs in hand the click reaction was carried
out using standard conditions.141 Cu (I) was generated in situ using copper sulfate
and sodium ascorbate. Two clicked emetine homodimers, E(2,2´) and E(3,3´), were
synthesized (Scheme 3.6). These dimers have 2 and 3 methylene units flanking the
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triazole ring, respectively. Typical reaction yields after 18 hours at 60 ⁰C were
approximately 30%, with the bulk of the material composed of unreacted starting
materials. The dimers were purified using RP‐HPLC, characterized by ESI mass
spectrometry and purity determined by analytical RP‐HPLC.

Scheme 3.6 Synthesis of clicked emetine homodimers E(n,n´). n and n´ refer to the
number of methylene units flanking the triazole ring.

3.2.1.6 Synthesis of Clicked Emetine‐Quinine Heterodimer
A

representative

emetine‐quinine

heterodimer,

EQ(3,3´)

was

also

synthesized. The emetine alkyne analog E3A and the quinine azide analog Q3Z, were
clicked under the conditions described above (Scheme 3.7). The dimer was purified
by RP‐HPLC, characterized by ESI mass spectrometry and purity determined by
analytical RP‐HPLC.

Scheme 3.7 Synthesis of emetine‐quinine heterodimer EQ(3,3´).
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3.2.1.7 Synthesis of Clicked Quinine Homodimers
We wished to probe the effect of tether length on activity with clicked
quinine dimers. Therefore a small library of clicked quinine homodimers, with
differing numbers of total intervening methylene groups, was synthesized (Scheme
3.8). The shortest symmetrical tether combination of Q2A and Q2Z resulted in a
dimeric agent Q(2,2´) with two methylene units flanking either side of the triazole
ring, whereas the longest tether combination resulted in Q(8,8´). Asymmetrical
dimers such as Q(2,3´), Q(2,4´) and Q(2,6´) were also synthesized. The
corresponding asymmetrical dimers that differ only in the orientation of the triazole
ring (Q(3,2´), Q(4,2’) and Q(6,2’)) were not expected to differ substantially in activity
and were thus not pursued. However, to test this hypothesis one such pair of dimers

Scheme 3.8 Synthesis of clicked quinine homodimers Q(n,n´). n and n´ refer to the
number of methylene units flanking the triazole ring.

Q(4,6´) and Q(6,4´) was synthesized. To improve solubility, the solvent was changed
to a biphasic system, DCM‐Water (1:1).142 Purification was performed using silica gel
flash chromatography. Typical reaction yields after 12 hours were ~55%. Running the
reaction longer (up to 3 days) did not improve the yield. Characterization of all the
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dimers was performed by ESI mass spectrometry and purity of the dimers was
assessed by analytical RP‐HPLC.140

3.2.1.8 P‐gp Inhibition of Clicked Emetine Dimers
The fluorescent substrate accumulation assay was used to investigate P‐gp
inhibition of the dimers.143 This assay follows the accumulation of fluorescent P‐gp
substrates within P‐gp overexpressing cells as a measure of P‐gp inhibition. The P‐gp
overexpressing breast cancer cell MCF‐7 sub‐line MCF‐7/DX1 was utilized for the
assays. Flow cytometry was used to quantify fluorescence accumulation within
MCF7/DX1 cells. Rhodamine‐123 (R‐123) was employed as the fluorescent substrate
and the known P‐gp inhibitor GF120918 was used as the positive control. The
emetine homodimers E(2,2´) and E(3,3´) showed only marginal increase in cellular
fluorescence, indicating poor inhibition of P‐gp (Figure 3.7A). However, the emetine‐
quinine heterodimer EQ(3,3´) showed potent inhibition of P‐gp mediated efflux,

Figure 3.7(A) Flow cytometry data for MCF‐7/DX1 cells treated with R‐123 and
clicked emetine homo and heterodimers (B) IC50 curve generated for EQ(3,3´).
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with an IC50 of 2.5 ±0.1µM (Figure 3.7A‐B). EQ(3,3´) displays about 13‐ and 40‐fold
improvement in activity over the E (IC50 = 33 ±1.4 µM) and Q (IC50 = 101 ±2.1µM)
monomers, respectively.99,100 This observation is in accordance with our previous
reports with emetine homodimers, where we observed hydrophilic moieties to be
detrimental to activity.99 Since methylene tethered emetine homodimers are potent
inhibitors of P‐gp, it can be hypothesized that the triazole ring is reducing the P‐gp
binding affinity. As a result clicked emetine homodimers were not pursued further.
The observation that changing one emetine in the E(3,3´) dimer to quinine results in
a more potent inhibitor suggests that Q may be occupying a different binding region,
that is capable of tolerating the triazole ring.

3.2.1.9 P‐gp Inhibition of Clicked Quinine Dimers
The fluorescent substrate accumulation assay was used to study the Q(n,n´)
homodimers with calcein‐AM as the fluorescent substrate. The results are
summarized in Figure 3.8. All of the quinine dimers inhibited P‐gp in MCF7/DX1 cells,
with fairly similar potencies. Maximal efficacy is observed with Q(4,6´), Q(6,4´) and
Q(6,6´) in the 2 µM range. These dimers were about 40‐fold more active than
monomeric quinine (IC50 = 101 ±2.1µM). Equipotent P‐gp inhibition was observed
with Q(4,6´) and Q(6,4´), the two dimers that only differ in the orientation of the
triazole ring. When comparing the series with equivalent numbers of methylene
units flanking the triazole ring, such as Q(2,2´), Q(4,4´) and so on, optimum
inhibition was found with the Q(6,6´) dimer. A 2.3‐fold increase in potency was
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observed when the tether length was increased from Q(2,2´) to Q(6,6´). This effect
was lost upon further increasing the tether length to Q(8,8´). When comparing these
data to P‐gp inhibition with other quinine‐based dimers, we observe approximately
equipotent inhibition between a dimer with a central phenyl moiety in the tether, as
compared to triazole‐linked dimers.100 However, the triazole‐containing inhibitors,
such as Q(6,6´), were found to 10‐fold more potent against P‐gp when compared to
quinine dimers with an intervening naphthalene unit in the tether.100

Figure 3.8(A) Histograms displaying MCF7/DX1 fluorescence upon addition of
calcein‐AM alone (red) and with a representative dimer Q(6,6´) (black, 5 µM) or
GF120918 (green, 1 µM). (A) IC50 values for P‐gp inhibition with the clicked quinine
dimer library.

3.2.2 Bivalent Quinine Photoaffinity‐Click Probes (BQ‐PCP) for P‐gp

3.2.2.1 Design
To gain mechanistic insights into P‐gp binding, we aimed to develop
photoaffinity‐click probes based on our bivalent inhibitors. Photoaffinity‐click probes
display a photoactive group and a click handle. As discussed earlier, almost all
photoaffinity labels of P‐gp have utilized an aromatic azide as the photoactive group.

120
We chose an aromatic azide, positioned in the tether, in our design. The majority of
photoaffinity‐click probes utilize an alkyne (not azide) as the click handle. In keeping

Scheme 3.9 Chemical structures of the Lead Dimer‐para, Dimer‐ortho and BQ‐PCP.

with this observation, we decided to incorporate an alkyne moiety into the probe
itself, to click with azide bearing fluorescent dyes or biotin. Thus we searched for P‐
gp drug substrates that: (i) form bivalent P‐gp inhibitors (ii) tolerate aromatic groups
in the tether and (iii) contain a pendant terminal alkyne or surrogate functionality.
Quinine was identified to satisfy all three criteria. Quinine dimers are potent P‐gp
inhibitors and tolerate aromatic rings in the tether.100 The terminal alkene of the
quinuclidine ring of quinine provides a surrogate for the incorporation of the
terminal alkyne. Previous efforts in our lab have identified a quinine dimer bearing a
phenyl ring in the tether (Scheme 3.9, Lead Dimer‐para) as a potent P‐gp
inhibitor.100 An azide moiety can be introduced into the phenyl ring to form the
photoactive functionality, while the terminal alkene would be converted to an
alkyne to setup the click handle. Thus the Lead Dimer‐para served as a template to
develop bivalent quinine photoaffinity‐click probes (BQ‐PCP). For the initial proof of
concept studies shown here BQ‐PCP would be clicked with biotin‐(PEG)3‐azide, since
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biotin can be visualized by both fluorescence (using streptavidin‐dy) and
chemiluminescence144 (using NeutraAvidin‐HRP) (Figure 3.9). Both ortho‐ and para‐

Figure 3.9 Overview of BQ‐PCP labeling experiments. The aromatic azide (green
triangle) of BQ‐PCP photo cross‐links with P‐gp upon UV irradiation. Next, the alkyne
(orange arc) moiety of BQ‐PCP clicks with the azide (cyan pentagon) end of the
biotin‐(PEG)3‐azide reporter. Finally, the biotin is bound by streptavidin (red star)
which is detected by fluorescence or chemiluminescence.

phenyl substituted BQ‐PCP were envisioned, to diversify the orientation of the
quinines within the P‐gp binding pocket. Herein, investigation using the ortho
substituted BQ‐PCP will be described (Scheme 3.9). Since we had not previously
investigated the ortho‐attachment of quinine to 2,2'‐(1,2‐phenylene)diacetic acid,
this compound, Dimer‐ortho (Scheme 3.9), was also prepared to investigate the
impact of ortho‐functionalization on P‐gp inhibition. This dimer would also be used
as a control in photolabeling and competition studies experiments.
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3.2.2.2 Synthesis and P‐gp Inhibition of BQ‐PCP
The synthesis of BQ‐PCP requires the incorporation of a terminal alkyne at
the quinuclidine ring of quinine (quinyne) and a tether containing the photoactive
phenyl azide ring. The synthesis of the quinyne was carried out using the protocol
reported by Kacprzak.145 (Scheme 3.10A). Quinine was first brominated to form
dibromo‐quinine using bromine in DCM. The product was obtained as a yellow solid
and was used further without purification. Double dehydrohalogenation of dibromo‐
quinine was performed using potassium hydroxide in THF, with a catalytic amount of
aliquat‐336 as a phase transfer catalyst, to form quinyne. Quinyne was purified by

Scheme 3.10 Synthesis of (A) BQ‐PCP and (B) Dimer‐ortho.

recrystallization and characterized by ESI mass spectrometry. 2,2'‐(4‐azido‐1,2‐
phenylene)diacetic acid was prepared from the commercially available aniline
precursor by diazotization, followed by treatment with sodium azide (Scheme
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3.10A).146 The product was characterized by 1H‐NMR. The coupling of this tether and
quinyne was accomplished using EDC as a coupling reagent to obtain BQ‐PCP. The
product was purified by RP‐HPLC, characterized by ESI mass spectrometry and purity
was assessed by analytical RP‐HPLC. Dimer‐ortho was synthesized similarly (Scheme
3.10B). In the calcein‐AM accumulation assay with MCF‐7/DX1 cells, the Lead Dimer‐
para (IC50 = 1.3 ±0.2µM) and Dimer‐ortho (IC50 = 3.3 ±0.1µM) showed potent activity
(Figure 3.10). The wider spatial distribution of the quinine units in the Lead Dimer‐
para could potentially allow for enhanced binding to P‐gp, thus resulting in about
the 2.5‐fold higher activity compared to Dimer‐ortho. BQ‐PCP displayed
approximately an IC50 of 4.8 µM, which is comparable to Dimer‐ortho (Figure 3.10).
This shows that the incorporation of the alkyne and azide into BQ‐PCP does not
significantly alter P‐gp inhibitory activity. Interestingly, the para analog of BQ‐PCP
(IC50 = 2.1 ±0.3µM) displayed about 2.3 fold higher activity than BQ‐PCP, similar to
the parent dimers.

Figure 3.10 Evaluation of activity of Lead dimer‐para (blue), Dimer‐ortho (red) and
BQ‐PCP (green) against P‐gp mediated efflux of calcein‐AM in MCF‐7/DX1 cells.
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3.2.2.3 Photoaffinity‐Click Labeling in Live Cells
The ability of BQ‐PCP to photolabel P‐gp was tested in live MCF‐7/DX1 cells.
This cell line derived from MCF‐7 cells expresses high levels of P‐gp and is about 200‐
fold more resistant to the cytotoxic agent doxorubicin.147,148 The cells were
incubated with 40 µM BQ‐PCP followed by washing to remove excess probe. The
cells were then exposed to UV (365 nm) light for 30 minutes to allow photo‐cross
linking of BQ‐PCP. Next, the cells were treated with biotin‐(PEG)3‐azide, copper
sulfate and sodium ascorbate, to click with the biotin reporter tag to the protein‐
probe complex. The biotin was probed with red fluorescent streptavidin‐dy and
analyzed by flow cytometry. Streptavidin‐Dy was selected as the fluorescent probe
since it is non‐cell permeant.149 Samples were treated with treated with BQ‐PCP or
just DMSO, under both UV exposed (+UV) and non‐exposed (‐UV) conditions. To
ascertain that the streptavidin‐dy fluorescent signal was membrane bound, all
samples were treated with trypan blue (TB). TB is a non‐cell permeant dye that
selectively quenches all extracellular fluorescent signals.139
As seen in Figure 3.11A, BQ‐PCP treated cells (+UV) showed strong
streptavidin‐dy fluorescence. In contrast cells treated with DMSO (+UV), instead of
BQ‐PCP, displayed minimal fluorescence. The BQ‐PCP treated cells that were not
exposed to UV (‐UV) showed about a 4‐fold lower fluorescence compared to the
corresponding +UV sample.
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Figure 3.11 (A) Analysis of BQ‐PCP (40 µM) photolabeling in live MCF‐7/DX1 cells
using streptavidin‐dy by flow cytometry. (B) Comparison of BQ‐PCP (40 µM)
photolabeling (+UV) in MCF‐7/DX1 and MCF‐7 cells.

This could be a result of non‐covalently bound dimer residing within P‐gp that is
clicked with biotin and binds streptavidin‐dy. Once again the DMSO treated (‐UV)
samples showed no fluorescence. Upon treatment with TB, both the BQ‐PCP (+UV)
and BQ‐PCP (‐UV) signals dropped dramatically to basal levels. This shows that the
fluorescence due to streptavidin‐dy is membrane associated. The DMSO treated
samples showed a slight increase in fluorescent signal probably due to background
signal from TB binding to the cell. To investigate the P‐gp specificity of BQ‐PCP, the
above assay was carried out in MCF‐7/DX1 cells and MCF‐7 cells in parallel (+UV). As
seen in Figure 3.11B, a 1.6‐fold reduction in cellular fluorescence was evident for
MCF‐7 cells treated with BQ‐PCP compared to MCF‐7/DX1 cells. These data suggest
that besides P‐gp, other plasma membrane proteins are potentially being
photolabeled. Given the complexity of the cell system, we moved to a model system
using enriched P‐gp to perform photolabeling.
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3.2.2.4 Photoaffinity‐Click Labeling in Enriched P‐gp
Enriched P‐gp provide a higher protein abundance, compared to whole cells
or crude membranes systems.150 This allows for the P‐gp photolabeling to be carried
out with maximum efficiency and minimal interference from other membrane
proteins. Potential complications such as low ion abundance and poor signal‐to‐
noise ratio during mass spectrometric analysis can also be avoided. Enriched P‐gp
was developed by Allison Lange, Hrycyna lab, Purdue University. Wild‐type P‐gp with
a 6‐His tag (P‐gp.H6) was expressed in Sf9 insect cells and purified by metal affinity
chromatography.151 The enriched P‐gp was reconstituted into proteoliposomes by a
rapid dilution method. 151 These were incubated with the BQ‐PCP (40 µM) followed
by UV cross‐linking at 360 nm. The click cocktail, consisting of biotin‐(PEG)3‐azide,
copper sulfate and sodium ascorbate, was added next. Finally, SDS was added to this
mixture and subsequently loaded onto a 10% precast acrylamide gel. SDS‐PAGE was
carried out and the gel was transferred to a nitrocellulose membrane and blocked
overnight. The membrane was probed with NeutrAvidin‐HRP and visualized by
chemiluminescence. BQ‐PCP treated samples but without exposure to UV (‐UV) as
well as samples incubated to DMSO, in place of BQ‐PCP (+UV), were employed as
controls.
As seen in Figure 3.12A, biotinylated P‐gp was only labeled in (+UV) BQ‐PCP
treated samples. No labeling was evident when UV irradiation or BQ‐PCP treatment
was omitted. Some background due to insufficient washing is visible in Lane A.
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Figure 3.12 Analysis of BQ‐PCP photolabeling of enriched P‐gp (A) Western blot
probed with neutratividin‐HRP signal. (B) Western blot probed with C219 antibody
detecting P‐gp in each sample. (C) Table summarizing conditions of the Western
blots. Molecular weight markers are drawn in as red bars in Lane 2. The arrow points
to the P‐gp band. Some background is visible due to insufficient washing in Lane A1.

Approximately equal quantities of enriched P‐gp were loaded in each well as
determined by Western blot using C219 P‐gp antibody (Figure 3.12B). These data
suggest successful photoaffinity‐click labeling of enriched P‐gp by BQ‐PCP.

3.3

Conclusion

We have applied click chemistry in the design and synthesis of bivalent P‐gp
substrates based on emetine and quinine to probe the binding region of P‐gp. While
the emetine homodimers showed poor inhibitory activity, we discovered a potent
heterodimeric inhibitor EQ(3,3´). Dimer activity is a balance between the nature of
the tether as well as the substrate monomer. Further, we have developed a
synthetic protocol for the rapid assembly of a small library of quinine homodimers,
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Q(n,n´) employing click chemistry. These bivalent agents encompass a range of
tether lengths, incorporating the triazole ring. This approach allowed us to explore
the chemical space in the P‐gp substrate binding region and study inhibitory trends.
We found that while the activity is broadly similar, P‐gp inhibition is maximum for
dimers with 10 to 12 methylene units flanking the triazole ring. Inhibition was found
to drop off on lengthening or shortening the tether length further. Finally, we have
designed and synthesized a novel, non‐radioactive P‐gp mechanistic probe, BQ‐PCP,
based on the photoaffinity‐click labeling paradigm. Preliminary studies in live MCF‐
7/DX1 cells and enriched P‐gp vesicles suggest successful labeling of P‐gp by BQ‐PCP.

3.4

Future Directions

The click strategy for bivalent inhibitors may be extended to other P‐gp drug
substrates, provided the triazole ring is well tolerated. Both clicked homo‐ and
heterodimers can be envisioned to explore the integral membrane P‐gp transporter
region and potentially discover novel inhibitors and probes. In mechanistic pursuits,
BQ‐PCP labeled P‐gp has to be isolated for proteomic analysis. For visualization on
the gel, clicking with azide‐conjugated fluorescent dyes has been challenging and
conditions need to be optimized.
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3.5

Materials and Methods

3.5.1 Materials
Emetine was purchased from TCI America (Portland, OR) and quinine from
Acros Organics. Calcein‐AM and Rhodamine 123 were purchased from Molecular
Probes, Inc. (Eugene, OR). 4‐pentynoic acid was purchased from Alfa Aesar, 7‐
bromoheptanoic acid from Matrix Scientific, 6‐heptynoic acid from GFS Chemicals.
Sodium ascorbate was obtained from TCI America. Streptavidin‐Dylight and
Neutravidin‐HRP antibody were purchased from Invitrogen. 2,2'‐(4‐azido‐1,2‐
phenylene)diacetic acid was purchased from Allichem (Baltimore, MD). Benzotriazol‐
1‐yl‐oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) was obtained
from Genscript (Piscataway, NJ). 1‐ethyl‐3‐(3‐dimethylaminopropyl)carbodiimide
(EDC) was purchased from AK Scientific (Union City, CA). 4‐dimethylaminopyridine
(DMAP) was obtained from GenScript (Piscataway, NJ). All other chemicals were
purchased from Sigma‐Aldrich. A UVP XX‐15L UV Lamp (365 nm) was used for the
photolabeling experiments.

3.5.2 Cell Culture
MCF‐7/DX1 cells were cultured at 37 ⁰C in 5% CO2 and maintained in RPMI
1640 media supplemented with 10% fetal bovine serum (FBS), 2 mM of L‐glutamine
(Cellgro) 50 units/mL of penicillin (Cambrex), 50 μg/mL streptomycin (Cellgro) and 1
μM doxorubicin. MCF‐7 cells were cultured as above, with media deficient of
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doxorubicin. Basal Medium Eagle Media (BME) (Cellgro) supplemented, with 10 %
fetal bovine serum, at a pH of 7.3‐7.5 was used. Sterile Trypan Blue solution (0.4%)
was purchased from Sigma Aldrich.

3.5.3 Synthesis of Azido‐ and Alkynoic Acids
Synthesis of 3‐azido propanoic acid was performed according to a reported
procedure.136 The product was obtained in 30% yield. Synthesis of 4‐azidobutanoic
acid, 5‐azidopentanoic acid and 7‐azidoheptanoic acid were performed according to
reported procedures.137,152 The products were obtained in a typical yield of ~90%.
Synthesis of 8‐nonynoic acid was performed according to a reported procedure.138
The product was obtained in 58% yield. All products were characterized by 1H‐NMR
and were found to be consistent with literature values.

3.5.4 General Synthesis of Azide(EnZ) and Alkyne(EnA) Conjugated Emetine
To a solution of the azido‐ or alkynoic acid (0.70 mmol) in dry DMF under
nitrogen atmosphere, HATU (0.70 mmol) and DIEA (2.3 mmol) were added. The
solution was stirred at room temperature for 20 minutes. Emetine (0.23 mmol) was
added next and the reaction stirred overnight. The reaction mixture was diluted with
saturated aqueous sodium bicarbonate solution and extracted thrice with ethyl
acetate. The combined organic layers were washed with brine, dried with MgSO4,
filtered and concentrated under vacuum. The crude material was purified by flash
column chromatography using a 5% methanol‐DCM solvent system. Requisite
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fractions were combined and concentrated under vacuum. The products were
obtained in a typical yield of ~80%. Characterization was done by ESI mass
spectrometry (Table 3.2).

Table 3.2 Mass spectral data for Azide and Alkyne Conjugated Emetine.
Compound

Expected Mass [M+H]+

Observed Mass M+H]+

E2A

561.7

561.8

E3A

575.7

575.1

E3Z

592.7

592.2

3.5.5 Synthesis of E2Z
3‐azido propanoic acid (110 mg, 0.95 mmol) was added to thionyl chloride (1
mL) under nitrogen atmosphere at 0 ⁰C. The reaction mixture was refluxed at 80 ⁰C
for 3 h. The mixture was cooled to room temperature, concentrated under vacuum
and dissolved in minimum amount of anhydrous DCM. The solution was added
dropwise to a stirred solution of emetine (88 mg, 0.16 mmol), anhydrous TEA (0.45
mL, 3.2 mmol) and DMAP (3 mg, 0.01 mmol) in anhydrous DCM (2 mL). The reaction
mixture was further refluxed for 3 h. The mixture was cooled to room temperature,
filtered and concentrated under vacuum. Purification was done by flash silica
column chromatography using a 5% methanol‐DCM solvent system. Requisite
fractions were combined and concentrated under vacuum. The product was
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obtained in a yield of 36% (32 mg). Characterization was done by ESI mass
spectrometry: E2Z [M+H]+=578.71(expected), [M+H]+= 578.52(observed).

3.5.6 General Synthesis of Azide(QnZ) and Alkyne(QnA) Conjugated Quinine
To a solution of the azido‐ or alkynoic acid (1.8 mmol) in dry DMF under
nitrogen atmosphere, EDC (1.8 mmol), DMAP (0.24 mmol) and DIEA (6.1 mmol)
were added. The solution was stirred at 0 ⁰C for 20 minutes. Quinine (0.61 mmol)
was added and the reaction stirred at 0 ⁰C for 4 h and then at room temperature
overnight. The reaction mixture was diluted with saturated aqueous sodium
bicarbonate solution and extracted thrice with ethylacetate. The organic layers were
combined, washed with brine, dried with MgSO4, filtered and concentrated under
vacuum. The crude material was purified by flash silica column chromatography
using a 5% methanol‐DCM solvent system. Requisite fractions were combined and
concentrated under vacuum. The products were obtained on a typical yield of ~85%.
Characterization was done by ESI mass spectrometry and purity determined by TLC
(Table 3.3).
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Table 3.3 Mass spectrometry data for Azide and Alkyne Conjugated Quinine.

Expected Mass[M+H]+

Observed Mass [M+H]+

Q2A

405.5

405.0

Q3A

419.2

419.0

Q4A

433.5

433.1

Q6A

461.6

461.1

Q8A

489.7

489.2

Q3Z

436.5

436.1

Q4Z

450.5

450.1

Q6Z

478.6

478.1

Q8Z

506.7

506.1

Compound

3.5.7 General Synthesis of Clicked Emetine Dimers
In a 2:1 mixture of tert‐butanol : water (300 µL total volume), EnA (0.05
mmol) and EnZ (0.06 mmol) were added. Next, sodium ascorbate (10 mol%) was
added followed by copper sulfate (5 mol%). The mixture was stirred at 60 ⁰C for 24 h.
The contents were diluted with methanol, filtered and purified using RP‐HPLC on a
C5 Vydac column. The eluent consisted of solvent A (water and 0.1% TFA) and
solvent B (methanol and 0.1%TFA). A 60 min gradient of 30‐95% B, at 10mL/min,
with monitoring at 230 and 280nm was used. Dimers were isolated in a typical yield
of 30% and characterized by ESI mass spectrometry (Table 3.4). Purity was
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determined by analytical RP‐HPLC on a C5 Vydac analytical column using a 30 minute
gradient of 30‐95% B, at a flow rate of 1.2mL/min with monitoring at 230 nm (Table
3.4).

Table 3.4 Mass spectrometry and purity data for emetine homodimers.
Dimer

Purity (%)

Retention time (min)

Expected Mass [M+H]+

Observed Mass M+H]+

E(2,2´)

99

21

1138.6

1138.1

E(3,3´)

99

23

1166.6

1166.7

3.5.8 Synthesis of EQ(3,3´)
In a 2:1 mixture of tert‐butanol: water (300 µL total volume), E3A (50 mg,
0.09 mmol) and Q3Z (50 mg, 0.11 mmol) were added. Next, sodium ascorbate (10
mol%, 8.7 µL of a 1M solution) was added, followed by copper sulfate (5 mol%, 4.3
µL of a 1M solution). The mixture was heated to 60 ⁰C and stirred for 24 h. The
contents were diluted with methanol, filtered and purified using RP‐HPLC on a C4
Vydac column. The eluent consisted of solvent A (water and 0.1% TFA) and solvent B
(methanol and 0.1%TFA). A 60 minute gradient of 30‐95% B, at 10mL/min, with
monitoring at 230 and 280nm was used. EQ(3,3´) was obtained in 33% yield ( 28 mg)
and characterized using MALDI‐TOF mass spectrometry: EQ(3,3´) [M+H]+= 1010.29
(expected), [M+H]+= 1010.57 (observed). Purity (99%, retention time=15.4 min) was
determined using analytical RP‐HPLC on a C5 Vydac analytical column using a 30
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minute gradient of 15‐95% B, at a flow rate of 1.2 mL/min, with monitoring at 230
nm.

3.5.9 General Synthesis of Clicked Quinine Dimers
In a 1:1 mixture of DCM: water (2 mL total volume), QnZ (0.13 mmol) and
alkyne QnA (0.14 mmol) were added. Sodium ascorbate (10 mol%) was added,
followed by copper sulfate (5 mol%). The reaction mixture was stirred for 24 h at
room temperature. The reaction mixture was diluted with saturated aqueous
sodium bicarbonate solution and extracted with DCM thrice. The organic layers were
combined, dried with MgSO4, filtered and concentrated under vacuum. The crude
reaction mixture was purified by flash gel column chromatography using 5%
methanol‐DCM. Relevant fractions were combined and the dimeres obtained in a
~55%

typical yield. Characterization wad done by ESI mass spectrometry and purity

of the dimers determined using analytical RP‐HPLC on a C8 analytical column
(Phenomenex) using an eluent consisting of solvent A (acetonitrile/0.05% TFA) and
solvent B (water and 0.05% TFA) with gradient 5–95% A at a flow rate of 1.2mL/min
with monitoring at 254 nm (Table 3.5).
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Table 3.5 Mass spectrometry and purity data for quinine homodimers.

Dimer

Purity (%)

Retention time

Expected Mass

Observed Mass

(min)

[M+H]+

[M+H]+

Q(2,2´)

99

12.8

826.01

826.2

Q(2,4´)

98

13.2

854.06

854.2

Q(4,4´)

95

13.6

882.1

882.6

Q(4,6´)

99

14.2

910.2

910.3

Q(6,4´)

97

14.1

910.2

910.4

Q(6,2´)

98

13.7

882.1

882.3

Q(6,6´)

99

14.6

938.2

938.4

Q(8,8´)

99

16.3

994.3

994.3

3.5.10 Synthesis of BQ‐PCP
Quinyne145 and 2,2'‐(4‐azido‐1,2‐phenylene)diacetic acid146 were synthesized
according

to

reported

procedures.

To

a

solution

of

2,2'‐(4‐azido‐1,2‐

phenylene)diacetic acid (16 mg, 0.06 mmol) in dry DCM (3 mL) under nitrogen
atmosphere, were added EDC (39 mg, 0.20 mmol), DMAP (25 mg, 0.20 mmol) and
DIEA (120 µL, 0.68 mmol). The solution was stirred at 0 ⁰C for 20 minutes. Quinyne
(66 mg, 0.20 mmol) was added and the reaction stirred at 0 ⁰C for 4 h and then at
room temperature for 24 h. The reaction mixture was diluted with saturated
aqueous sodium bicarbonate solution and extracted thrice with DCM. The organic
layers were combined, dried with sodium sulfate, filtered and concentrated under
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vacuum. The crude material was dissolved in acetonitrile and the purification was
carried out using RP‐HPLC on a C8 Vydac column. The eluent consisted of solvent A
(acetonitrile and 0.1% TFA) and solvent B (water and 0.1% TFA) with a 60 min
gradient of 5–75% solvent A, a flow rate of 10.0 mL/min with monitoring at 254 nm.
BQ‐PCP was isolated in 7% yield (4 mg) and characterized by ESI mass spectrometry:
BQ‐PCP [M+H]+ = 845.4 (expected), [M+H]+ = 845.0 (observed); Purity (94%,
retention time = 17.0 min) was determined using analytical RP‐HPLC on a C18
analytical column (Phenomenex) with an eluent consisting of solvent A (acetonitrile
and 0.05% TFA) and solvent B (water and 0.05% TFA) with gradient of 5–75% solvent
A, using a flow rate of 1.20 mL/min, with monitoring at 254 nm.

3.5.11 Synthesis of Dimer‐ortho
To a solution of the commercially available 2,2'‐(1,2‐phenylene)diacetic acid
(40 mg, 0.20 mmol) in dry DMF (3 mL) at 0 ⁰C was added EDC (118 mg, 0.61 mmol),
DMAP (75 mg, 0.61 mmol) and DIEA (360 µL, 2.05 mmol) under nitrogen
atmosphere. After 20 min, quinine (200 mg, 0.61 mmol) was added. The reaction
mixture was stirred for 24 h at room temperature. The reaction mixture was diluted
with saturated aqueous sodium bicarbonate solution and extracted thrice with DCM.
The organic layers were combined, dried with sodium sulfate, filtered and
concentrated under vacuum. The crude material was dissolved in acetonitrile and
purification was done using RP‐HPLC on a C8 Vydac column with an eluent consisting
of solvent A (acetonitrile and 0.1% TFA) and solvent B (water and 0.1% TFA) with a
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60 min gradient of 5–55% A, a flow rate of 10.0 mL/min with monitoring at 254 nm.
The Dimer‐ortho was isolated in 6% yield (9 mg) and characterized by ESI mass
spectrometry: [M+H]+ = 807.9.4 (expected), [M+H]+ = 807.8.0 (observed); Purity of
the dimer (99%, retention time = 16.6 min) was determined using analytical RP‐HPLC
on a C18 analytical column (Phenomenex) with an eluent consisting of solvent A
(acetonitrile and 0.05% TFA) and solvent B (water and 0.05% TFA) with gradient of
5–75% A using a flow rate of 1.20 mL/min with monitoring at 254 nm.

3.5.12 Fluorescent Substrate Accumulation Assay
The substrate accumulation assay was carried out as described earlier with
minor modifications.143 125,000 MCF‐7/DX1 cells were suspended in a 1 mL BME
solution containing 0.5 µM calcein‐AM or 1.3 µM Rhodamine‐123 (R‐123) and
increasing concentrations of the dimers (10 µL). Cells treated with only DMSO and
GF120918 (1 μM) were used as controls. All compounds were dissolved in DMSO to
give a final 1% concentration in media. The cells were incubated at 37 ⁰C for 15 min
in case of calcein‐AM or 40 min in case of R123 in the incubator. The cells were
harvested by centrifugation at 1200 RPM at 4 ⁰C for 5 minutes, the media aspirated
and the cells re‐suspended in 400 µL ice cold PBS. For R‐123 containing samples,
cells were collected by centrifugation, resuspended in 1 mL of BME medium
containing increasing concentrations of the dimers and incubated for another 40
minutes at 37 °C. The cells were analyzed using FACS Calibur flow cytometer. Data
was obtained in duplicates from two independent experiments run on separate days.
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BQ‐PCP data were obtained from a single experiment. Ten thousand cells were
counted for each data point. A 488 nm argon laser and a 530 band pass filter were
employed. The IC50 values were acquired from the concentration‐dependent data
that were fitted using Sigma Plot software.

3.5.13 Photoaffinity Labeling in Live Cells
100,000 MCF‐7/DX1 cells were plated in a 24‐well plate and incubated with
BQ‐PCP (40 µM in 400 µL RPMI media) or DMSO for 20 min at 37 ⁰C in the incubator.
The final DMSO concentration was 0.5% in media. The cells were washed with PBS
(2x500 µL). Next, 500 µL PBS was added to each well and the plate kept in an ice
bath. The lid of the 24‐well plate was removed and the UV lamp was placed on top
of the entire plate. The UV lamp was placed in direct contact with the plate, such
that only the depth of the well (~17 mm) separated the light source and the cells.
The cells were irradiated with UV light (365 nm) for 30 minutes in the dark room.
During this time a click mix stock solution, composed of 400 µM biotin‐PEG3‐azide
(26 µL of 50 mM stock in DMSO), 1 mM copper sulfate (32 µL of 100 mM aqueous
solution) and 100 mM sodium ascorbate (320 µL of 1M aqueous solution) in 2822 µL
PBS, was freshly prepared. The UV‐lamp was removed from the 24‐well plate and
the PBS was aspirated. The click mix solution was added to each well (400 µL)
followed by incubation at 37 ⁰C for 30 minutes in the incubator. The cells were
washed with PBS (3x500 µL) and incubated with streptavidin‐dylight (500 nM in 400
µL RPMI media) for 35 min. The cells were washed with PBS (2x500 µL) to remove
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excess dye. The PBS was aspirated and 150 µL trypsin added to each well. The plate
was incubated for 2 minutes at 37 ⁰C in the incubator. Ice cold PBS (350 µL) was
added to each well. The cell suspension was pipetted into FACS tubes and analyzed
using FACS Calibur flow cytometer equipped with a 635 nm red diode laser and a
661nm (FL4 channel) band pass filter. For the TB+ samples, 10 µL trypan blue (0.01%
final concentration) was added to the cell suspension before FACS analysis. Ten
thousand cells were counted for each data point and histogram plots were obtained.
Data was obtained in duplicates from independent experiments run on separate
days.

3.5.14 Photoaffinity Labeling in Enriched P‐gp
Enriched P‐gp were prepared as reported earlier.150 The enriched P‐gp (3 µL
of 1.3 µg/µL stock) were thawed on ice for 2 minutes and re‐suspended in 30 μL 2X
buffer (50 mM Tris HCl, 0.01% aprotinin, 2 mM AEBSF), 40 μM BQ‐PCP (2 μl of 1.2
mM stock in DMSO) or 2 μL DMSO and 25 μL water (total volume of 60 μL). Samples
were incubated at ambient temperature for 10 minutes. Designated samples for UV
treatment were transferred to a 96‐well plate and irradiated under UV light (365 nm)
for 30 minutes on ice. The UV lamp was placed in direct contact with the plate, such
that only the depth of the well (~10 mm) separated the light source and the samples.
After irradiation, the samples were transferred back into microcentrifuge tubes.
Next, to each sample was added 1 mM biotin azide (2 μL of 35 mM stock in DMSO),
2.3 mM CuSO4 (2 μL of 75 mM aqueous stock), and 22.7 mM sodium ascorbate (2 μL
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of 750 mM aqueous stock). The eppendorf tubes were gently agitated on a plate
shaker for 30 minutes at room temperature. The samples were then incubated in
laemli loading buffer (2X final SDS concentration) for 30 minutes and loaded (~0.5 μg
total protein) onto a precast 10% polyacrylamide gel (Mini‐PROTEAN TGX®, Bio Rad)
and run for 90 minutes at 160 V 1X TGS buffer (25 mM Tris, 192 mM glycine and 0.1%
SDS in water). The gel was transferred to 0.45 µm nitrocellulose membrane (Fisher
Scientific) by electrophoresis in 1X TG buffer (25 mM Tris, 192 mM glycine, 20% v/v
methanol in water) for 2 hours at 100 V on ice. The nitrocellulose membrane was
blocked overnight in 20% milk (4 g of milk powder + 20 mL PBS + tween) at 4 °C on
rotary shaker. The next day, the nitrocellulose membrane was washed with 20 ml
PBS + tween, probed in a 1:2000 dilution (4 µL) of Neutravidin‐HRP antibody in 10%
bovine serum albumin (8 mL) and incubated with shaking for 3 hours at room
temperature. Following PBS + tween washes (3x20ml), the blot was developed using
500 µl SuperSignal® West Pico Luminol and Peroxide solution (Thermo Scientific),
exposed to X‐ray film and developed for 2 – 10 minutes.
For the P‐gp Western blot, 10 µL (~0.25 µg protein) was loaded onto a 7.5
mm 7.5% acrylamide gel and run for 160 V for 90 minutes in 1X TGS buffer. The gel
was transferred to 0.45 µm nitrocellulose membrane (Fisher Scientific) by
electrophoresis in 1X TG buffer (25 mM Tris, 192 mM glycine, 20% v/v methanol in
water) for 2 hours at 100 V on ice. The nitrocellulose membrane was blocked
overnight in 20% milk (4 g of milk powder + 20 mL PBS + tween) at 4°C on rotary
shaker. The next day, the nitrocellulose membrane was washed with 20 ml PBS +
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tween and probed with C219 antibody at a 1:4000 dilution in 5% milk (2 µL antibody
+ 8 mL PBSt + 0.4 g milk powder). Following three PBS + tween washes (20 mL/wash),
the blot was probed with 2 µl goat α‐mouse antibody in 5% milk (0.4 g milk powder
+ 8 ml PBSt). Following three PBS + tween washes (20 mL/wash), the blot was
developed using 500 µl SuperSignal® West Pico Luminol and Peroxide solution
(Thermo Scientific), incubated for 5 minutes, exposed to x‐ray film for 0.5‐10
minutes and developed.
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CHAPTER 4.

TOWARDS TAXOL BASED PRODRUG AND COMBINATION THERAPIES
TO OVERCOME P‐GLYCOPROTEIN MEDIATED TRANSPORT

4.1

Introduction

4.1.1 Taxol and P‐glycoprotein
The anticancer drug Taxol (also known as Paclitaxel) is one of the most highly
studied drugs in medicinal chemistry.1,2 Its isolation from Taxus brevifolia is
considered as one of the greatest natural product discoveries.3 Classified as a mitotic
inhibitor, taxol binds to β‐tubulin and blocks the disassembly of microtubules,
resulting in downstream apoptosis.4,5 It is a widely applicable anticancer agent,
which is used for treatment in lung, breast and ovarian cancer among others.6 The
emergence of tumors resistant to taxol dealt a major blow to cancer treatment.
While several mechanisms have been implicated for taxol resistance,7,8,9 its efflux by
P‐glycoprotein (P‐gp) is considered the leading cause.10 Using P‐gp knock‐out mice,
Van Tellingen et. al. proved the reduction of taxol bioavailability to be a
consequence of P‐gp mediated efflux.11 Further, P‐gp is the most highly expressed
transporter at the apical membrane of the endothelial cells that line the blood‐brain
barrier (BBB).12,13 Here, P‐gp limits the brain absorption taxol by effluxing
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it into the blood lumen, thus impeding the application of taxol in treatment of brain
cancer. 14,15,16 Hence, there is an urgent need to develop platforms to enhance taxol
accumulation within resistant tumors and the brain.

4.1.2 Taxol and P‐gp Inhibitors: Co‐administration Strategy
The first approach used to improve taxol bioavailability was co‐
administration with P‐gp inhibitors.17,18,19,20 In several in vivo studies, taxol
bioavailability was observed to be substantially elevated when co‐administered with
P‐gp

inhibitors

such

as

GF120918,17

PSC83321

and

cyclosporine.22 The

aminoquinoline antimalarial drugs quinine (Q) and chloroquine (CQ) are first
generation inhibitors of P‐gp. Their well‐established pharmacokinetic profile and
commercial availability made them favorable compared to other P‐gp inhibitors.
When used in combination with anticancer drugs, including taxol, they successfully
reversed P‐gp mediated resistance in vitro.23,24,25,26 Clinical trials using a combination
of Q and an anticancer drug (taxol or mitoxantrone or vincristine) in various drug
resistant cancers (acute myelogenous leukemia, non‐hodgkin lymphoma) have
shown modest results.27,28,29,30 Q and quinidine were recently identified as two of
the most effective inhibitors of P‐gp at the BBB clinically.14 These molecules were
reported to achieve a favorable balance between P‐gp inhibitory potency and high
unbound plasma concentrations, that other P‐gp inhibitors lacked. Further, the
aminoquinolines (Q, CQ, HCQ) are known lysosomotropic agents, capable of
inhibiting autophagy. Autophagy is used by cancer cells to resist taxol’s cytotoxic

160
action.31,32,33 Taxol and autophagy inhibitors have been shown to synergize and
hence achieve higher potency in vitro.34 In summary, a combination therapy of taxol
and aminoquinoline based P‐gp inhibitors could enhance taxol’s bioavailability and
produce a synergistic therapeutic effect.

4.1.3 Taxol Delivery Vehicles and Analogs: P‐gp Evasion Strategy
More recent approaches to improve taxol bioavailability have attempted to
circumvent rather than inhibit P‐gp.35 This has been achieved by either
encapsulating taxol in delivery vehicles or designing novel taxol analogs that are not
transported by P‐gp. A variety of drug delivery vehicles loaded with taxol have been
developed including gold nanoparticles,36 micelles,37 dendrimers,38 hyaluronic
nanoconjugates39 and cell penetrating peptides (Figure 4.1B‐C).40,41 Among the three
alcohol moieties of taxol, the C2´ alcohol is the most reactive and is most commonly
used as the site for functionalization (Figure 4.1A). 40,52,53 Since the C2´ alcohol is
vital for binding to tubulin, it is critical that taxol reverts to its original unmodified
structure in the cell.42 Thus the C2´ alcohol is functionalized by ester or carbonate
bonds that can be hydrolyzed inside the cell. Wender et. al. synthesized an
octaarginine‐taxol conjugate which employed a bio‐cleavable disulfide bridged
linker.40 This conjugate was shown to be more cytotoxic than taxol itself in P‐gp
overexpressing cells and in ovarian cancer mouse models.
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Structural analogs of taxol that are not transported by P‐gp, yet retain its
cytotoxic activity, have also been developed. These modifications range from minor
functionalization of the pendant alcohols to extensive re‐modeling of the core

Figure 4.1 Structures of (A) taxol with C2´ and C7 alcohols highlighted. The red
dotted line indicates the characteristic site of fragmentation observed in taxol’s
mass spectra. (B) Example of drug delivery vehicles developed for taxol and (C‐D)
taxol analogs that evade P‐gp.43,45,47

structure (Figure 4.1D).43,44,45,46,47 These molecules do not inhibit P‐gp mediated
transport and accumulate within P‐gp expressing cells in vitro. For instance, DJ‐927,
was shown to internalize to much higher levels within P‐gp overexpressing cells and
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displayed higher cytotoxicity than taxol in vitro. Moreover, in multiple mice models,
DJ‐927 displayed superior activity against P‐gp expressing tumors, relative to taxol
itself.43

4.2

Results and Discussion

4.2.1 Design
We envisioned two approaches to overcome P‐gp mediated taxol resistance:
(i) development of bivalent taxol analogs and (ii) co‐administration with the P‐gp
inhibitor Q2 in vivo. First, we designed taxol homo‐ and heterodimers as potential P‐
gp inhibitors, taking advantage of the multiple binding sites of P‐gp. These dimers
could potentially block P‐gp efflux in resistant cancer cells and consequently gain
access to the cell cytosol. Alternatively, the taxol dimers could no longer be P‐gp
substrates and thus evade transport. In either case, it is vital to deliver unmodified
taxol in the cell to avoid any loss in function. This would be achieved by utilizing
“traceless” disulfide linked tethers linked via ester bonds at the C2´ alcohol. The
disulfide bond reduces inside the cytosol, due to the high glutathione concentration,
leading to an intramolecular rearrangement that yields the unmodified drug. Our
group has previously utilized this traceless tethering strategy in the development of
two bivalent inhibitors, based on the P‐gp substrates abacavir and quetiapine.48,49
We envisioned heterodimers of taxol with aminoquinolines, to mimic the
combination therapy into a single inhibitor/prodrug molecule. As discussed earlier,
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the aminoquinolines can (i) augment P‐gp inhibition by forming vital binding
interactions with P‐gp and (ii) potentially synergize with taxol by inhibiting
autophagy. We designed heterodimers of taxol with Q and HCQ linked by a disulfide
bridged tether. GF120918 is highly potent P‐gp inhibitor. 17 In an effort to gain higher
binding affinity with P‐gp we designed a dimer composed of moieties from
GF120918 and taxol. Hence a heterodimer with a fragment of the P‐gp inhibitor
GF120918 (GFaniline) was synthesized.
Further, homodimers of taxol with different tether lengths (4 and 8
methylene units) were designed to test the effect of tether length on activity. To
improve the solubility of these hydrophobic dimers, a polyethylene glycol (PEG)
based taxol homodimer was also synthesized. These homodimers were linked by
ester bonds and thus could be potentially hydrolyzed inside the cell to generate
monomeric taxol. The C2´ alcohol moiety was used as the site of functionalization.
The second approach aimed to improve the brain penetration of taxol in vivo
by co‐administering it with Q2. Our group has previously demonstrated the ability of
Q2 to sensitize MCF‐7/DX1 cells to taxol.18 Q2 has an approximately 100‐fold higher
P‐gp inhibitory activity than monomeric Q. Q2 could potentially preserve Q’s
beneficial in vivo properties (high unbound plasma concentration and safe toxicity
profile) while enhancing P‐gp inhibition at the BBB. Herein the ability of Q2 to inhibit
P‐gp at the BBB and improve the brain accumulation of a model P‐gp substrate,
verapamil, was studied using the in situ rat brain perfusion model.49,51

164
4.2.2 Synthesis of Taxol Homodimers
Homodimers of taxol linked with tethers composed of four (Tax‐C4) and
eight methylene units (Tax‐C8) were synthesized using PyBOP coupling (Scheme 4.1).
The PEG tethered homodimer, Taxol‐PEG, was also synthesized under similar
conditions (Scheme 4.1). The dimers were purified to homogeneity by RP‐HPLC,
characterized by ESI mass spectrometry and purity was assessed by analytical RP‐
HPLC. Taxol has a characteristic mass spectrometry fragmentation pattern, which
was used to discern the site of functionalization of the dimers (Figure 4.1A).50 The
fragmentation pattern observed in the mass spectrum was consistent with
functionalization at the C2´ alcohol. The tail fragment containing the C2’ linked
tether was seen, in addition to the core fragment with an unmodified C7 alcohol.

Scheme 4.1 Synthesis of taxol homodimers.
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4.2.3 Synthesis of Taxol Heterodimers
Taxol‐monotether was synthesized by PyBOP coupling of taxol with 4,4’‐
dithiodibutyric acid (Scheme 4.2A). The product was purified by RP‐HPLC,
characterized by ESI mass spectrometry and the purity determined by analytical RP‐
HPLC. The fragmentation pattern observed in the mass spectra was consistent with
functionalization at the C2´ alcohol of taxol. Next, Taxol‐monotether was conjugated
with Q and HCQ using PyBOP as the coupling reagent to form Tax‐Q and Tax‐HCQ,
respectively (Scheme 4.2A).

Scheme 4.2 Synthesis of taxol heterodimers (A) Tax‐Q, Tax‐HCQ and (B) Tax‐GF.
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The heterodimers were purified by RP‐HPLC, characterized by ESI mass spectrometry
and their purity determined by analytical RP‐HPLC. Further, we coupled a sub‐unit
(GFanline) of the potent P‐gp inhibitor GF120918 to taxol, in an effort to enhance
binding affinity with P‐gp. GFaniline was conjugated with sebacic acid by HATU
coupling to obtain the GFaniline‐monotether (Scheme 4.2B). The Tax‐GF heterodimer
was synthesized by coupling GFaniline‐monotether and taxol using PyBOP as the
coupling reagent (Scheme 4.2B). Tax‐GF was purified by RP‐HPLC, characterized by
ESI mass spectrometry and its purity determined by analytical RP‐HPLC.

4.2.4 P‐gp Inhibition
To investigate P‐gp inhibition with the taxol dimers, the fluorescent substrate
accumulation assay was carried out. The P‐gp overexpressing breast cancer cell
MCF‐7 sub‐line, MCF‐7/DX1 was utilized for the assays. Assays were carried out
using either Calcein‐AM or Rhodamine‐123 (R‐123) as the fluorescent substrates.
None of the taxol dimers caused a significant increase in cellular fluorescence
relative to GF120918 up to 50 µM concentration. As seen for model dimers Tax‐PEG
and Taxol‐HCQ in Figure 4.2, the R‐123 fluorescence levels in the dimer treated cells
were similar to that of monomeric taxol. Tax‐PEG showed a slight increase in cellular
fluorescence, but about 40‐fold lower in comparison to GF120918. At concentrations
greater than 50 µM the taxol dimers and monomer were found to be insoluble. Even
with the hydrophilic PEG tether based Tax‐PEG, no improvement in solubility was
observed. Hence, the taxol dimers were observed to not inhibit P‐gp mediated efflux.
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Figure 4.2 Histograms displaying MCF7/DX1 fluorescence upon addition of R‐123
accumulation with 50 µM taxol (red), 50 µM Tax‐PEG (grey), 40 µM Tax‐HCQ (blue),
and 1 µM GF120918 (green) in MCF‐7/DX1 cells.

4.2.5 Cellular Internalization of Taxol Dimers
Next, we wished to investigate whether the taxol dimers were not interacting
with P‐gp and were consequently internalizing within MCF‐7/DX1 cells. This study
was carried out in collaboration with Allison Lange (Hrycyna Lab, Purdue University)
using an RP‐HPLC based cellular internalization assay. The assay was performed in
MCF‐7 and MCF‐7/DX1 cells. Initially, control studies using 10 µM taxol with MCF‐7
and MCF‐7/DX1 cells were carried out. The taxol monomer accumulated rapidly
within MCF‐7 cells and reached a maximum within 5 hours (Figure 4.3A). In contrast
no taxol was observed within MCF‐7/DX1 cells up to 24 hours (Figure 4.3A).
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Figure 4.3 (A) Cellular internalization of taxol (10 µM) in MCF‐7 and MCF‐7/DX1 cells.
Internalization of (10 µM) Tax‐HCQ and appearance of taxol in (B) MCF‐7 and (C)
MCF‐7/DX1 cells.

Next, the assay was performed with Tax‐HCQ at 10 µM concentration, in
MCF‐7 and MCF‐7/DX1 cells. In contrast to monomeric taxol, Tax‐HCQ successfully
internalized within MCF‐7 cells, as well as the P‐gp overexpressing MCF‐7/DX1 cells
(Figure 4.3B‐C). Further, the Tax‐HCQ peak was observed to decrease with time and
a subsequent increase in the appearance of taxol was observed in MCF‐7 cells. This
suggests that the disulfide linked tether is reducing inside the MCF‐7 cells and
undergoes rearrangement to release taxol. Unlike the data obtained with MCF‐7
cells, the taxol levels generated with MCF‐7/DX1 cells were very low (Figure 4.3B‐C).
In summary, accumulation of the Tax‐HCQ within MCF‐7/DX1 cells, relative to taxol
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alone, showed that this dimer successfully evades P‐gp mediated transport.
However, the dimer‐reverted taxol was not observed in MCF‐7/DX1, presumably
because it is effluxed out of these cells.

4.2.6 In Situ Brain Perfusion Studies
The in situ brain perfusion assay was carried out by our collaborator Dr.
David Miller at the National Institutes for Health (NIH). [3H]verapamil was used as a
model P‐gp drug substrate that is known to suffer from poor brain accumulation.49
[14C]sucrose, which does not permeate into the brain unless the BBB tight junctions
are compromised, was used as a control to assess BBB integrity. These radioactive
substrates were infused into the carotid artery of anesthetized male sprague dawley
rats for 20 min, in the presence or absence of Q or Q2. As seen in Figure 4.4A, no
increase in [14C]sucrose levels were seen even when using the highest concentration
of Q2 (10 µM), relative to the control or Q. Thus the BBB integrity is not
compromised under the experimental conditions. Further, an approximately 1.5‐fold
improvement in the brain‐to‐blood ratio of the [3H]verapamil in the presence of 10
µM Q2 relative to 10 µM Q was observed (Figure 4.4B). A similar trend was also
observed at 1 µM concentrations of Q and Q2. This data shows the ability of Q2 to
inhibit P‐gp at the BBB and aid the brain accumulation of [3H]verapamil, albeit
modestly. Studies with [3H]taxol as the drug substrate in the presence of Q2 are
underway. Taxol is a better substrate of P‐gp than verapamil and hence a more
substantial improvement in the blood‐brain ratio is expected.
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Figure 4.4 Brain accumulation of (A) [14C]sucrose or (B) [3H]verapamil in rats
perfused for 20 min in the presence or absence of 10 μM Q or Q2.

4.2.7 Other Taxol Derivatives
We aimed to obtain crystal structures of C. elegans P‐gp bound with taxol in
collaboration with Prof. Jue Chen at Purdue University. To this end taxol modified
with a heavy atom, such as bromine, was envisioned. Bromine was conjugated to
the C2´ position of taxol by esterification with 3‐bromo propionic acid to form
Bromo‐Taxol, using PyBPOP as the coupling reagent (Scheme 4.3A). The product was
purified by RP‐HPLC, characterized by ESI mass spectrometry and its purity
determined by analytical RP‐HPLC. The mass spectrum was consistent with
functionalization at the C2´ position of taxol. Crystals of the C. elegans P‐gp bound
with Bromo‐Taxol complex were obtained, but diffracted poorly at a resolution of
~8‐10 Å. An alternative future strategy could employ cephalomanine, an natural
congener of taxol. Bromination of the pendant alkene of cephalomanine could
provide di‐bromo taxol analogs, for future crystallographic studies.54,55
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Scheme 4.3 (A) Synthesis of Bromo‐taxol (B) TBDMS‐taxol and (C) cephalomanine.

Finally, we envisioned taxol dimers linked via the C7 alcohol. In contrast to
C2´ alcohol, this moiety can be modified without significant loss of anticancer
activity. Thus, the C7 linked dimers could: (i) evade P‐gp and gain access to the cell’s
cytosol as well as (ii) possess cytotoxic activity in their own right. This strategy would
abrogate the need for dimer breakdown to monomeric taxol inside the cell. To this
end the C2´ alcohol of taxol was protected by TBDMS, following the protocol
described by Kingston et. al (Scheme 4.3B).56 TBDMS‐taxol was purified by RP‐HPLC
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and characterized by ESI mass spectrometry. Next, TBDMS‐taxol was subject to
coupling using either PyBOP or EDC as the coupling reagent. However no dimer was
formed in each case, with unreacted taxol as the major constituent. For future
explorations DCC coupling, as utilized by Wender et. al. could be employed. 40

4.3

Conclusion

A small library of taxol homo‐ and heterodimers was synthesized. The
homodimers contained either flexible methylene (Tax‐C4, Tax‐C8) or PEG based
tethers (Tax‐PEG). Heterodimers of taxol with the aminoquinoline drugs Q (Tax‐Q)
and HCQ (Tax‐HCQ), linked by a bio‐reversible disulfide tether, were developed.
Taxol was also linked with GFaniline (Tax‐GF) in an effort to maximize binding with P‐
gp. Both the homo and heterodimers were found to not inhibit P‐gp mediated efflux
of fluorescent substrates. However, Taxol‐HCQ was shown to evade P‐gp mediated
efflux and successfully internalize within both MCF‐7 and P‐gp overexpressing MCF‐
7/DX1 cells. Further, Taxol‐HCQ reduced and reverted to taxol in cyto in MCF‐7 cells,
as seen by the reduction in dimer levels and appearance of taxol with time. The
dimer‐reverted taxol accumulation however was very low in MCF‐7/DX1 cells, as
compared to MCF‐7 cells, possibly due to efflux by P‐gp in the MCF‐7/DX1 cell line.
Further, the in situ rat brain perfusion assay showed that 10 µM Q2 does not cause
compromise integrity of the BBB and is able to improve the accumulation of
[3H]verapamil in the brain by approximately 1.6‐fold. The assay is presently being
studied with [3H]taxol.
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4.4

Materials and Methods

4.4.1 Materials
Taxol was purchased from LC laboratories (Woburn, MA). 3,6,9‐
trioxaundecanedioic (PEG) acid was purchased from Sepctrum Chemicals (Gardena,
CA). Quinine was purchased from TCI America (Portland, OR). Q2 was synthesized as
described in Chapter 2. GFanline was synthesized by previous group members and was
available in house. Sebacic acid was purchased from Fluka. Hydroxychloroquine was
purchased from Acros organics. Benzotriazol‐1‐yl‐oxytripyrrolidinophosphonium
hexafluorophosphate (PyBOP) was obtained from Genscript (Piscataway, NJ). All
other chemicals were purchased from Sigma Aldrich. TBDMS‐taxol was synthesized
by the procedure described by Kingston et. al.56

4.4.2 Cell Culture
MCF‐7/DX1 cells were cultured at 37 ⁰C in 5% CO2 and maintained in RPMI
1640 media supplemented with 10% fetal bovine serum, 2 mM of L‐glutamine
(Cellgro Mediatech) 50 units/mL of penicillin (cambrex bioscience, Walkersville), 50
μg/mL streptomycin (Cellgro Mediatech) and 1 μM doxorubicin. MCF‐7 cells were
cultured similarly but with media deficient of doxorubicin. Basal Medium Eagle
Media (BME) (Cellgro, Mediatech) supplemented, with 10 % fetal bovine serum
(FBS), at a pH of 7.3‐7.5 was used.
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4.4.3 General Synthesis of Taxol Homodimers (Tax‐C4, Tax‐C8 and Tax‐PEG)
To a solution of the biscarboxylic acid (0.1 mmol) in anhydrous DMF (2 mL)
under nitrogen atmosphere, were added PyBOP (0.3 mmol), DMAP (0.05 mmol), and
DIEA (1.0 mmol). After stirring at room temperature for 20 minutes, taxol (0.3 mmol)
was added and stirred for 24 hours. The solvent was concentrated under vacuum
and the crude material dissolved in acetonitrile. Purification was done by RP‐HPLC
using a C18 column (Phenomenex) with an eluent consisting of solvent A
(acetonitrile and 0.1% TFA) and solvent B (water and 0.1% TFA) with a 60 minute
gradient of 10–95% A, at a flow rate of 12.0 mL/min, with monitoring at 230 nm and
254 nm. The homodimers were obtained in a typical yield of 25% and were
characterized by ESI mass spectrometry (Table 4.1). Purity was determined by
analytical RP‐HPLC using a C8 (Tax‐PEG and Tax‐C8) or C18 (Tax‐C4) analytical
column (Phenomenex) with an eluent of solvent A (acetonitrile and 0.05% TFA) and
solvent B (water and 0.05% TFA) with gradient of 50–95% A (Tax‐C4) or 30‐95% A
(Tax‐PEG and Tax‐C8), at flow rate of 1.2 mL/min, monitoring at 254 nm (Table 4.1).
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Table 4.1 Mass spectral and purity data for taxol homodimers.
Dimer

Purity (%)

Retention time (min)

Observed Mass

Observed Mass

[M+H]

+

[M+H]+

Tail fragment

Expected Mass

Tax‐C4

93

18.4

1818.9

1818.9

681.7

Tax‐C8

94

25.9

1875.0

1875.6

738.0

Tax‐PEG

94

23.5

1894.0

1895.6

758.0

4.4.4 Synthesis of Taxol‐Monotether
To a solution of 4,4’‐dithiodibutyric acid (29 mg, 0.12 mmol) in anhydrous
DMF (2 mL) under nitrogen atmosphere, were added PyBOP (56 mg, 0.11 mmol) and
DIEA (40 µL, 0.23 mmol). After stirring at room temperature for 20 minutes, taxol
(40 mg, 0.04 mmol) was added. The reaction mixture was stirred for 24 hours. The
solvent was concentrated under vacuum and the crude material dissolved in
acetonitrile. The crude material was purified by RP‐HPLC using a C18 column
(Phenomenex) with an eluent consisting of solvent A (acetonitrile and 0.1% TFA) and
solvent B (water and 0.1% TFA) with a 60 minute gradient of 5–95% A, a flow rate of
12.0 mL/min, with monitoring at 230 nm and 254 nm. Taxol‐monotether was
obtained in 28% yield (12 mg) and characterized by ESI mass spectrometry: [M+H]+ =
1075.2 (expected), [M+H]+ = 1075.1 (observed), 506.5 (observed tail fragment).
Purity was determined (99%, retention time = 14.3 min) using analytical RP‐HPLC on
a C18 analytical column (Phenomenex) with an eluent consisting of solvent A
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(acetonitrile and 0.05% TFA) and solvent B (water and 0.05% TFA) with a gradient of
40–95% A, a flow rate of 1.20 mL/min, monitoring at 254 nm.

4.4.5 General Synthesis of Taxol Heterodimers (Tax‐Q and Tax‐HCQ)
To a solution of taxol‐monotether (0.017 mmol) in anhydrous DMF (2 mL)
under nitrogen atmosphere, were added PyBOP (0.05 mmol) and DIEA (0.17 mmol).
The reaction mixture was stirred for 20 minutes at room temperature. Q or HCQ
(0.05 mmol) was added next and stirred for 24 hours. The reaction mixture was
concentrated under vacuum and dissolved in DMSO. Purification was done by RP‐
HPLC using a C18 column (Phenomenex) with an eluent consisting of solvent A
(acetonitrile and 0.1% TFA) and solvent B (water and 0.1% TFA) with a 60 minute
gradient of 10–95% solvent A, a flow rate of 12.0 mL/min with monitoring at 230 nm
and 254 nm. The dimers were obtained in a typical yield of 26% and were
characterized by ESI mass spectrometry (Table 4.2). Purity was determined by
analytical RP‐HPLC using a C8 analytical column with an eluent consisting of solvent
A (acetonitrile and 0.05% TFA) and solvent B (water and 0.05% TFA) with gradient of
5‐75% A, a flow rate of 1.20 mL/min with monitoring at 254 nm (Table 4.2).
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Table 4.2 Mass spectrometry and purity data for taxol heterodimers.
Dimer

Purity (%)

Retention time (min)

Expected Mass
[M+H]

Observed Mass

+

[M+H]

+

Observed Mass
Tail fragment

Tax‐Q

99

22.8

1381.6

1381.5

812.8

Tax‐HCQ

98

18.5

1393.0

1392.9

823.9

4.4.6 Synthesis of Tax‐GF
To a solution of sebacic acid (194 mg, 0.96 mmol) in anhydrous DMF (3 mL)
under nitrogen atmosphere, were added HATU (365 mg, 0.96 mmol) and DIEA (0.56
mL, 3.2 mmol). The reaction mixture was stirred for 20 minutes at room
temperature. GFaniline (100 mg, 0.32 mmol) was added next and stirred for 24 hours.
The reaction mixture was diluted with water and extracted with DCM thrice. The
organic layers were combined, filtered and concentrated under vacuum. The residue
was dissolved in acetonitrile. Purification was done by RP‐HPLC using a C8 column
(Vydac) with an eluent consisting of solvent A (acetonitrile and 0.1% TFA) and
solvent B (water and 0.1% TFA) with a 60 min gradient of 10–95% solvent A, a flow
rate of 12.0 mL/min with monitoring at 230 nm and 254 nm. GFaniline‐monotether
was obtained in 52% yield (83 mg) and characterized by ESI mass spectrometry:
[M+H]+ = 497.6 (expected), [M+H]+ = 497.4 (observed).
To a solution of the GFaniline‐monotether (10 mg, 0.02 mmol) in anhydrous
DMF (3 mL) under nitrogen atmosphere, were added PyBOP (38 mg, 0. 06 mmol)
and DIEA (35 µL, 0.2 mmol). The reaction mixture was stirred for 20 minutes at room
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temperature. Taxol (51 mg, 0.06 mmol) was added and the stirred for 48 hours. The
reaction mixture was concentrated under vacuum and dissolved in acetonitrile. The
crude material was purified by RP‐HPLC using a C8 column (Phenomenex) with an
eluent consisting of solvent A (acetonitrile and 0.1% TFA) and solvent B (water and
0.1% TFA) with a 60 minute gradient of 15‐95% A, a flow rate of 12.0 mL/min with
monitoring at 230 nm and 254 nm. Tax‐GF was obtained in 20% yield (1.5 mg) and
characterized by ESI mass spectrometry: [M+H]+ = 1333.5 (expected), [M+H]+ =
1333.3 (observed). Purity (retention time = 22.6 min, 98%) was determined by
analytical RP‐HPLC using a C8 analytical column (Phenomenex) with an eluent
consisting of solvent A (acetonitrile and 0.05% TFA) and solvent B (water and 0.05%
TFA) with gradient of 5–75% A, a flow rate of 1.20 mL/min with monitoring at 254
nm.

4.4.7 Synthesis of Bromo‐Taxol
To a solution of 3‐bromopropanoic acid (23 mg, 0.15 mmol) in anhydrous
DMF (2 mL) under nitrogen atmosphere, were added PyBOP (70 mg, 0.13 mmol) and
DIEA (60 µL, 0.35 mmol). After stirring at room temperature for 20 minutes, taxol
(50 mg, 0.06 mmol) was added. The reaction mixture was stirred for 24 hours. The
solvent was concentrated under vacuum, the crude material dissolved in water and
extracted with DCM thrice. The organic layers were combined, dried with sodium
sulfate and concentrated under vacuum. The residue was dissolved in acetonitrile.
Purification was done using RP‐HPLC on a C18 column (Phenomenex) with an eluent
consisting of solvent A (acetonitrile and 0.1% TFA) and solvent B (water and 0.1%
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TFA) with a 60 minute gradient of 5–95% A, a flow rate of 12.0 mL/min with
monitoring at 230 nm and 254 nm. Bromo‐Taxol was obtained in 10% yield (5 mg)
and characterized by ESI mass spectrometry: [M+Na]+ = 1010.8 (expected), [M+Na]+
= 1010.2 (observed), 340.4 (observed tail fragment). Purity of Bromo‐Taxol was
determined (99%, retention time = 11.8 min) using analytical RP‐HPLC on a C8
analytical column (Phenomenex) with an eluent consisting of solvent A (acetonitrile
and 0.05% TFA) and solvent B (water and 0.05% TFA) with a gradient of 50–95% A, a
flow rate of 1.20 mL/min with monitoring at 230 nm.

4.4.8 Fluorescent Substrate Accumulation Assay
The substrate accumulation assay was carried out as described earlier with
minor modifications.57 125,000 MCF‐7/DX1 cells were suspended in a 1 mL BME
solution containing 0.5 µM calcein‐AM or 1.3 µM Rhodamine‐123 (R‐123) and
increasing concentrations of the dimers (10 µL). Cells treated with only DMSO and
GF120918 (1 μM) were used as controls. All compounds were dissolved in DMSO to
give a final 1% concentration. The cells were incubated at 37 ⁰C for 15 minute in case
of calcein‐AM or 40 minute in case of R123. The cells were harvested by
centrifugation at 1200 RPM at 4 ⁰C for 5 minutes, the media aspirated and the cells
re‐suspended in 400 µL ice cold PBS. For R‐123 containing samples, cells were
collected by centrifugation, resuspended in 1 mL of BME medium containing
increasing concentrations of the dimers and incubated for another 40 minute at
37 °C. The cells were analyzed using FACS Calibur flow cytometer equipped with a
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488 nm argon laser and a 530 band pass filter. Ten thousand cells were counted for
each data point and histogram plots were obtained.

4.4.9 Internalization Assay
MCF7/DX1 or MCF‐7 cells were plated at 500,000 cells/well in 6‐well plates
and cultured overnight in RPMI media. The media was aspirated and replaced with 1
mL RPMI media containing 10 µM taxol or taxol dimers. The cells were incubated at
37 ⁰C. At relevant time points, the cells were washed with PBS (5x 1 mL) and the
cells lysed with 200 µL ice cold RIPA buffer (150 mM NaCl, 0.25% sodium
deoxycholate, 1% SDS, 20mM Tris‐HCl, pH=7.5). The lysate was collected with a
sterile cell scraper. 500 µL ice cold acetonitrile containing the internal standard
bromo‐phenol was added and the lysate transferred into 1.5 mL microcentrifuge
tubes. The samples were vortexed, followed by centrifugation at 10000xg for 10
minutes. The supernatant was collected and stored at ‐80 ⁰C until analysis. Samples
were analyzed using analytical RP‐HPLC on a C18 analytical column (Phenomenex)
with an eluent consisting of solvent A (acetonitrile and 0.05% TFA) and solvent B
(water and 0.05% TFA) with a gradient of 30‐90% A, at a flow rate of 1.2mL/min,
with monitoring at 254 nm. The peak areas corresponding to the taxol monomer and
dimer were quantified and plotted using Microsoft Excel.
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4.4.10 In Situ Rat Brain Perfusion Assay
In situ brain perfusion assays were performed as described previously with
minor modifications.51 Briefly, male rats were anaesthetized by i.p. injection with 1
mL/kg ketamine cocktail (79 mg/mL ketamine, 3 mg/mL xylazine, 0.6 mg/ mL
acepromazine) and administered heparin (10 kU/kg). The common carotid arteries
were exposed and cannulated using silicone tubing connected to a perfusion circuit
system, and perfused with oxygenated Ringer’s solution (37 °C) (in mM: NaCl 117,
KCl 4.7, MgSO4 0.8, NaHCO3 24.8, KH2PO4 1.2, CaCl2 2.5, D‐glucose 10, plus 39 g/L
170 kDa dextran, 1 g/L BSA, and 0.055 g/L Evans Blue) at 3 mL/min. [14C]Sucrose (0.5
μCi/mL) or [3H]verapamil (0.1 μCi/mL) and either Q (10 μM) or Q2 (10 μM) were
infused into the circuit via syringe pump at 0.5 mL/min for 20 minutes. Following
perfusion, a sample of perfusate was collected from each cannula as a reference.
Cerebral hemisphere sections were separated and stripped of meninges, midbrain
and choroid plexuses, and minced. Tissue and 100 μL perfusate samples were
digested for 2 days with tissue solubilization solution (Hyamine Hydroxide, MP
Biomedicals, Santa Ana, CA). Samples were prepared for scintillation counting by
adding 100 μL of 30% acetic acid and 4 mL of liquid scintillation cocktail (CytoScint ES,
MP Biomedicals), and incubated overnight in the dark. Results were expressed as the
ratio of radioactivity in the brain to that of perfusate (Rbr μL/g): (Rbr =
Cbrain/Cperfusate) where Cbrain is the dpm/g in the brain tissue and Cperfusate is
the dpm/μL in the perfusate.
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Dual-Action Antibiotic Peptides

Targeting Intracellular Pathogenic Bacteria with Unnatural ProlineRich Peptides: Coupling Antibacterial Activity with Macrophage
Penetration**
Jerrin Kuriakose, Victor Hernandez-Gordillo, Manish Nepal, Anna Brezden, Vanessa Pozzi,
Mohamed N. Seleem,* and Jean Chmielewski*
The emergence of drug-resistant bacteria is a growing challenge to anti-infective therapy. Pathogens such as methicillinand vancomycin-resistant Staphylococcus aureus (MRSA and
VRSA) have undermined most, and sometimes all, clinically
usable antibacterial drugs.[1] Another challenge in the development of effective antibacterial agents arises from bacterial
pathogens that have evolved to inhabit mammalian cells, such
as phagocytic macrophages.[2] Bacteria, such as Mycobacterium tuberculosis, Salmonella, Listeria, and Brucella, reproduce within these host mammalian cells and form a repository
that a significant subset of antibiotics, such as b-lactams and
aminoglycosides, are unable to access.[3] These difficulties
have spurred efforts to target intracellular pathogens using
delivery vehicles containing antibiotics.[4]
Antimicrobial peptides (AMPs) are a class of antibiotics
that generally act by targeting the microbial cell membrane,
resulting in cell lysis.[5] This mechanism of action is also one of
the major drawbacks associated with clinical use of AMPs
owing to host cell toxicity. However, a small class of nonmembrane lytic AMPs have been identified.[6] Unifying
features of these non-membrane lytic AMPs, including
bactenectin, PR-39, and drosocin, are a high proline content
and an overall cationic charge owing to high levels of arginine.
While proline-rich AMPs (P-AMPs) are less toxic than
membrane-lytic AMPs, as seen in their lack of hemolytic
activity and safety in animal models,[6] the majority do not
enter mammalian cells,[7] with a few exceptions.[8]
AMP-inspired analogues have been widely explored.[9–12]
We sought to interrogate the interplay of structure and
function for P-AMPs with idealized, de novo designed
sequences. At the same time, we wished to enhance the
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antibiotic activity of these proline-rich structures with an
innate mammalian cell penetrating ability. Ultimately we
sought to generate non-lytic antibacterial peptides with the
ability to localize within mammalian cells, thereby providing
agents that target elusive intracellular pathogenic bacteria.
P-AMPs have an abundance of proline residues (25–
50 %), and as a result have a propensity to adopt a polyproline
type II helical (PPII) conformation.[6a,c] P-AMPs, such as PR39 and bactenicin, contain triad repeats of PRP and RPP,
respectively, often with hydrophobic amino acids.[6c] With
these key features in mind, we designed a series of peptides
starting with a sequence containing four copies of the PRP
triad repeat found in PR-39, namely Fl-PRP-4 (Figure 1 a),
and a sequence with more cationic PRR triad (Fl-PRR-4) in
an effort to improve mammalian cell uptake (Figure 1 a). This
latter sequence was further modified to contain all prolinebased residues, including an unnatural amino acid containing
a guanidinium group (PR, Fl-PPRPR-4) to investigate possible
links between activity and the ability to adopt a PPII
conformation (Figure 1 b,c). Finally, using PR-39 and bactenicin as models, we introduced additional hydrophobicity into
the PPRPR design by replacing proline with an isobutylmodified proline analogue (PL) in two different length
peptides Fl-PLPRPR-3 and Fl-PLPRPR-4 (Figure 1 b). These
latter three peptides were designed to possess a PPII scaffold
such that every third amino acid along the peptide backbone
would be aligned along the same face of the helix, resulting in
amphiphilic structures (Figure 1 c). Additionally, fluorescein
(Fl) was incorporated at the N-terminus of each peptide, after
a glycine spacer, to image cellular localization.
The peptides were synthesized using an Fmoc-based,
solid-phase strategy on the Rink amide resin. The unnatural
proline-based amino acids with the appropriate protecting
groups were synthesized as previously described.[13] All of the
peptides were purified to homogeneity by reverse-phase
HPLC and characterized by MALDI mass spectrometry.
Circular dichroism (CD) was used to evaluate the conformation of the designed peptides, as a PPII conformation displays
a characteristic maximum in the CD spectrum at 225 nm.[14]
The CD spectrum of Fl-PRP-4 exhibited a very weak
maximum at 225 nm, while Fl-PRR-4 lacked the characteristic 225 nm maximum entirely (see the Supporting Information). Alternatively, Fl-PPRPR-4, Fl-PLPRPR-3, and Fl-PLPRPR4 each displayed a strong peak at 225 nm, indicating that an
all-proline backbone facilitated the formation of a PPII helix.
The antibacterial activity of the five peptides was explored
with E. coli and S. aureus. The minimalistic PRP-based
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Table 1: Antibacterial and hemolysis activity of designed P-AMPs.

Fl-PRP-4
Fl-PRR-4
Fl-PPRPR-4
Fl-PLPRPR-3
Fl-PLPRPR-4
Melittin

E. coli
MIC[a] [mm]

S. aureus
MIC [mm]

Hemolysis [mm]

> 100
40
60
60
4
4.6[15]

> 100
20
> 100
60
12
2.1[15]

> 100
> 100
> 100
> 100
> 100
5[b]

[a] The minimum inhibitory concentration (MIC). [b] Greater than 80 %
hemolysis was observed at this concentration.

Figure 1. Structures of the idealized P-AMP sequences containing
a) natural amino acids and b) unnatural proline-based residues PR
(blue modification) and PL (red modification). c) Model of Fl-PPRPR-4
looking down the PPII helix (Pro in red, PR in blue).

peptide (Fl-PRP-4) was not active against both bacterial
strains up to a concentration of 100 mm. However, increasing
the cationic character with the PRR-based peptide (Fl-PRR4) led to modest but observable activity in both Gram-positive
and -negative bacteria (Table 1). Electrostatic interactions
between cationic AMPs and the negatively charged bacterial
membrane are believed to be the first step in antibacterial
action,[5] thereby explaining the improved antibacterial activity when going from Fl-PRP-4 (+ 4 charge) to Fl-PRR-4 (+ 8
charge). A similar trend was also observed for Fl-PLPRPR-3
and Fl-PLPRPR-4. Interestingly, restricting Fl-PRR-4 to a rigid
PPII conformation had a detrimental effect on activity, as
seen with Fl-PPRPR-4. However, the addition of hydrophobic
isobutyl groups to the proline backbone of Fl-PPRPR-4 (FlPLPRPR-4) resulted in a dramatic improvement in activity
against both bacteria (Table 1). For E. coli, this data is
comparable to the MIC for melittin (4.6 mm) and buforin II
(1.6 mm), but significantly better than magainin II
Angew. Chem. Int. Ed. 2013, 52, 9664 –9667

(40.5 mm).[15] Replacing the fluorescein moiety in this peptide
with an acetyl group led to no discernible change in the
antibacterial activity. The de novo designed proline-rich
peptides also caused only low levels of damage to human
red blood cells (hRBCs) (< 5 %) after 1 h of incubation up to
a concentration of 100 mm (see Table 1 and the Supporting
Information), whereas melittin was highly hemolytic at 5 mm.
This lack of observed hemolysis with our designed P-AMPs is
a crucial feature for potential in vivo applications. Fl-PLPRPR4 was therefore identified as the most potent, non-hemolytic
antibacterial among our designed proline-rich peptides.
To rescue mammalian cells infected with intracellular
bacteria, antimicrobial agents need to effectively penetrate
within these host cells. We evaluated the cell penetrating
ability of all five peptides by flow cytometry with J774A.1
macrophage cells. Macrophages are commonly invaded by
intracellular bacteria and were thus selected for uptake
studies. The three peptides (Fl-PRR-4, Fl-PPRPR-4, FlPLPRPR-4) with the highest cationic charge (+ 8) showed
significantly higher cellular fluorescence as compared to FlPLPRPR-3 (+ 6) and Fl-PRP-4 (+ 4) (Figure 2).[16] The fluorescence associated with Fl-PPRPR-4 uptake, however, was
significantly reduced with trypan blue, a dye used to quench
external fluorescence that may be due to cell surface binding.[17] Among the most cationic peptides, there was approximately a four-fold increase in uptake in going from Fl-PRR-4
to Fl-PLPRPR-4. The higher uptake of this structurally
restricted peptide is in agreement with reports where rigidity

Figure 2. Cellular internalization of the designed P-AMPs. J774A.1 cells
were incubated with the peptides (15 mm) for 1 h and analyzed by flow
cytometry. Trypan blue (TB) was used to quench fluorescence of
membrane-bound peptide.[17]
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and an enforced PPII conformation, enhanced cellular
internalization of arginine rich peptides.[13a, 18] Additionally,
the designed peptides were found to not compromise the
integrity of the cellular membranes using propidium iodide
(see the Supporting Information). Thus among the designed
P-AMPs, Fl-PLPRPR-4 was found to be most potently internalized within J774A.1 macrophage cells. Fl-PLPRPR-4 was
also found to satisfy two vital properties for application
against intracellular bacteria: limited toxicity towards
J774A.1 macrophage cells (at 15 mm) and resistance to
proteolytic degradation by trypsin (see the Supporting
Information).
Confocal microscopy was used to investigate the subcellular localization of Fl-PLPRPR-4 within J774A.1 cells
(Figure 3). We observed co-localization with each of the

Figure 3. Confocal microscopy images of co-localization studies using
Fl-PLPRPR-4 (15 mm) and MitoTracker (a–c) or LysoTracker (d–f) within
J774A.1 cells after 1 h. Scale bars: 10 mm.

tracking dyes and Fl-PLPRPR-4 across a range of time points
(1 h: Figure 3; 10 and 30 min: see the Supporting Information) pointing to association with both mitochondria and
endosomes. Under these conditions, Fl-PLPRPR-4 was found
to have a limited influence on mitochndrial membrane
depolarization (ca. 10 %), whereas the known mitochondrial
depolarizer FCCP showed strong depolarization (ca. 30 %;
see the Supporting Information). Arginine-rich cell-penetrating peptides and synthetic vectors are believed to internalize
by endocytosis or direct translocation or a combination of
both pathways depending on concentration, cell type, and
cargo.[19] For instance, Fl-PLPRPR-4 has previously been shown
to preferentially localize with mitochondria or lysosomes in
HeLa cells depending upon the concentration used.[20] The
presence of Fl-PLPRPR-4 in both endosomes and at the
mitochondria of J774A.1 cells suggests that both mechanisms
are at play. Crucially these data suggest that Fl-PLPRPR-4
could access bacteria residing within infected J774A.1 cells
while having a limited impact on mitochondrial function.
As Fl-PLPRPR-4 displayed potent antibacterial activity and
macrophage penetration, we proceeded to test this peptide
against a range of bacterial pathogens. Fl-PLPRPR-4 has potent
broad-spectrum antibacterial activity (Table 2), including
MRSA (8 mm) as well as the biological warfare agents
Bacillus anthracis (8 mm) and Brucella (16 mm). Also of
interest was the activity against the biofilm-forming clinical-
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Table 2: Antibacterial activity of Fl-PLPRPR-4 against pathogenic bacteria.
MIC[a]/MBC[b] [mm]

Pathogen
Gram positive
Bacillus anthracis
S. aureus
methicillin-resistant S. aureus (MRSA)
Listeria monocytogenes
Gram negative
Salmonella typhimurium
Brucella abortus
Pseudomonas aeruginosa

8/8
8/32
8/16
16/32
8/8
16/32
32/32

[a] The minimum inhibitor concentration (MIC) was the lowest concentration of the peptide where no growth was observed. [b] The minimum
bactericidal concentration (MBC) was reported as the lowest concentration of the peptide producing more than 99.9 % reduction of the initial
inoculum.

isolates of Pseudomonas aeruginosa and Staphylococcus
aureus. Fl-PLPRPR-4 was further shown to inhibit the growth
of Salmonella, Listeria, and Brucella at 8, 16, and 16 mm
respectively, which are all classified as intracellular pathogens.
AMPs have been shown to often exert their antimicrobial
activity by lysing the bacterial membrane. For instance, E. coli
treated with melittin has been reported to rapidly release bgalactosidase as a consequence of membrane lysis. To test the
effect of Fl-PLPRPR-4 on the membrane integrity of E. coli, we
performed the b-galactosidase leakage assay, with melittin as
a positive control.[9c, 21] In contrast to melittin, Fl-PLPRPR-4
showed no b-galactosidase leakage at both its MIC (4 mm) as
well as 5 times its MIC (20 mm). These data support
a mechanism of antibacterial action for Fl-PLPRPR-4 that
does not involve lysing the bacterial membrane. Fl-PLPRPR-4
was found to associate with E. coli, as visualized by confocal
microscopy.[22] Strong fluorescence was visible within 10 min
of treatment with Fl-PLPRPR-4, and after 6 hours the bacteria
displayed a fragmented morphology, pointing to a possible
mode of antibacterial action (see the Supporting Information).
With a knowledge of the separate cell penetrating and
antibacterial activities of Fl-PLPRPR-4, we investigated the
ability of this P-AMP to clear intracellular bacterial pathogens, Salmonella and Brucella, within J774A.1 cells using an
in vitro bacterial protection assay (Figure 4).[23] While intra-

Figure 4. Intracellular antibacterial activity of Fl-PLPRPR-4 (15 mm) in
J774A.1 cells infected with Salmonella typhimurium and Brucella abortus
after 9 h of treatment. The data without error bars indicate that the
standard deviation is too small to be seen.
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cellular Salmonella was reduced by approximately 62 % with
the addition of Fl-PLPRPR-4, intracellular Brucella was found
to be significantly reduced by 90 %. The difference in
inhibition between Salmonella and Brucella could be the
result of many factors, such as the sub-cellular localization of
Salmonella and compartmentalization within phagosomes.
Overcoming bacterial resistance will necessitate the
continuous development of therapeutic agents that also
target intracellular bacterial reservoirs, so as to avoid
recurrence and emergence of resistance. The substantial
reduction in intracellular pathogen levels observed upon
treatment with Fl-PLPRPR-4 provides strong evidence for its
potential application for treatment of stubborn intracellular
bacterial pathogens.
Received: April 1, 2013
Revised: June 12, 2013
Published online: August 20, 2013
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a b s t r a c t
P-glycoprotein (P-gp) efﬂuxes a diverse set of drug substrates out of cells in an ATP dependent manner,
thereby limiting the effective accumulation of therapeutic agents. Herein we demonstrate the use of click
chemistry to rapidly generate bivalent quinine dimers, containing an intervening triazole ring, as potential inhibitors of P-gp mediated efﬂux. Calcein-AM substrate accumulation assays were performed in an
MCF7/DX1 cell line that overexpresses P-gp to monitor the inhibitory activity of the clicked quinine
dimers. A small library of potent P-gp inhibitors with varying tether lengths is reported, with the best
dimer demonstrating low micromolar efﬁcacy.
Ó 2012 Elsevier Ltd. All rights reserved.

P-glycoprotein (P-gp) is an integral membrane protein that is a
member of the ATP binding cassette (ABC) super family of transporters.1 P-gp is over expressed at a range of anatomical and cellular sites, such as brain capillary endothelial cells of the blood–brain
barrier (BBB), epithelial cells of the small intestine and cancer
cells.2,3 P-gp efﬂuxes a large and highly diverse set of therapeutically-relevant substrates such as the anticancer agents taxol4
and gleevec5, and the antipsychotic agents olanzapine6,7 and
quetiapine8, thereby precluding the accumulation of these drugs
at the site of therapeutic action. Because of this efﬂux of therapeutics, the development of P-gp inhibitors has been a target of intense
interest.9–13
Numerous biochemical studies have pointed to the presence of
at least two distinct binding pockets within P-gp.14–16 The recent
X-ray crystal structure of mouse P-gp, which has 87% homology
with its human counterpart, has further conﬁrmed the presence
of two binding sites that are capable of stereochemical discrimination of substrates.17 Occupying the two binding sites in the transporter region of P-gp is a potential strategy for designing inhibitors.
As such, dimerization of P-gp substrates has been shown to afford
substantial P-gp inhibition in cells.18–23 For instance, we have demonstrated that cross-linking two molecules of the P-gp substrate
quinine via ester linkages leads to potent P-gp inhibitors.21 When
co-administered with taxol, these agents reversed the drug resistant phenotype of cells. The nature of the tether in such bivalent
inhibitors is of crucial importance for inhibition and may also be
used to interrogate the region between the transporter binding
⇑ Corresponding author. Tel.: +1 765 494 0135; fax: +1 765 494 0239.
E-mail address: chml@purdue.edu (J. Chmielewski).
0960-894X/$ - see front matter Ó 2012 Elsevier Ltd. All rights reserved.
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sites within P-gp. For instance, the tether length has been found
to signiﬁcantly inﬂuence the efﬁcacy of P-gp inhibition within
emetine homo-dimers20 whereas using highly rigid tethers within
quinine dimers limits P-gp inhibition.21
In an effort to more rapidly screen a variety of tethering
moieties, we turned to the copper(I) catalyzed Huisgen 1,3-dipolar
cycloaddition reaction between azides and alkynes (commonly
known as the click reaction24) as a way to quickly generate dimeric
P-gp inhibitors and probes from monomeric P-gp substrates, such
as quinine. The click reaction has shown great utility in bringing
together a wide range of functional molecules,25–27 including
in situ reactions.28 As shown in Figure 1, utilizing the pendant
alcohol functionality of quinine, we developed a series of alkyne(QnA) and azide-modiﬁed (Qn0 Z) quinine analogs, of varying tether
lengths. Using these functionalized quinine monomers, the click
reaction was used to synthesize a small library of unique quinine
dimers containing a triazole ring within the tether. The shortest
tether combination of Q2A and Q20 Z resulted in a dimeric agent
Q(2,20 ) with two methylene units ﬂanking either side of the triazole ring, whereas the longest tether combination resulted in
Q(8,80 ). A representative synthesis of the clicked quinine dimer
Q(4,40 ) is shown in Figure 2. The azido ester, Q40 Z, and the alkynyl
ester, Q4A, were synthesized from quinine with 5-azidopentanoic
acid29 and 6-heptynoic acid, respectively, using standard
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) coupling
conditions. The click reaction between Q4A and Q40 Z was performed using copper sulfate and sodium ascorbate in a 1:1 dichloromethane (DCM)–water solvent mixture to afford Q(4,40 ). All
clicked dimers were puriﬁed to homogeneity on silica gel and
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Figure 1. Structures of the alkyne- (QnA) and azide- (Qn0 Z) modiﬁed quinine
derivatives, and clicked quinine dimers Q(n,n0 ).

4411

characterized by mass spectrometry. Purity was assessed by
reverse phase HPLC.30
To investigate the ability of the clicked quinine dimers to inhibit
P-gp mediated efﬂux, calcein-AM accumulation assays were carried out using the MCF7/DX1 cell line. This sub-line is 200-fold
more resistant to doxorubicin and has been shown to over express
P-gp by immunoblot analysis.21,31 Calcein-AM is a known P-gp
substrate whose cellular internalization is possible only if P-gp efﬂux is inhibited.32 Calcein-AM undergoes ester hydrolysis within
cells generating ﬂuorescent calcein. Therefore, ﬂow cytometry
can be used to quantify cellular ﬂuorescence, and a measure of
inhibitory activity can be obtained. As shown in Figure 3a, there
is a marked increase in ﬂuorescence upon incubating MCF7/DX1
cells with calcein-AM in the presence of the clicked quinine dimer
Q(6,60 ).30 The known P-gp inhibitor GF120918 was used as a positive control in these experiments.
As seen in Figure 3b all of the clicked dimers are capable of
inhibiting P-gp in MCF7/DX1 cells with fairly similar potencies
while being much more potent than quinine itself (IC50
100 lM). Maximal efﬁcacy is observed with Q(4,60 ), Q(6,40 ) and
Q(6,60 ). Equipotent P-gp inhibition is observed with Q(4,60 ) and
Q(6,40 ), two dimers that differ only in the orientation of the triazole
ring. As a consequence of these results, only tether length

Figure 2. Representative synthesis for Q(4,40 ) (i) 5-azidopentanoic acid (3 equiv) or 6-heptynoic acid (3 equiv), EDC (3 equiv), DIEA (6 equiv), DMAP (0.4 equiv), DMF, 12 h,
0 °C to rt, 92–94% yield; (ii) copper sulfate (5 mol %), sodium ascorbate (10 mol %), DCM/water (1:1), rt, 12 h, 54% yield.
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Figure 3. (a) Histograms displaying MCF7/DX1 ﬂuorescence upon addition of
calcein-AM alone (red) and with Q(6,60 ) (black, 5 lM) or GF120918 (green, 1 lM)
and (b) IC50 values for P-gp inhibition with the clicked quinine dimer library. All
experiments were performed in duplicate.33 Histogram plot shows the relationship
between ﬂuorescence intensity (FL1 channel) and cell count.

combinations with differing numbers of total intervening methylene groups were studied further. When comparing the series with
equivalent numbers of methylene units ﬂanking the triazole ring,
such as Q(2,20 ), Q(4,40 ) and so on, optimum inhibition was found
with the Q(6,60 ) dimer. A 2.3-fold increase in potency was observed
when the tether length was increased from Q(2,20 ) to Q(6,60 ). This
effect was lost upon further increasing the tether to Q(8,80 ). When
comparing these data to P-gp inhibition with other quinine-based
dimers, we observe approximately equipotent inhibition between
a dimer with a central phenyl moiety in the tether, as compared
to triazole-linked dimers.21 However, the triazole-containing
inhibitors, such as Q(6,60 ), were found to be greater than 10-fold
more potent against P-gp when compared to quinine dimers with
an intervening naphthalene unit in the tether.21
In conclusion, we have developed a synthetic protocol for the
rapid assembly of a small library of quinine dimers employing click
chemistry. These bivalent agents encompass a range of tether
length, incorporating the triazole ring. This approach allowed us
to explore the chemical space in the P-gp substrate binding region
and study inhibitory trends. Using calcein-AM as the P-gp substrate in MCF7-DX1 cells, we found that while the activity is
broadly similar, P-gp inhibition is maximum for dimers with 10
to 12 methylene units ﬂanking the triazole ring. Inhibition was
found to drop off on lengthening or shortening the tether length
further. Given the tolerance of the triazole moiety in the P-gp substrate binding region, this strategy may potentially be extended to
other P-gp drug substrates. Thus both homo- and hetero-clicked
dimers can be envisioned to explore the integral membrane P-gp
transporter region and potentially discover novel inhibitors and
probes.
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